<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants - Doyle, LW - 2021 | Cochrane Library</title> <meta content="Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants - Doyle, LW - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001146.pub6/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants - Doyle, LW - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001146.pub6/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001146.pub6" name="dc.identifier" scheme="DOI"/> <meta content="Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants" name="citation_title"/> <meta content="Lex W Doyle" name="citation_author"/> <meta content="lwd@unimelb.edu.au" name="citation_author_email"/> <meta content="Jeanie L Cheong" name="citation_author"/> <meta content="Susanne Hay" name="citation_author"/> <meta content="Beth Israel Deaconess Medical Center, Harvard Medical School" name="citation_author_institution"/> <meta content="Brett J Manley" name="citation_author"/> <meta content="Henry L Halliday" name="citation_author"/> <meta content="Retired Honorary Professor of Child Health, Queen's University Belfast" name="citation_author_institution"/> <meta content="Roger Soll" name="citation_author"/> <meta content="Larner College of Medicine at the University of Vermont" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD001146.pub6" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001146.pub6/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001146.pub6/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001146.pub6/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [adverse effects]; Anti-Inflammatory Agents; *Bronchopulmonary Dysplasia [prevention &amp; control]; Dexamethasone [therapeutic use]; Glucocorticoids [adverse effects]; Infant, Premature" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001146.pub6&amp;doi=10.1002/14651858.CD001146.pub6&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="tIsQXAzh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001146\x2epub6\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001146\x2epub6\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ko","ms","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001146.pub6",title:"Early (\u003c 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants",firstPublishedDate:"Oct 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001146.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001146.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001146.pub6/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001146.pub6/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001146.pub6%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001146.PUB6" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001146.pub6/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001146.PUB6" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001146.pub6/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001146.pub6/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5204 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001146.pub6" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0085"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-sec-0079"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/appendices#CD001146-sec-0090"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/table_n/CD001146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/table_n/CD001146StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Early (&lt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Lex W Doyle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0005">Jeanie L Cheong</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0006">Susanne Hay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0007">Brett J Manley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0008">Henry L Halliday</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information#CD001146-cr-0009">Roger Soll</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information/en#CD001146-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001146.pub6">https://doi.org/10.1002/14651858.CD001146.pub6</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001146-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001146-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001146-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001146-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001146-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001146-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001146-abs-0001" lang="en"> <section id="CD001146-sec-0001"> <h3 class="title" id="CD001146-sec-0001">Background</h3> <p>Bronchopulmonary dysplasia (BPD) remains a major problem for infants born extremely preterm. Persistent inflammation in the lungs is important in its pathogenesis. Systemic corticosteroids have been used to prevent or treat BPD because of their potent anti‐inflammatory effects. </p> </section> <section id="CD001146-sec-0002"> <h3 class="title" id="CD001146-sec-0002">Objectives</h3> <p>To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first six days after birth for preterm infants at risk of developing BPD. </p> </section> <section id="CD001146-sec-0003"> <h3 class="title" id="CD001146-sec-0003">Search methods</h3> <p>We ran an updated search of the following databases on 25 September 2020: CENTRAL via CRS Web and MEDLINE via OVID. We also searched clinical trials databases and reference lists of retrieved articles for randomised controlled trials (RCTs). We did not include cluster randomised trials, cross‐over trials, or quasi‐RCTs. </p> </section> <section id="CD001146-sec-0004"> <h3 class="title" id="CD001146-sec-0004">Selection criteria</h3> <p>For this review, we selected RCTs examining systemic (intravenous or oral) postnatal corticosteroid treatment started within the first six days after birth (early) in high‐risk preterm infants. We included studies that evaluated the use of dexamethasone, as well as studies that assessed hydrocortisone, even when the latter was used primarily for management of hypotension, rather than for treatment of lung problems. We did not include trials of inhaled corticosteroids. </p> </section> <section id="CD001146-sec-0005"> <h3 class="title" id="CD001146-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. We extracted and analysed data regarding clinical outcomes that included mortality, BPD, mortality or BPD, failure to extubate, complications during the primary hospitalisation, and long‐term health and neurodevelopmental outcomes. We used the GRADE approach to assess the certainty of evidence. </p> </section> <section id="CD001146-sec-0006"> <h3 class="title" id="CD001146-sec-0006">Main results</h3> <p>Use of the GRADE approach revealed that the certainty of evidence was high for the major outcomes considered, except for BPD at 36 weeks for all studies combined, which was downgraded one level to moderate because of evidence of publication bias. </p> <p>We included 32 RCTs (4395 infants). The overall risk of bias of included studies was low; all were RCTs, and most trials used rigorous methods. </p> <p>Early systemic corticosteroids overall have little or no effect on mortality to the latest reported age (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.85 to 1.06; 31 studies, 4373 infants; high‐certainty evidence), but hydrocortisone alone reduces mortality (RR 0.80, 95% CI 0.65 to 0.99; 11 studies, 1433 infants; high‐certainty evidence). </p> <p>Early systemic corticosteroids overall probably reduce BPD at 36 weeks' postmenstrual age (PMA) (RR 0.80, 95% CI 0.73 to 0.88; 26 studies, 4167 infants; moderate‐certainty evidence), as does dexamethasone (RR 0.72, 95% CI 0.63 to 0.82; 17 studies, 2791 infants; high‐certainty evidence), but hydrocortisone has little to no effect (RR 0.92, 95% CI 0.81 to 1.06; 9 studies, 1376 infants; high‐certainty evidence). </p> <p>Early systemic corticosteroids overall reduce the combined outcome of mortality or BPD at 36 weeks' PMA (RR 0.89, 95% CI 0.84 to 0.94; 26 studies, 4167 infants; high‐certainty evidence), as do both dexamethasone (RR 0.88, 95% CI 0.81 to 0.95; 17 studies, 2791 infants; high‐certainty evidence) and hydrocortisone (RR 0.90, 95% CI 0.82 to 0.99; 9 studies, 1376 infants; high‐certainty evidence). </p> <p>Early systemic corticosteroids overall increase gastrointestinal perforation (RR 1.84, 95% CI 1.36 to 2.49; 16 studies, 3040 infants; high‐certainty evidence), as do both dexamethasone (RR 1.73, 95% CI 1.20 to 2.51; 9 studies, 1936 infants; high‐certainty evidence) and hydrocortisone (RR 2.05, 95% CI 1.21 to 3.47; 7 studies, 1104 infants; high‐certainty evidence). </p> <p>Early systemic corticosteroids overall increase cerebral palsy (RR 1.43, 95% CI 1.07 to 1.92; 13 studies, 1973 infants; high‐certainty evidence), as does dexamethasone (RR 1.77, 95% CI 1.21 to 2.58; 7 studies, 921 infants; high‐certainty evidence) but not hydrocortisone (RR 1.05, 95% CI 0.66 to 1.66; 6 studies, 1052 infants; high‐certainty evidence). </p> <p>Early systemic corticosteroids overall have little to no effect on the combined outcome of mortality or cerebral palsy (RR 1.03, 95% CI 0.91 to 1.16; 13 studies, 1973 infants; high‐certainty evidence), nor does hydrocortisone (RR 0.86, 95% CI 0.71 to 1.05; 6 studies, 1052 infants; high‐certainty evidence). However, early dexamethasone probably increases the combined outcome of mortality or cerebral palsy (RR 1.18, 95% CI 1.01 to 1.37; 7 studies, 921 infants; high‐certainty evidence), </p> <p>In sensitivity analyses by primary intention for treatment with hydrocortisone (lung problems versus hypotension), there was little evidence of differences in effects on major outcomes of mortality, BPD, or combined mortality or BPD, by indication for the drug. </p> </section> <section id="CD001146-sec-0007"> <h3 class="title" id="CD001146-sec-0007">Authors' conclusions</h3> <p>Early systemic postnatal corticosteroid treatment (started during the first six days after birth) prevents BPD and the combined outcome of mortality or BPD. However, it increases risks of gastrointestinal perforation, cerebral palsy, and the combined outcome of mortality or cerebral palsy. Most beneficial and harmful effects are related to early treatment with dexamethasone, rather than to early treatment with hydrocortisone, but early hydrocortisone may prevent mortality, whereas early dexamethasone does not. Longer‐term follow‐up into late childhood is vital for assessment of important outcomes that cannot be assessed in early childhood, such as effects of early corticosteroid treatment on higher‐order neurological functions, including cognitive function, executive function, academic performance, behaviour, mental health, motor function, and lung function. Further RCTs of early corticosteroids, particularly of hydrocortisone, should include longer‐term survival free of neurodevelopmental disability as the primary outcome. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001146-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001146-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001146-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001146-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001146-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD001146-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001146-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001146-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001146-abs-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001146-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001146-abs-0002" lang="en"> <h3>Early (started within six days) systemic postnatal corticosteroids for preventing bronchopulmonary dysplasia in preterm infants </h3> <p><b>Review objective:</b> to determine the relative benefits and harms of treatment with drugs that suppress inflammation, called corticosteroids, given to babies born too early during the first week after birth to prevent lung injury, known as bronchopulmonary dysplasia (sometimes also called “chronic lung disease”). </p> <p><b>Background:</b> bronchopulmonary dysplasia is a major problem for newborn babies in neonatal intensive care units. Persistent inflammation of the lungs is the most likely cause. Corticosteroid drugs have been used to prevent or treat bronchopulmonary dysplasia through their strong anti‐inflammatory effects, but they may produce major adverse effects. </p> <p><b>Study characteristics:</b> we reviewed all clinical trials in preterm babies for whom corticosteroids had been given systemically, that is, either as an injection or as a medicine, during the first week after birth, and for whom data on the rate of bronchopulmonary dysplasia later in the newborn period were available. We included 32 studies (4395 infants). The search is up‐to‐date as of 25 September 2020. </p> <p><b>Key results:</b> this review of trials revealed that the benefits of giving systemic corticosteroids to infants starting within six days after birth may not outweigh the known adverse effects. However, a particular corticosteroid called hydrocortisone shows promise in improving short‐term outcomes without adversely affecting long‐term neurodevelopment, although the data on long‐term outcomes are limited so far. Beneficial effects of systemic corticosteroids overall included shorter time on the ventilator and less bronchopulmonary dysplasia; adverse effects included higher blood pressure, bleeding from the stomach or bowel, perforation of the bowel, excessive glucose in the bloodstream, and increased risk of cerebral palsy at follow‐up, particularly in those treated with dexamethasone ‐ another type of corticosteroid. Early use of corticosteroids, especially dexamethasone, to treat or prevent bronchopulmonary dysplasia should be curtailed until additional research has been performed. </p> <p><b>Certainty of evidence:</b> overall, the certainty of evidence supporting our conclusions is high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001146-sec-0085" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001146-sec-0085"></div> <h3 class="title" id="CD001146-sec-0086">Implications for practice</h3> <section id="CD001146-sec-0086"> <p>Benefits of early systemic postnatal corticosteroids for preterm infants at risk of developing BPD may not outweigh real or potential adverse effects. Early systemic postnatal corticosteroid treatment resulted in short‐term benefits, including earlier extubation and decreased risk of BPD and of 'mortality or BPD' at 28 days of life and at 36 weeks' postmenstrual age but was associated with significant short‐term and long‐term adverse effects. Adverse effects included short‐term risk of gastrointestinal bleeding, intestinal perforation, hyperglycaemia, and hypertension, as well as long‐term risks of abnormal neurological examination findings and cerebral palsy. However, the methodological quality of studies determining long‐term outcomes was limited in some cases; children were assessed predominantly before school age, and no study was sufficiently powered to detect important adverse long‐term neurosensory outcomes. Therefore, given the risks of potential short‐term and long‐term adverse effects versus potential short‐term benefits, this review supports curtailment of early systemic corticosteroid treatment for prevention of BPD. </p> </section> <h3 class="title" id="CD001146-sec-0087">Implications for research</h3> <section id="CD001146-sec-0087"> <p>Through this systematic review, we have identified a compelling need for long‐term follow‐up and reporting of late outcomes, especially neurological and developmental outcomes, among surviving infants who participated in all randomised trials of early postnatal corticosteroid treatment. These follow‐up studies should include tests of gross motor function, cognitive functioning, hearing, and visual acuity. </p> <p>Future studies are needed to identify accurately infants who are at greatest risk of developing BPD. Future placebo‐controlled trials of systemic postnatal corticosteroids in preterm infants should include long‐term neurodevelopmental follow‐up. Studies comparing different types, doses, and durations of corticosteroid treatment, and examining effects of inhaled corticosteroids, are urgently needed.  </p> <p>Short‐term and longer‐term effects of early hydrocortisone given to prevent BPD require further evaluation. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001146-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001146-sec-0008"></div> <div class="table" id="CD001146-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Early systemic postnatal corticosteroids (dexamethasone and hydrocortisone) compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preventing bronchopulmonary dysplasia in preterm infants<br/><b>Setting:</b> multiple neonatal intensive care units, most from high‐income countries<br/><b>Intervention:</b> early systemic postnatal corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with early systemic postnatal corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/>(0.85 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4373<br/>(31 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> <p>P = 0.05 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(197 to 246) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.02<br/>(0.90 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2940<br/>(20 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>241 per 1000</p> <p>(212 to 274)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.65 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1433<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/>(146 to 222) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>BPD (36 weeks' PMA)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.73 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4167<br/>(26 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>important</p> <p>P = 0.01 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(225 to 271) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.72<br/>(0.63 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2791<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>194 per 1000<br/>(170 to 221) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.92<br/>(0.81 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1376<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>385 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>354 per 1000<br/>(312 to 408) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality or BPD at 36 weeks' PMA</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.84 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4167<br/>(26 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/>(432 to 484) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.88<br/>(0.81 to 0.95 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2791<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>487 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>429 per 1000<br/>(395 to 463) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.90<br/>(0.82 to 0.99 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1376<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>569 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>512 per 1000<br/>(467 to 563) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Gastrointestinal perforation during primary hospitalisation</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.84<br/>(1.36 to 2.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3040<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/>(53 to 96) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.73<br/>(1.20 to 2.51 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1936<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>41 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>71 per 1000<br/>(50 to 104) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of infants treated with hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 2.05<br/>(1.21 to 3.47 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1104<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000<br/>(41 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Cerebral palsy at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/>(1.06 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> <p>P = 0.09 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(79 to 142) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.77<br/>(1.21 to 2.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>921<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>89 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>158 per 1000<br/>(108 to 230) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.05<br/>(0.66 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1052<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000<br/>(41 to 103) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality or cerebral palsy at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.03<br/>(0.91 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1973<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> <p>P = 0.02 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>335 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>345 per 1000<br/>(305 to 389) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.18<br/>(1.01 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>921<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>383 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>452 per 1000<br/>(387 to 525) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.71 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1052<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000<br/>(210 to 310) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BPD:</b> bronchopulmonary dysplasia; <b>CI:</b> confidence interval; <b>PMA:</b> postmenstrual age; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> </p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations owing to evidence of publication bias for studies overall, but not within subgroups. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001146-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001146-sec-0009"></div> <section id="CD001146-sec-0010"> <h3 class="title" id="CD001146-sec-0010">Description of the condition</h3> <p>Advances in neonatal care, including use of antenatal corticosteroids and surfactant therapy, have improved the outcomes of preterm infants with respiratory distress syndrome (also called hyaline membrane disease), but risk of chronic lung disease or bronchopulmonary dysplasia (BPD) has been only modestly reduced (<a href="./references#CD001146-bbs2-0075" title="EgbertsJ , BrandR , WaltiH , BevilacquaG , BreartG , GardiniF .Mortality, severe respiratory distress syndrome and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf. Pediatrics1997;100(1):E4. [DOI: 10.1542/peds.100.1.e4] [PMID: 9200378]">Egberts 1997</a>). More recent data suggest approximately 50% of infants born at &lt; 28 weeks' gestation who survive to 36 weeks' gestation have BPD, with rates remaining stubbornly high, even though exogenous surfactant and more non‐invasive ventilation have been introduced into clinical care over the past 30 years (<a href="./references#CD001146-bbs2-0068" title="CheongJL , OlsenJE , HuangL , DalzielKM , BolandRA , BurnettAC , et al, Members of the Victorian Infant Collaborative Study Group.Changing consumption of resources for respiratory support and short-term outcomes in four consecutive geographical cohorts of infants born extremely preterm over 25 years since the early 1990s. BMJ Open2020;10(9):e037507. [DOI: 10.1136/bmjopen-2020-037507] [PMID: 32912950]">Cheong 2020</a>). The terms 'chronic lung disease' and 'bronchopulmonary dysplasia' are often used interchangeably; for the purposes of this review, we have decided to use 'bronchopulmonary dysplasia' to describe the condition of infants with oxygen dependency at 28 days after birth or at 36 weeks' postmenstrual age. More infants with BPD are now cared for in neonatal intensive care units (NICUs), and management of their condition is both time‐consuming and costly. BPD refers to injury with maldevelopment of the lung that follows preterm birth and is a major problem in NICUs. Persistent inflammation in the lungs is a major feature in its pathogenesis. </p> </section> <section id="CD001146-sec-0011"> <h3 class="title" id="CD001146-sec-0011">Description of the intervention</h3> <p>Postnatal corticosteroid treatment has been shown to have some beneficial acute effects on lung function in infants with established BPD, especially among those who are ventilator‐dependent (<a href="./references#CD001146-bbs2-0037" title="Collaborative Dexamethasone Trial Group.Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics1991;88(3):421-7. [PMID: 1881718]JonesR , WincottE , ElbourneD , GrantA .Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics1995;96(5 Pt 1):897-906. [PMID: 7478833]JonesRA , Collaborative Dexamethasone Trial Follow-up Group.Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics1995;116(2):370-8. [DOI: 10.1542/peds.2004-1818] [PMID: 16061591]JonesRA , Collaborative Dexamethasone Trial Follow-up Group.Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics2005;116(2):379-84. [DOI: 10.1542/peds.2004-1819] [PMID: 16061592]">CDTG 1991</a>; <a href="./references#CD001146-bbs2-0085" title="MammelMC , GreenTP , JohnsonDE , ThompsonTR .Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet1983;1(8338):1356-8. [DOI: 10.1016/s0140-6736(83)92139-6] [PMID: 6134136]">Mammel 1983</a>). However, clinicians have been concerned that the benefits of corticosteroids might not outweigh associated adverse effects, which include hypertension, hyperglycaemia, intestinal perforation, and extreme catabolism (<a href="./references#CD001146-bbs2-0063" title="[No authors listed].Dexamethasone for neonatal chronic lung disease. Lancet1991;338(8773):982-3. [PMID: 1681347]">Anonymous 1991</a>; <a href="./references#CD001146-bbs2-0086" title="NgPC .The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Archives of Disease in Childhood1993;68(3 Spec No):330-6. [DOI: 10.1136/adc.68.3_spec_no.330] [PMID: 8466274]">Ng 1993</a>). </p> <p>Systemic (enteral or parenteral) corticosteroids have been used to try to prevent BPD by treating at‐risk preterm infants, starting within the first four days after birth. It is not clear whether early use of systemic corticosteroids provides long‐term benefits, neither is it clear if adverse neurological outcomes observed in some animal studies apply to the immature human newborn infant. </p> </section> <section id="CD001146-sec-0012"> <h3 class="title" id="CD001146-sec-0012">How the intervention might work</h3> <p>Systemic corticosteroids might prevent BPD through their potent anti‐inflammatory effects. </p> </section> <section id="CD001146-sec-0013"> <h3 class="title" id="CD001146-sec-0013">Why it is important to do this review</h3> <p>Multiple systematic reviews have examined the use of postnatal corticosteroids in infants with or at risk of BPD (<a href="./references#CD001146-bbs2-0064" title="Arias-CamisonJM , LauJ , ColeCH , Frantz ID 3rd.Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatric Pulmonology1999;28(3):167-74. [DOI: 10.1002/(sici)1099-0496(199909)28:3&lt;167::aid-ppul2&gt;3.0.co;2-y] [PMID: 10495332]">Arias‐Camison 1999</a>; <a href="./references#CD001146-bbs2-0067" title="BhutaT , OhlssonA .Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Archives of Disease in Childhood. Fetal and Neonatal Edition1998;79(1):F26-33. [DOI: 10.1136/fn.79.1.f26] [PMID: 9797621]">Bhuta 1998</a>; <a href="./references#CD001146-bbs2-0069" title="DoyleLW , DavisPG .Postnatal corticosteroids in preterm infants: systematic review of effects on mortality and motor function. Journal of Paediatrics and Child Health2000;36(2):101-7. [DOI: 10.1046/j.1440-1754.2000.00481.x] [PMID: 10760004]">Doyle 2000</a>; <a href="./references#CD001146-bbs2-0070" title="DoyleLW , EhrenkranzRA , HallidayHL .Postnatal hydrocortisone for preventing or treating bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology2010;98(2):111-7. [DOI: 10.1159/000279992] [PMID: 20150750]">Doyle 2010a</a>; <a href="./references#CD001146-bbs2-0071" title="DoyleLW , EhrenkranzRA , HallidayHL .Dexamethasone treatment in the first week of life for preventing bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology2010;98(3):217-24. [DOI: 10.1159/000286210] [PMID: 20389126]">Doyle 2010b</a>; <a href="./references#CD001146-bbs2-0072" title="DoyleLW , EhrenkranzRA , HallidayHL .Dexamethasone treatment after the first week of life for bronchopulmonary dysplasia in preterm infants: a systematic review. Neonatology2010;98(4):289-96. [DOI: 10.1159/000286212] [PMID: 20453523]">Doyle 2010c</a>; <a href="./references#CD001146-bbs2-0113" title="DoyleLW , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub4]">Doyle 2014a</a>; <a href="./references#CD001146-bbs2-0073" title="DoyleLW , EhrenkranzRA , HallidayHL .Late (&gt; 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD001145. [DOI: 10.1002/14651858.CD001145.pub3]">Doyle 2014b</a>; <a href="./references#CD001146-bbs2-0114" title="DoyleLW , CheongJLY , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub5]">Doyle 2017a</a>; <a href="./references#CD001146-bbs2-0081" title="HallidayHL .A review of postnatal corticosteroids for treatment and prevention of chronic lung disease in the preterm infant. Prenatal and Neonatal Medicine1997;2:1-12.">Halliday 1997</a>; <a href="./references#CD001146-bbs2-0082" title="HallidayHL .Clinical trials of postnatal corticosteroids: inhaled and systemic. Biology of the Neonate1999;76(Suppl 1):29-40. [DOI: 10.1159/000047044] [PMID: 10393391]">Halliday 1999</a>; <a href="./references#CD001146-bbs2-0105" title="Tarnow-MordiW , MitraA .Postnatal dexamethasone in preterm infants is potentially life saving, but follow up studies are urgently needed. BMJ1999;319(7222):1385-6. [DOI: 10.1136/bmj.319.7222.1385] [PMID: 10574836]">Tarnow‐Mordi 1999</a>). Other systematic reviews have explored early versus late use of inhaled corticosteroids and comparisons of systemic versus inhaled steroids for prevention or treatment of BPD (<a href="./references#CD001146-bbs2-0087" title="OnlandW , OffringaM , vanKaamA .Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 8. Art. No: CD002311. [DOI: 10.1002/14651858.CD002311.pub4]">Onland 2017</a>; <a href="./references#CD001146-bbs2-0098" title="ShahV , OhlssonA , HallidayH , DunnMS .Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews2007, Issue 4. Art. No: CD001969. [DOI: 10.1002/14651858.CD001969.pub2]">Shah 2007b</a>; <a href="./references#CD001146-bbs2-0099" title="ShahSS , OhlssonA , HallidayHL , ShahVS .Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD002058. [DOI: 10.1002/14651858.CD002058.pub2]">Shah 2012a</a>; <a href="./references#CD001146-bbs2-0100" title="ShahSS , OhlssonA , HallidayHL , ShahVS .Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews2012, Issue 5. Art. No: CD002057. [DOI: 10.1002/14651858.CD002057.pub3]">Shah 2012b</a>; <a href="./references#CD001146-bbs2-0101" title="ShahhVS , OhlssonA , HallidayHL , DunnM .Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD001969. [DOI: 10.1002/14651858.CD001969.pub4]">Shah 2017</a>). </p> <p>Two existing Cochrane Reviews have reviewed separately trials in which systemic postnatal corticosteroids were started before eight days of birth or after the first seven days following birth (<a href="./references#CD001146-bbs2-0114" title="DoyleLW , CheongJLY , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub5]">Doyle 2017a</a>; <a href="./references#CD001146-bbs2-0074" title="DoyleLW , CheongJ , EhrenkranzRA , HallidayHL .Late (&gt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001145. [DOI: 10.1002/14651858.CD001145.pub4]">Doyle 2017b</a>). This review examines the outcomes of trials in which preterm infants were treated with corticosteroids starting within six days after birth. Several trials that started on Day 7 after birth have been included in the late review (<a href="./references#CD001146-bbs2-0074" title="DoyleLW , CheongJ , EhrenkranzRA , HallidayHL .Late (&gt; 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001145. [DOI: 10.1002/14651858.CD001145.pub4]">Doyle 2017b</a>), which is an update of previous Cochrane Reviews and includes long‐term outcome data from 13 trials. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001146-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001146-sec-0014"></div> <p>To examine the relative benefits and adverse effects of systemic postnatal corticosteroids commenced within the first six days after birth for preterm infants at risk of developing BPD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001146-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001146-sec-0015"></div> <section id="CD001146-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001146-sec-0017"> <h4 class="title">Types of studies</h4> <p>We sought to identify randomised controlled trials (RCTs) of systemic postnatal corticosteroid therapy for preterm infants at risk of developing BPD, who were enrolled within the first six days after birth (early postnatal corticosteroids). We included trials of hydrocortisone in the first six days after birth when BPD and mortality were reported, even if hydrocortisone had been used primarily to treat or prevent hypotension. </p> </section> <section id="CD001146-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included preterm infants at risk of developing BPD, including those who are ventilator‐dependent.</p> </section> <section id="CD001146-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials of Intravenous or oral corticosteroids versus control (placebo or no treatment). We did not include in this review trials of inhaled corticosteroids. </p> </section> <section id="CD001146-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Outcome measures are divided into primary and secondary outcomes.</p> <section id="CD001146-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001146-list-0001"> <li> <p>Mortality (at 28 days after birth, at 36 weeks' postmenstrual age, at discharge home, and at the latest reported age) </p> </li> <li> <p>Bronchopulmonary dysplasia (at 28 days after birth, at 36 weeks' postmenstrual age, and at 36 weeks' postmenstrual age in survivors) </p> </li> <li> <p>Mortality or bronchopulmonary dysplasia (at 28 days after birth and at 36 weeks' postmenstrual age) </p> </li> <li> <p>Long‐term outcomes (including blindness, deafness, cerebral palsy, and major neurodevelopmental disability) </p> </li> </ul> </p> </section> <section id="CD001146-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001146-list-0002"> <li> <p>Failure to extubate (at 3, 7, 14, and 28 days)</p> </li> <li> <p>Late rescue with corticosteroids (for all infants and for survivors)</p> </li> <li> <p>Need for home oxygen therapy</p> </li> <li> <p>Complications during the primary hospitalisation (including infection, hyperglycaemia, hypertension, pulmonary air leak, patent ductus arteriosus, severe intraventricular haemorrhage, cystic periventricular leukomalacia, necrotising enterocolitis, gastrointestinal bleeding, intestinal perforation, and severe retinopathy of prematurity) </p> </li> </ul> </p> </section> </section> </section> <section id="CD001146-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001146-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We conducted an update search in September 2020 of the following: Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 9), in the Cochrane Library; and OVID MEDLINE(R) and Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Daily and Versions(R) (1 January 2016 to 25 September 2020). We have included the search strategies for each database in <a href="./appendices#CD001146-sec-0091">Appendix 1</a>. We did not apply language restrictions. </p> <p>We searched clinical trial registries for ongoing and recently completed trials. We searched the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), along with the US National Library of Medicine’s ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>), via Cochrane CENTRAL. Additionally, we searched the International Standard Randomized Controlled Trials Number Registry (ISRCTN) for any unique trials not found through the Cochrane CENTRAL search (<a href="http://www.isrctn.com/" target="_blank">http://www.isrctn.com/</a>). </p> <p>Although we searched Embase in 2017, we did not search Embase for this update. Although Embase records are included in CENTRAL, we acknowledge that its omission for this update may have reduced the sensitivity of our search.  </p> <p>This is the fifth update of this review. Our previous search details are listed in <a href="./appendices#CD001146-sec-0095">Appendix 2</a> and <a href="./appendices#CD001146-sec-0096">Appendix 3</a>. </p> </section> <section id="CD001146-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We also searched the reference lists of all published trials to identify trials overlooked during the electronic literature search. </p> </section> </section> <section id="CD001146-sec-0026"> <h3 class="title" id="CD001146-sec-0026">Data collection and analysis</h3> <p>We used the methods of Cochrane Neonatal for data collection and analysis.</p> <section id="CD001146-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We included all RCTs that fulfilled the selection criteria described in the previous section. We did not include cluster randomised, cross‐over, or quasi‐randomised trials Two review authors (LWD and JC) independently reviewed results of the updated search and selected studies for inclusion. We resolved disagreements by discussion. </p> </section> <section id="CD001146-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>For each trial, we sought information regarding methods of randomisation, blinding, stratification, and reporting of outcomes for all infants enrolled, and whether the trial used a single‐centre or multi‐centre setting. Information on trial participants included birth weight, gestational age, severity of respiratory distress syndrome, need for mechanical ventilation via an endotracheal tube or other respiratory support not requiring an endotracheal tube and surfactant, and sex. We analysed information on clinical outcomes for mortality, survival without BPD, BPD defined at 28 days of life and at 36 weeks' postmenstrual age, failure to extubate, pneumothorax, infection, hyperglycaemia, hypertension, severe retinopathy of prematurity, patent ductus arteriosus, severe intraventricular haemorrhage, cystic periventricular leukomalacia, necrotising enterocolitis, gastrointestinal bleeding, intestinal perforation, and need for late corticosteroid treatment, as well as long‐term outcomes such as developmental delay, blindness, deafness, cerebral palsy, and major neurosensory disability. </p> <p>For each study, one review author (LD) entered final data into Review Manager (RevMan) 5 software (<a href="./references#CD001146-bbs2-0092" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>); a second review author (JC or SH) checked the data for accuracy. We resolved discrepancies through discussion or by consultation with a third assessor (HH).  </p> <p>We attempted to contact authors of the original reports to request further details when information regarding any of the above was unclear. </p> </section> <section id="CD001146-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (LD and JC) independently assessed risk of bias (low, high, or unclear) for all included trials using the Cochrane ‘Risk of bias’ tool for the following domains (<a href="./references#CD001146-bbs2-0083" title="HigginsJP , AltmanDG , SterneJA , on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group.Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> <p> <ul id="CD001146-list-0003"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>We resolved disagreements by discussion or by consultation with a third assessor. See <a href="./appendices#CD001146-sec-0097">Appendix 4</a> for a more detailed description of risk of bias for each domain.  </p> </section> <section id="CD001146-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used standard methods of Cochrane Neonatal when analysing data.</p> <p>We performed statistical analyses using Review Manager 5 (RevMan) 5 software (<a href="./references#CD001146-bbs2-0092" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We analysed dichotomous data using risk ratio (RR), risk difference (RD), and the number needed to treat for an additional beneficial outcome (NNTB), or the number needed to treat for an additional harmful outcome (NNTH). We reported 95% confidence intervals (CIs) for all estimates. </p> <p>We included no continuous outcomes in this review. If included, we planned to analyse continuous data using the mean difference (MD) or the standardised mean difference (SMD) to combine trials that measure the same outcome using different methods. </p> </section> <section id="CD001146-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For clinical outcomes such as episodes of sepsis, we analysed the data as proportions of neonates having one or more episodes. </p> </section> <section id="CD001146-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. If we had concerns regarding the impact of including studies with high levels of missing data in the overall assessment of treatment effect, we planned to explore this concern via sensitivity analysis. </p> <p>We conducted all outcome analyses on an intention‐to‐treat basis, that is, we included in the analyses all participants randomised to each group. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing. </p> </section> <section id="CD001146-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined heterogeneity between trials by inspecting forest plots and by quantifying the impact of heterogeneity using the I² statistic. If noted, we planned to explore possible causes of statistical heterogeneity by conducting prespecified subgroup analyses (e.g. differences in study quality, participants, intervention regimens, outcome assessments). </p> </section> <section id="CD001146-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed possible publication bias and other biases by examining symmetry/asymmetry of funnel plots. In addition, we computed Egger's statistic on funnel plots to assess the strength of the evidence for publication bias. </p> <p>For included trials that were recently performed (and therefore were prospectively registered), we explored possible selective reporting of study outcomes by comparing primary and secondary outcomes described in the reports against primary and secondary outcomes proposed at trial registration, using the websites <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and <a href="http://www.controlled-trials.com" target="_blank">www.controlled-trials.com</a>. If we found such discrepancies, we planned to contact the primary investigators to request missing outcome data on outcomes prespecified at trial registration. </p> </section> <section id="CD001146-sec-0035"> <h4 class="title">Data synthesis</h4> <p>When we judged meta‐analysis to be appropriate, we carried out the analysis using Review Manager (RevMan) 5 (<a href="./references#CD001146-bbs2-0092" title="The Cochrane CollaborationReview Manager 5 (RevMan 5).Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>), as supplied by Cochrane. We used the Mantel‐Haenszel method to obtain estimates of typical RR and RD. We included no continuous outcomes in this review. We planned to use the inverse variance method to analyse continuous measures, if included.  </p> <p>We used the fixed‐effect model for all meta‐analyses.</p> </section> <section id="CD001146-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses by type of corticosteroid used (dexamethasone or hydrocortisone) when we identified sufficient numbers of trials to make such subgroup analyses meaningful. </p> </section> <section id="CD001146-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses for situations that might affect interpretation of significant results (e.g. when risk of bias is associated with the quality of some included trials). </p> <p>Because the indication for early hydrocortisone treatment might be primarily to treat lung problems or low blood pressure, we performed a sensitivity analysis by indication for hydrocortisone for major outcomes of mortality at the latest age, BPD at 36 weeks, or mortality or BPD at 36 weeks. </p> </section> <section id="CD001146-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the GRADE Handbook (<a href="./references#CD001146-bbs2-0096" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s).Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>), to assess the certainty of evidence for the following clinically relevant outcomes: mortality, BPD, the combined outcome of mortality or BPD, intestinal perforation, cerebral palsy, and the combined outcome of mortality or cerebral palsy. </p> <p>Two review authors (LD and JC) independently assessed the certainty of evidence for each of the outcomes above. We considered evidence from RCTs as high certainty but downgraded the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. We used the <a href="./references#CD001146-bbs2-0078" title="GRADE Working Group, McMaster University (developed by Evidence Prime)GRADEpro GDT.Version accessed 21 February 2017. Hamilton (ON): GRADE Working Group, McMaster University (developed by Evidence Prime).">GRADEpro GDT</a> Guideline Development Tool to create <a href="./full#CD001146-tbl-0001">summary of findings Table 1</a> to report the certainty of the evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence as one of four grades. </p> <p> <ul id="CD001146-list-0004"> <li> <p>High certainty: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate certainty: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low certainty: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low certainty: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001146-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001146-sec-0039"></div> <section id="CD001146-sec-0040"> <h3 class="title">Description of studies</h3> <p>We have provided results of the search for this review update in the study flow diagram (<a href="#CD001146-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD001146-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update." data-id="CD001146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> </div> <section id="CD001146-sec-0041"> <h4 class="title">Results of the search</h4> <p>We included 32 studies (4395 infants) in this review (<a href="#CD001146-fig-0001">Figure 1</a>). We identified no new studies compared with the previous version of the review (<a href="./references#CD001146-bbs2-0114" title="DoyleLW , CheongJLY , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub5]">Doyle 2017a</a>). Most of the included studies enrolled low birth weight infants with respiratory distress syndrome who were receiving mechanical ventilation. </p> </section> <section id="CD001146-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD001146-sec-0114" title="">Characteristics of included studies</a>. </p> <p>Twenty‐one studies used primarily dexamethasone (<a href="./references#CD001146-bbs2-0001" title="AnttilaE , PeltonemiO , HaumontD , HertingE , ter HorstH , HeinonenK , et al.Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics2005;164(8):472-81. [DOI: 10.1007/s00431-005-1645-8] [PMID: 15864643]">Anttila 2005</a>; <a href="./references#CD001146-bbs2-0008" title="GarlandJS , AlexCP , PaulyTH , WhiteheadVL , BrandJ , WinstonJF , et al.A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics1999;104(1 Pt 1):91-9. [DOI: 10.1542/peds.104.1.91] [PMID: 10390266]">Garland 1999</a>: <a href="./references#CD001146-bbs2-0009" title="HalacE , HalacJ , BegueEF , CasañasJM , IndiveriDR , PetitJF , et al.Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics1990;117(1 Pt 1):132-8. [DOI: 10.1016/s0022-3476(05)72461-6] [PMID: 2196355]">Halac 1990</a>; <a href="./references#CD001146-bbs2-0011" title="KopelmanAE , MoiseAA , HolbertD , HegemierSE .A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics1999;135(3):345-50. [DOI: 10.1016/s0022-3476(99)70132-0] [PMID: 10484801]">Kopelman 1999</a>; <a href="./references#CD001146-bbs2-0012" title="LauterbachR , Szymura-OleksiakJ , PawlikD , WarcholJ , Lisowska-MiszczykI , RytlewskiK .Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. Journal of Maternal-Fetal &amp; Neonatal Medicine2006;19(7):433-8. [DOI: 10.1080/14767050600736754] [PMID: 16923699]">Lauterbach 2006</a>; <a href="./references#CD001146-bbs2-0013" title="LinYJ , YehTF , HsiehWS , ChiYC , LinHC , LinCH .Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology1999;27(1):21-6. [DOI: 10.1002/(sici)1099-0496(199901)27:1&lt;21::aid-ppul5&gt;3.0.co;2-y] [PMID: 10023787]">Lin 1999</a>; <a href="./references#CD001146-bbs2-0014" title="MukhopadhyayK , KumarP , NarangA .Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics1998;35(2):117-22. [PMID: 9707853]">Mukhopadhyay 1998</a>; <a href="./references#CD001146-bbs2-0017" title="MoralesP , RastogiA , BezML , AkintorinSM , PyatiS , AndesSM , et al.Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology1998;19(3):225-9. [DOI: 10.1007/s002469900290] [PMID: 9568218]RastogiA , AkintorinSM , BezML , MoralesP , PildesPS .A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics1996;98(2 Pt 1):204-10. [PMID: 8692619]">Rastogi 1996</a>: <a href="./references#CD001146-bbs2-0018" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [PMID: 12042579]RomagnoliC , ZeccaE , VentoG , De CarolisMP , PapacciP , TortoroloG .Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine1999;25(7):717-21. [DOI: 10.1007/s001340050935] [PMID: 10470576]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1999</a>: <a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a>; <a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a>: <a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a>: <a href="./references#CD001146-bbs2-0022" title="SollRF , Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research1999;45:226A. Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics2001;108(3):741-8. [DOI: 10.1542/peds.108.3.741] [PMID: 11533345]">Soll 1999</a>: <a href="./references#CD001146-bbs2-0023" title="StarkAR , CarloWA , TysonJE , PapileLA , WrightLL , ShankaranS , et al, National Institute of Child Health and Human Development Neonatal Research Network.Adverse effects of early dexamethasone in extremely-low-birth-weight infants. New England Journal of Medicine2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203] [PMID: 11150359]StarkAR , CarloWA , VohrBR , PapileL , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2001</a>: <a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a>: <a href="./references#CD001146-bbs2-0025" title="SuskeG , OestreichK , VarnholtV , LaschP , KachelW .Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica1996;85(6):713-8. [DOI: 10.1111/j.1651-2227.1996.tb14132.x] [PMID: 8816210]">Suske 1996</a>: <a href="./references#CD001146-bbs2-0026" title="TapiaJL , RamirezR , CifuentesJ , FabresJ , HubnerME , BancalariA , et al.The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics1998;132(1):48-52. [DOI: 10.1016/s0022-3476(98)70483-4] [PMID: 9469999]">Tapia 1998</a>: <a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a>: <a href="./references#CD001146-bbs2-0028" title="WangJY , YehTF , LinYC , MiyamuraK , HolmskovU , ReidKB .Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax1996;51(9):907-13. [DOI: 10.1136/thx.51.9.907] [PMID: 8984701]WangJY , YehTF , LinYJ , ChenWY , LinCH .Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatric Pulmonology1997;23(3):193-7. [DOI: 10.1002/(sici)1099-0496(199703)23:3&lt;193::aid-ppul4&gt;3.0.co;2-p] [PMID: 9094727]">Wang 1996</a>: <a href="./references#CD001146-bbs2-0031" title="YehTF , TorreJA , RastogiA , AnyebunoMA , PildesRS .Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. Journal of Pediatrics1990;117(2 Pt 1):273-82. [DOI: 10.1016/s0022-3476(05)80547-5] [PMID: 2199642]">Yeh 1990</a>: <a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a>), The most common treatment regimen consisted of 0.50 mg/kg/d of dexamethasone for three days followed by 0.25 mg/kg/d for three days, then 0.12 mg/kg/d for three days followed by 0.05 mg/kg/d for three days. However, trialists described considerable variation in treatment regimens, including short courses of one to two days, and longer courses of up to four weeks. </p> <p>Eleven studies used hydrocortisone (<a href="./references#CD001146-bbs2-0002" title="BadenM , BauerCR , ColeE , KleinG , TaeuschHW , SternL .A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics1972;50(4):526-34. [PMID: 4561296]FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Baden 1972</a>; <a href="./references#CD001146-bbs2-0003" title="BattonBJ , LiL , NewmanNS , DasA , WatterbergKL , YoderBA , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics2012;161(1):65-9. [DOI: 10.1016/j.jpeds.2012.01.014] [PMID: 22336574]">Batton 2012</a>; <a href="./references#CD001146-bbs2-0004" title="BaudO , BiranV , TroussonC , LeroyE , MohamedD , AlbertiC .Two-year outcomes after prophylactic hydrocortisone in extremely preterm neonates. In: European Journal of Pediatrics. Vol. 175. 2016:1507. BaudO , MauryL , LebailF , RamfulD , El MoussawiF , NicaiseC , et al, PREMILOC Trial Study Group.Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet2016;387(10030):1827-36. [DOI: 10.1016/S0140-6736(16)00202-6] [PMID: 26916176]BaudO , TroussonC , BiranV , LeroyE , MohamedD , AlbertiC , PREMILOC Trial Group.Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA2017;317(13):1329-37. [DOI: 10.1001/jama.2017.2692] [PMID: 28384828]">Baud 2016</a>; <a href="./references#CD001146-bbs2-0005" title="BiswasS , BufferyJ , EnochH , BlandM , MarkiewiczM , WaltersD .Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial - thyroid hormone replacement in neonates. Pediatric Research2003;53(1):48-56. [DOI: 10.1203/00006450-200301000-00011] [PMID: 12508081]BiswasS .Personal communication. email2002. ">Biswas 2003</a>; <a href="./references#CD001146-bbs2-0006" title="BonsanteF , LatorreG , LacobelliS , ForziatiV , LaforgiaN , EspositoL , et al.Early low-dose hydrocortisone in very preterm infants: a randomized placebo-controlled trial. Neonatology2007;91(4):217-21. [DOI: 10.1159/000098168] [PMID: 17568152]">Bonsante 2007</a>; <a href="./references#CD001146-bbs2-0007" title="EfirdMM , HeerensAT , GordonPV , BoseCL , YoungDA .A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology2005;25(2):119-24. [DOI: 10.1038/sj.jp.7211193] [PMID: 15329742]">Efird 2005</a>; <a href="./references#CD001146-bbs2-0010" title="HochwaldO , PalegraG , OsiovichO .Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian Journal of Pediatrics2014;81(8):808-10. [DOI: 10.1007/s12098-013-1151-3] [PMID: 23904065]">Hochwald 2014</a>; <a href="./references#CD001146-bbs2-0015" title="NgPC , LeeCH , BnurFL , ChanIH , LeeAW , WongE , et al.A double-blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics2006;117(2):367-75. [DOI: 10.1542/peds.2005-0869] [PMID: 16452355]">Ng 2006</a>; <a href="./references#CD001146-bbs2-0016" title="PeltoniemiO , KariA , HeinonenK , SaarelaT , NikolajevK , AnderssonS , et al.Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics2005;146(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040] [PMID: 15870666]PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2005</a>; <a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>; <a href="./references#CD001146-bbs2-0030" title="WatterbergKL , GerdesJS , ColeCH , AucottSW , ThiloEH , MammelMC , et al.Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics2004;114(6):1649-57. [DOI: 10.1542/peds.2004-1159] [PMID: 15574629]WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2004</a>). In some cases, when low (almost physiological) doses were used, the indication was management of hypotension (see under <a href="#CD001146-sec-0040">Description of studies</a>). </p> <p><a href="./references#CD001146-bbs2-0001" title="AnttilaE , PeltonemiO , HaumontD , HertingE , ter HorstH , HeinonenK , et al.Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics2005;164(8):472-81. [DOI: 10.1007/s00431-005-1645-8] [PMID: 15864643]">Anttila 2005</a> was a multi‐centre, double‐blind, placebo‐controlled trial of infants with birth weight of 500 grams to 999 grams, gestation less than 32 weeks, and respiratory failure by four hours of age. Investigators randomised 53 infants to receive four doses of dexamethasone (0.25 mg/kg at 12‐hour intervals) and 56 infants to receive saline placebo. Country: Finland. Participants were recruited between June 1998 and February 2001. Supported by grants from the Foundation for Pediatric Research, the Foundation of Alma and K.A. Snellman, and the Sigrid Juselius Foundation (Finland). </p> <p><a href="./references#CD001146-bbs2-0002" title="BadenM , BauerCR , ColeE , KleinG , TaeuschHW , SternL .A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics1972;50(4):526-34. [PMID: 4561296]FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Baden 1972</a> included 44 infants with respiratory distress syndrome, mild hypoxia and hypercapnia, and a chest radiograph compatible with respiratory distress syndrome. Researchers randomised infants to receive hydrocortisone 15 mg/kg on admission and 12 hours later intravenously (total dose 30 mg/kg hydrocortisone) (n = 22), or placebo (n = 22). Birth weight ranged from 800 grams to 2805 grams, and gestational age from 26 to 36 weeks. Country: Canada. Participants were recruited between August 1971 and August 1972. Upjohn and Company supplied the hydrocortisone and placebo. </p> <p><a href="./references#CD001146-bbs2-0003" title="BattonBJ , LiL , NewmanNS , DasA , WatterbergKL , YoderBA , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics2012;161(1):65-9. [DOI: 10.1016/j.jpeds.2012.01.014] [PMID: 22336574]">Batton 2012</a> was a pilot study of infants at 23 to 26 weeks' gestation with low blood pressure in the first 24 hours of life. Investigators compared dopamine and hydrocortisone versus placebo using a factorial design. The dose of hydrocortisone was 1 mg/kg loading, then 0.5 mg/kg 12‐hourly for six doses (total dose, 4.0 mg/kg hydrocortisone over three days). The trial was stopped early because of slow recruitment after only 10 infants were enrolled; four received hydrocortisone and six received placebo. Country: USA. Participants were recruited between 3 December 2009 and 3 December 2010. The National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development provided grant support, including funding from the Best Pharmaceuticals for Children Act, for the Neonatal Research Network’s Early Blood Pressure Pilot Study. </p> <p><a href="./references#CD001146-bbs2-0004" title="BaudO , BiranV , TroussonC , LeroyE , MohamedD , AlbertiC .Two-year outcomes after prophylactic hydrocortisone in extremely preterm neonates. In: European Journal of Pediatrics. Vol. 175. 2016:1507. BaudO , MauryL , LebailF , RamfulD , El MoussawiF , NicaiseC , et al, PREMILOC Trial Study Group.Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet2016;387(10030):1827-36. [DOI: 10.1016/S0140-6736(16)00202-6] [PMID: 26916176]BaudO , TroussonC , BiranV , LeroyE , MohamedD , AlbertiC , PREMILOC Trial Group.Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA2017;317(13):1329-37. [DOI: 10.1001/jama.2017.2692] [PMID: 28384828]">Baud 2016</a> was a multi‐centre double‐blind RCT of 523 infants at 24 to 27 weeks’ gestational age who were recruited from 21 French centres with NICU facilities in the first 24 hours after birth between 25 May 2008 and 31 January 2014. Parents of one infant in each group withdrew consent after randomisation, hence results are reported for 421 infants overall. The treatment group received hydrocortisone hemisuccinate 1 mg/kg/d divided into two doses for seven days, then 0.5 mg/kg/d once per day for three days (total dose, 8.5 mg/kg hydrocortisone over 10 days) (n = 255). Control infants were given an equivalent volume of 5% glucose placebo (n = 266). The trial was halted early because of lack of funding, with 523 of a planned total of 786 infants recruited. Country: France. Funded by Assistance Publique‐Hôpitaux de Paris. </p> <p><a href="./references#CD001146-bbs2-0005" title="BiswasS , BufferyJ , EnochH , BlandM , MarkiewiczM , WaltersD .Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial - thyroid hormone replacement in neonates. Pediatric Research2003;53(1):48-56. [DOI: 10.1203/00006450-200301000-00011] [PMID: 12508081]BiswasS .Personal communication. email2002. ">Biswas 2003</a> was a multi‐centre randomised trial of 253 infants at less than 30 weeks' gestational age. Investigators mechanically ventilated infants and entered them into the study within nine hours of birth. They gave all infants surfactant during the first 24 hours of life. Those randomised to the treatment group (n = 125) received an infusion of hydrocortisone 1 mg/kg/d and tri‐iodothyronine (T3) 6 µg/kg/d for five days, then hydrocortisone 0.5 mg/kg/d and T3 3 µg/kg/d for two days (total dose 6 mg/kg hydrocortisone over 7 days). The placebo group (n = 128) received an equal volume of 5% dextrose. Country: England. Participants were recruited between January 1996 and April 1998. </p> <p><a href="./references#CD001146-bbs2-0006" title="BonsanteF , LatorreG , LacobelliS , ForziatiV , LaforgiaN , EspositoL , et al.Early low-dose hydrocortisone in very preterm infants: a randomized placebo-controlled trial. Neonatology2007;91(4):217-21. [DOI: 10.1159/000098168] [PMID: 17568152]">Bonsante 2007</a> enrolled a total of 50 infants of birth weight less than 1250 grams or at 24 to 30 weeks' gestation who were less than 48 hours old and were ventilator‐dependent after surfactant treatment. Exclusion criteria were cardiopulmonary malformations, perinatal asphyxia, mortality within 12 hours after recruitment, or use of steroids for any reason within 12 days after birth. Researchers excluded no infants for these latter two reasons. They stratified infants by birth weight (not specified), gestational age (not specified), and antenatal steroid exposure, then randomly allocated infants to a 12‐day course of hydrocortisone (1.0 mg/kg for nine days, then 0.5 mg/kg/d for three days) (total dose 10.5 mg/kg hydrocortisone over 12 days) (n = 25), or an equivalent volume of 0.9% saline placebo (n = 25). Study authors based the sample size calculation on the results of <a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>, resulting in an estimate of 138 infants to be recruited. The study was stopped early when 50 infants had been enrolled because of reports from other trials of spontaneous intestinal perforation with early hydrocortisone treatment. Country: Italy. Participants were recruited between April 2003 and September 2005. Supported by the University of Bari, Bari, Italy. </p> <p><a href="./references#CD001146-bbs2-0007" title="EfirdMM , HeerensAT , GordonPV , BoseCL , YoungDA .A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology2005;25(2):119-24. [DOI: 10.1038/sj.jp.7211193] [PMID: 15329742]">Efird 2005</a> was an RCT of hydrocortisone to prevent hypotension in infants of birth weight less than 1000 grams at gestation of 24 to 28 weeks. Trialists randomised 16 infants to receive 1 mg/kg of intravenous hydrocortisone 12‐hourly for two days, followed by 0.3 mg/kg 12‐hourly for three days (total dose 5.8 mg/kg hydrocortisone over five days), or a normal saline placebo (n=18). Country: USA. Participants were recruited between May 2000 and May 2002. Supported by Forest Pharmaceuticals, Inc. </p> <p><a href="./references#CD001146-bbs2-0008" title="GarlandJS , AlexCP , PaulyTH , WhiteheadVL , BrandJ , WinstonJF , et al.A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics1999;104(1 Pt 1):91-9. [DOI: 10.1542/peds.104.1.91] [PMID: 10390266]">Garland 1999</a> reported a prospective, multi‐centre, randomised trial comparing a three‐day course of dexamethasone therapy, beginning at 24 to 48 hours of life, versus placebo. Researchers enrolled 241 preterm infants (dexamethasone n = 118, placebo n = 123) who weighed between 500 grams and 1500 grams, had received surfactant therapy, and were at significant risk for BPD or mortality, using a predictive model at 24 hours. Trial authors gave dexamethasone to infants in a three‐day tapering course at 12‐hour intervals. The first two doses were 0.4 mg/kg, the third and fourth doses were 0.2 mg/kg, and the fifth and sixth doses were 0.1 mg/kg and 0.05 mg/kg, respectively (total dose 1.35 mg/kg dexamethasone over three days). They gave a similar volume of normal saline to placebo‐treated infants at similar time intervals. Country: USA. Participants were recruited between December 1992 and November 1997. Supported by the Perinatal Foundation, Milwaukee, WIsconsin. </p> <p><a href="./references#CD001146-bbs2-0009" title="HalacE , HalacJ , BegueEF , CasañasJM , IndiveriDR , PetitJF , et al.Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics1990;117(1 Pt 1):132-8. [DOI: 10.1016/s0022-3476(05)72461-6] [PMID: 2196355]">Halac 1990</a> was a randomised trial undertaken to determine if prenatal corticosteroid therapy would reduce the incidence of necrotising enterocolitis. Investigators randomised women to prenatal betamethasone or placebo when they were admitted in preterm labour and were expected to deliver within 24 hours. They then randomised infants of mothers who had received placebo to postnatal dexamethasone or placebo; we included in this review only infants who were randomised to postnatal therapy. Study infants weighed less than 1501 grams at birth or were born at less than 34 weeks' gestation and had evidence of "birth asphyxia" (one‐minute Apgar score &lt; 5, prolonged resuscitation, and metabolic acidosis (bicarbonate &lt; 15 mmol/L within one hour of birth)). Study groups were assigned via a table of random numbers. The treatment group (n = 130) received 2 mg/kg/d of dexamethasone phosphate intravenously for seven days (total dose 14 mg/kg dexamethasone over seven days); the control group (n = 118) received an equal volume of 10% dextrose. The major endpoint of this study was necrotising enterocolitis. Country: Argentina. Participants were recruited between January 1985 and December 1987. </p> <p><a href="./references#CD001146-bbs2-0010" title="HochwaldO , PalegraG , OsiovichO .Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian Journal of Pediatrics2014;81(8):808-10. [DOI: 10.1007/s12098-013-1151-3] [PMID: 23904065]">Hochwald 2014</a> reported a single‐centre randomised trial conducted to determine the effects of hydrocortisone on vasopressor dosing in hypotensive infants at &lt; 31 weeks' gestation or with birth weight &lt; 1251 grams during the first 48 hours after birth. Researchers randomly allocated 11 infants to hydrocortisone 2 mg/kg for one dose and 1 mg/kg for three doses, six hours apart, then 0.5 mg/kg for four doses, six hours apart (total dose 7 mg/kg hydrocortisone over two days), or an equal volume of saline placebo (n = 11). Country: Canada. Participants were recruited between January 2007 and December 2009. </p> <p><a href="./references#CD001146-bbs2-0011" title="KopelmanAE , MoiseAA , HolbertD , HegemierSE .A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics1999;135(3):345-50. [DOI: 10.1016/s0022-3476(99)70132-0] [PMID: 10484801]">Kopelman 1999</a> was a prospective blinded RCT of 70 infants who required mechanical ventilation at less than 28 weeks' gestation. Thirty‐seven infants received dexamethasone 0.20 mg/kg at delivery (total dose 0.2 mg/kg dexamethasone as one dose), and 33 infants received placebo consisting of an equal volume of saline. Country: USA. Participants were recruited between August 1994 and November 1995. </p> <p><a href="./references#CD001146-bbs2-0012" title="LauterbachR , Szymura-OleksiakJ , PawlikD , WarcholJ , Lisowska-MiszczykI , RytlewskiK .Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. Journal of Maternal-Fetal &amp; Neonatal Medicine2006;19(7):433-8. [DOI: 10.1080/14767050600736754] [PMID: 16923699]">Lauterbach 2006</a> presented a single‐centre randomised trial to determine the effects of two active drugs on occurrence of BPD at 36 weeks. The two active drugs were nebulised pentoxifylline diluted in distilled water and intravenous dexamethasone. Infants weighing &lt; 1251 grams at birth who were receiving supplemental oxygen on the fourth day after birth were eligible if they did not have a grade 3 or 4 intraventricular haemorrhage. Study authors randomly allocated a total of 150 infants to nebulised pentoxifylline every six hours for three days (n = 50), intravenous dexamethasone 0.25 mg/kg/12‐hourly for three days (total dose 1.5 mg/kg dexamethasone over three days, minimum) (n = 50), or nebulised saline placebo every six hours for three days (total dose 1.5 mg/kg dexamethasone over three days, minimum) (n = 50). Study drugs could be repeated every seven days if the infant was still ventilator‐ or oxygen‐dependent and a diagnosis of BPD had not been established. The number of repeat doses for any group.was not reported. Only data from the dexamethasone group and the control group were entered into the current meta‐analysis. Country: Poland. Participants were recruited between 1 January 2000 and 30 September 2003. </p> <p><a href="./references#CD001146-bbs2-0013" title="LinYJ , YehTF , HsiehWS , ChiYC , LinHC , LinCH .Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology1999;27(1):21-6. [DOI: 10.1002/(sici)1099-0496(199901)27:1&lt;21::aid-ppul5&gt;3.0.co;2-y] [PMID: 10023787]">Lin 1999</a> was a randomised trial with a sequential design involving infants weighing 500 grams to 1999 grams. Investigators stratified infants by birth weight into three groups: 500 grams to 999 grams, 1000 grams to 1500 grams, and 1501 grams to 1999 grams. Within each group, equal numbers of dexamethasone‐treated or control cards were placed into envelopes for random selection of the first infant of each pair. The next infant of the appropriate birth weight stratum was enrolled for the match. A pharmacist opened the envelope, and investigators administered dexamethasone or saline placebo blind. Entry criteria included the presence of severe radiographic respiratory distress syndrome, the need for assisted ventilation within six hours of birth, and receipt of one dose of surfactant. Treated infants were given dexamethasone starting within 12 hours of birth at 0.25 mg/kg/dose 12‐hourly for seven days, 0.12 mg/kg/dose 12‐hourly for seven days, 0.05 mg/kg/dose 12‐hourly for seven days, and 0.02 mg/kg/dose 12‐hourly for seven days, resulting in a total of four weeks of treatment (total dose 6.16 mg/kg dexamethasone over four weeks). Results were reported for 20 treated and 20 control infants. Country: Taiwan. Supported by the National Health Research Institute and Department of Health, Taiwan. </p> <p><a href="./references#CD001146-bbs2-0014" title="MukhopadhyayK , KumarP , NarangA .Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics1998;35(2):117-22. [PMID: 9707853]">Mukhopadhyay 1998</a> reported a randomised trial that included untreated controls. Study authors did not describe the method of randomisation used. Treated infants received dexamethasone 0.5 mg/kg/dose 12‐hourly for three days (total dose 3 mg/kg dexamethasone over three days), beginning within six hours of birth. Researchers included 19 infants (10 treated with dexamethasone; 9 control) at less than 34 weeks' gestation and weighing less than 2000 grams who could be provided with mechanical ventilation. These infants had severe respiratory distress syndrome but were not given surfactant. Country: India. Participants were recruited between February 1996 and July 1996. </p> <p><a href="./references#CD001146-bbs2-0015" title="NgPC , LeeCH , BnurFL , ChanIH , LeeAW , WongE , et al.A double-blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics2006;117(2):367-75. [DOI: 10.1542/peds.2005-0869] [PMID: 16452355]">Ng 2006</a> was a double‐blind RCT of a “stress dose” of hydrocortisone for treatment of refractory hypotension. Investigators randomised 48 infants of birth weight less than 1500 grams to receive hydrocortisone 1 mg/kg eight‐hourly for five days (total dose 15 mg/kg hydrocortisone over five days) (n = 24), or an equivalent volume of isotonic saline (n = 24). Country: China (Hong Kong). Participants were recruited between June 2001 and November 2004. Supported by Research Grants Council of the Hong Kong Special Administrative Region. </p> <p><a href="./references#CD001146-bbs2-0016" title="PeltoniemiO , KariA , HeinonenK , SaarelaT , NikolajevK , AnderssonS , et al.Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics2005;146(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040] [PMID: 15870666]PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2005</a> enrolled a total of 51 infants weighing less than 1251 grams at birth or born at less than 31 weeks' gestation, who were under 36 hours old and were ventilator‐dependent. Investigators conducted this trial at three collaborating centres in Finland. They stratified infants by centre and by birth weight (501 grams to 749 grams, 750 grams to 999 grams, and 1000 grams to 1250 grams) and randomly allocated them to a 10‐day tapering course of hydrocortisone (2 mg/kg/d for two days, 1.5 mg/kg/d for two days, 0.75 mg/kg/d for six days) (total dose 11.5 mg/kg hydrocortisone over 10 days) (n = 25), or an equivalent volume of 0.9% saline placebo (n = 26). Researchers based the sample size calculation on detecting an increase in survival without BPD from 50% to 70% and required inclusion of 160 participants per study arm (alpha and beta error 0.05 and 0.20, respectively). This study was stopped early at 51 infants because four of the hydrocortisone‐treated infants had intestinal perforation and other RCTs of early hydrocortisone had reported the same complication. Children were followed up at two years and at five to seven years of age. Long‐term outcomes included in the meta‐analysis pertain to the five‐ to seven‐year follow‐up study only. Country: Finland. Participants were recruited between 12 August 2002 and 4 March 2004. Supported by grants from Foundation for Pediatric Research, The Alma and K.A. Snellman Foundation (Oulu, Finland), and the Sigrid Juselius Foundation (Finland). </p> <p><a href="./references#CD001146-bbs2-0017" title="MoralesP , RastogiA , BezML , AkintorinSM , PyatiS , AndesSM , et al.Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology1998;19(3):225-9. [DOI: 10.1007/s002469900290] [PMID: 9568218]RastogiA , AkintorinSM , BezML , MoralesP , PildesPS .A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics1996;98(2 Pt 1):204-10. [PMID: 8692619]">Rastogi 1996</a> recruited 70 infants with birth weight of 700 grams to 1500 grams who had severe respiratory distress syndrome (assisted ventilation with ≥ 40% oxygen and/or 7 cmH₂O mean airway pressure and alveolar/arterial (a/A) partial pressure of oxygen (PO₂) ratio ≤ 0.24) who had been treated with surfactant before entry. Infants were less than 12 hours old, and trialists excluded them if they had major malformations, chromosome abnormalities, five‐minute Apgar scores &lt; 3, or severe infection. The intervention group received dexamethasone intravenously every 12 hours according to the following schedule: 0.50 mg/kg/d on Days 1 to 3, 0.30 mg/kg/d on Days 4 to 6, 0.20 mg/kg/d on Days 7 to 9, and finally 0.10 mg/kg/d on Days 10 to 12 (total dose 3.3 mg/kg dexamethasone over 12 days) (n = 36). The control group received a saline placebo intravenously (n = 34). Country: USA. Participants were recruited between July 1992 and August 1993. </p> <p><a href="./references#CD001146-bbs2-0018" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [PMID: 12042579]RomagnoliC , ZeccaE , VentoG , De CarolisMP , PapacciP , TortoroloG .Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine1999;25(7):717-21. [DOI: 10.1007/s001340050935] [PMID: 10470576]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1999</a> was a randomised trial that used numbered, sealed envelopes involving 25 dexamethasone‐treated infants and 25 untreated controls. Entry criteria were birth weight &lt; 1251 grams, gestational age &lt; 33 weeks, ventilator‐ and oxygen‐dependent at 72 hours, and high risk of BPD based on a local scoring system that predicted 90% risk. Treated infants were given dexamethasone beginning on the fourth day at a dose of 0.5 mg/kg/d for three days, 0.25 mg/kg/d for three days, and 0.125 mg/kg/d for one day (total dose 2.375 mg/kg dexamethasone over seven days). Country: Italy. Participants were recruited between November 1996 and October 1998. </p> <p><a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a> enrolled 40 infants at less than 30 weeks' gestation who had respiratory distress syndrome diagnosed by clinical and radiographic signs, required mechanical ventilation at 12 to 18 hours of age, and had received at least one dose of surfactant. Exclusion criteria at entry included a strong suspicion of sepsis or pneumonia, congenital heart disease, chromosome abnormalities, and receipt of an exchange transfusion. Infants were randomised to receive dexamethasone 0.50 mg/kg at between 12 and 18 hours of age and a second dose 12 hours later (total dose 1 mg/kg dexamethasone over one day) (n = 190), or a saline placebo (n = 21). They received both treatments intravenously. Country: USA. Participants were recruited between December 1989 and January 1991. Supported by a Pulmonary Specialized Center of Research (SCOR) grant from the NIH (HL‐36543), a clinical research grant from the March of Dimes (6‐0785), and a General Clinical Research Center grant (RR00044). </p> <p><a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a> reported a multi‐centre trial that randomised 248 infants of birth weight 500 grams to 2000 grams who had clinical and radiographic evidence of respiratory distress syndrome, required mechanical ventilation with more than 40% oxygen, were less than 12 hours old, and had no contraindications to corticosteroid treatment, such as a bleeding tendency, hypertension, hyperglycaemia, or active infection. Investigators excluded infants with lethal congenital malformations. The intervention group received dexamethasone 0.25 mg/kg intravenously every 12 hours for a total of six doses (total dose 1.5 mg/kg dexamethasone over three days) (n = 132). The control group received intravenous saline (n = 116). Country: Israel. Participants were recruited between April 1993 and January 1994. Supported by CTS Industries, Israel. Surfactant TA supplied by Tokyo Tanabe, Japan. </p> <p><a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a> was a multi‐centre randomised double‐blind trial that included 384 infants at less than 30 weeks' gestation with respiratory distress syndrome. A total of 189 infants received dexamethasone 0.50 mg/kg at 12 to 18 hours of age and a second dose 12 hours later (total dose 1 mg/kg dexamethasone over one day), and 195 infants received an equal volume of saline placebo. Country: USA. Participants were recruited between March 1992 and February 1997. Supported by a Pulmonary SCOR grant from the NIH (HL‐36543), General Clinical Research Center Grant 5 MO1 RR00044, and a clinical research grant from the March of Dimes (6‐0785), </p> <p><a href="./references#CD001146-bbs2-0022" title="SollRF , Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research1999;45:226A. Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics2001;108(3):741-8. [DOI: 10.1542/peds.108.3.741] [PMID: 11533345]">Soll 1999</a> described a multi‐centre randomised double‐blind controlled trial that compared dexamethasone given at 12 hours of age versus selective late dexamethasone therapy for preterm infants weighing 501 grams to 1000 grams (early dexamethasone n = 272, late selective therapy n = 270). Infants required assisted ventilation, had received surfactant therapy, were physiologically stable, had no obvious life‐threatening congenital anomaly, had blood cultures obtained, and had started antibiotic therapy. Infants were randomly assigned to early dexamethasone therapy or saline placebo. Intravenous dexamethasone was administered for 12 days according to the following schedule: 0.5 mg/kg/d for three days, 0.25 mg/kg/d for three days, 0.1 mg/kg/d for three days, and 0.05 mg/kg/d for three days (total dose 2.7 mg/kg dexamethasone over 12 days). Infants in either group could receive late postnatal corticosteroids beginning on Day 14 if they needed assisted ventilation, with supplemental oxygen greater than 30%. The trial was halted early because of concern about serious side effects in the early steroid treatment group and the unlikelihood that additional subject enrolment would yield a significant result regarding the primary outcome measure, with 542 of a planned total of 822 infants recruited. Countries: USA, Canada. Supported in part by a grant from the Children’s Miracle Network and the University of Vermont General Clinical Research Center Grant MO1 RR00109. </p> <p><a href="./references#CD001146-bbs2-0023" title="StarkAR , CarloWA , TysonJE , PapileLA , WrightLL , ShankaranS , et al, National Institute of Child Health and Human Development Neonatal Research Network.Adverse effects of early dexamethasone in extremely-low-birth-weight infants. New England Journal of Medicine2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203] [PMID: 11150359]StarkAR , CarloWA , VohrBR , PapileL , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2001</a> was a randomised multi‐centre controlled trial conducted to compare a tapering course of stress‐dose corticosteroid started on the first day versus placebo. Infants with birth weight 501 grams to 1000 grams needing mechanical ventilation before 12 hours of age were eligible for the study. Infants with birth weight over 750 grams also needed to have received surfactant and required an oxygen concentration of 30% or greater. The initial dose of dexamethasone was 0.15 mg/kg/d for three days, tapered over seven days (total dose 0.89 mg/kg dexamethasone over 10 days). After enrolling 220 infants (sample size was 1200), the trial was halted because of an excess of intestinal perforations in the dexamethasone‐treated group. Researchers randomised 111 infants to receive dexamethasone and 109 to receive placebo. Country: USA. Participants were recruited between February 1998 and September 1999. Supported by cooperative agreements with the National Institute of Child Health and Human Development (U10 HD34167, U10 HD34216, U10 HD21373, U10 HD27881, U10 HD21385, U10 HD27853, U10 HD27904, U01 HD21397, U01 HD36790, U10 HD27851, U10 HD21364, U10 HD27871, and U10 HD21415) and by grants from the General Clinical Research Centers Program (M01 RR 02635, M01 RR 02172, M01 RR 00997, M01 RR 08084, M01 RR 06022, M01 RR 08084, and M01 RR 00070). </p> <p><a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a> reported a randomised trial that enrolled infants into one of four treatment groups using a factorial design. Investigators compared both inhaled nitric oxide (iNO) and early dexamethasone separately versus controls. They randomised 42 infants: 10 to receive iNO alone, 11 dexamethasone alone, 10 both treatments, and 11 neither treatment. Researchers compared 21 infants receiving dexamethasone versus 21 controls. Infants were eligible for entry into the trial at 96 hours of age if they met the following criteria: gestational age less than 32 weeks, mechanical ventilation from birth, had received surfactant therapy, and were thought to be at high risk of developing BPD based on a scoring system (<a href="./references#CD001146-bbs2-0094" title="RyanSW , NycykJ , ShawNJ .Prediction of chronic neonatal lung disease on day 4 of life. European Journal of Pediatrics1996;155(8):668-71. [DOI: 10.1007/BF01957150] [PMID: 8839722]">Ryan 1996</a>). Exclusion criteria were major congenital anomaly, structural cardiac defect, significant ductus shunting, culture‐positive sepsis, intraventricular haemorrhage with parenchymal involvement, pulmonary or gastrointestinal haemorrhage, disordered coagulation, and platelet count &lt; 50,000. Infants received dexamethasone intravenously at 12‐hourly intervals for six days: 0.50 mg/kg/dose for six doses and 0.25 mg/kg/dose for a further six doses (total dose 4.5 mg/kg dexamethasone over six days). Control infants did not receive a placebo. Country: England. Participants were recruited between August 1996 and September 1997. NVS was supported by the British Heart Foundation (R.F.Martin Junior Research Fellowship). This study was also supported by an equipment grant from the North West Regional Health Authority Research and Development Executive, and by Micro Medical Ltd., which supplied some of the gas monitoring equipment. </p> <p><a href="./references#CD001146-bbs2-0025" title="SuskeG , OestreichK , VarnholtV , LaschP , KachelW .Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica1996;85(6):713-8. [DOI: 10.1111/j.1651-2227.1996.tb14132.x] [PMID: 8816210]">Suske 1996</a> randomised 26 infants with gestational age of 24 to 34 weeks who had respiratory distress syndrome and had been treated with surfactant. Infants with known septicaemia during the first week of life, haemodynamically relevant cardiac anomalies except for patent ductus arteriosus, or malformations of the lung or central nervous system (CNS) were excluded. Randomisation was performed by drawing lots before the age of two hours. The intervention group (n = 14) received dexamethasone 0.50 mg/kg intravenously in two divided doses for five days (total dose 2.5 mg/kg dexamethasone over five days), and controls (n = 12) received no placebo. Country: Germany. Participants were recruited between March 1991 and June 1993. </p> <p><a href="./references#CD001146-bbs2-0026" title="TapiaJL , RamirezR , CifuentesJ , FabresJ , HubnerME , BancalariA , et al.The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics1998;132(1):48-52. [DOI: 10.1016/s0022-3476(98)70483-4] [PMID: 9469999]">Tapia 1998</a> was a multi‐centre double‐blind placebo‐controlled trial of 109 preterm infants with respiratory distress syndrome and birth weight between 700 grams and 1600 grams who were treated with mechanical ventilation and surfactant. Researchers randomised 55 infants to receive dexamethasone 0.50 mg/kg/d for three days, followed by 0.25 mg/kg/d for three days, followed by 0.12 mg/kg/d for three days, then 0.06 mg/kg/d for three days (total dose 2.79 mg/kg dexamethasone over 12 days). A total of 54 control infants received an equal volume of saline. Country: Chile. Participants were recruited between 1 December 1992 and 30 June 1995. Supported by The Wellcome Foundation and Laboratorios Saval. </p> <p><a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a> enrolled 20 neonates with birth weight less than 1251 grams and gestation less than 33 weeks who were oxygen‐ and ventilator‐dependent on the fourth day of life and randomised them to receive dexamethasone 0.50 mg/kg/d for three days, 0.25 mg/kg/d for three days, and 0.125 mg/kg/d for one day (total dose 2.375 mg/kg dexamethasone over seven days) (n = 10), or no corticosteroid treatment (n = 10). Country: Italy. Participants were recruited between August 1998 and July 2000. </p> <p><a href="./references#CD001146-bbs2-0028" title="WangJY , YehTF , LinYC , MiyamuraK , HolmskovU , ReidKB .Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax1996;51(9):907-13. [DOI: 10.1136/thx.51.9.907] [PMID: 8984701]WangJY , YehTF , LinYJ , ChenWY , LinCH .Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatric Pulmonology1997;23(3):193-7. [DOI: 10.1002/(sici)1099-0496(199703)23:3&lt;193::aid-ppul4&gt;3.0.co;2-p] [PMID: 9094727]">Wang 1996</a> reported a randomised trial of a 21‐day course of dexamethasone or saline placebo given in a double‐blind fashion. Study authors did not state the method of randomisation used. Entry criteria were birth weight 1000 grams to 1999 grams, appropriate for gestational age, clinical and radiological severe respiratory distress syndrome, mechanical ventilation, and age less than 12 hours. Surfactant was not given, as it was not commercially available in Taiwan at the time of the study. Treated infants were given dexamethasone 0.25 mg/kg/dose 12‐hourly for seven days, 0.125 mg/kg/dose 12‐hourly for seven days, and 0.05 mg/kg/dose 12‐hourly for seven days (total dose 5.95 mg/kg dexamethasone over 21 days). The first dose of dexamethasone was given during the first 12 hours of life. Participants included 34 infants in the dexamethasone group and 29 in the placebo control group. Country: Taiwan. Participants were recruited between October 1992 and September 1993. Supported in part by grants NSC 80‐0412‐B006‐27 and NSC 80‐0412‐B006‐47 from National Science Councils, and by grant DOH 82‐HR‐C17 from the National Institute of Health Research, Department of Health, Taiwan, Republic of China. </p> <p><a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a> described a randomised double‐masked placebo‐controlled pilot study conducted to compare early treatment with low‐dose hydrocortisone (1.0 mg/kg/d for nine days, then 0.5 mg/kg/d for three days) (total dose 10.5 mg/kg hydrocortisone over 12 days), begun before 48 hours of age, versus placebo. Researchers enrolled at two centres 40 infants weighing between 500 grams and 999 grams who were mechanically ventilated: 20 hydrocortisone‐treated infants and 20 placebo controls. Country: USA. Participants were recruited between June 1996 and May 1998. Supported by Grant MCJ‐420633 from the Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services. </p> <p><a href="./references#CD001146-bbs2-0030" title="WatterbergKL , GerdesJS , ColeCH , AucottSW , ThiloEH , MammelMC , et al.Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics2004;114(6):1649-57. [DOI: 10.1542/peds.2004-1159] [PMID: 15574629]WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2004</a> was a multi‐centre masked randomised trial of hydrocortisone to prevent early adrenal insufficiency. Investigators randomised 360 infants with birth weight of 500 grams to 999 grams who were mechanically ventilated to receive hydrocortisone 1 mg/kg/d for 12 days, then 0.5 mg/kg/d for three days (total dose 13.5 mg/kg hydrocortisone over 15 days) (n = 180), or saline placebo (n = 180). They enrolled infants at between 12 and 48 hours of life. The trial was stopped because of an increase in spontaneous gastrointestinal perforation in the hydrocortisone group. Country: USA. Participants were recruited between 1 November 2001 and  30 April 2003. Supported by National Institute of Child Health and Human Development grant R01‐HD38540, grant MO1 RROOO54 from the General Clinical Research Centers Programs at the University of New Mexico, Tufts‐New England Medical Center grant 5MO1 RROO997, and University of Colorado grant MO1‐RROOO69. </p> <p><a href="./references#CD001146-bbs2-0031" title="YehTF , TorreJA , RastogiA , AnyebunoMA , PildesRS .Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. Journal of Pediatrics1990;117(2 Pt 1):273-82. [DOI: 10.1016/s0022-3476(05)80547-5] [PMID: 2199642]">Yeh 1990</a> enrolled 57 infants whose birth weight was &lt; 2000 grams and who had severe respiratory distress syndrome diagnosed on the basis of a chest radiograph and the need for mechanical ventilation within four hours after birth. Absence of infection was required for inclusion. Infants were randomly assigned to receive dexamethasone 0.50 mg/kg/dose 12‐hourly from Days 1 to 3, then 0.25 mg/kg/dose 12‐hourly from Days 4 to 6, then 0.12 mg/kg/dose 12‐hourly from Days 7 to 9, and finally 0.05 mg/kg/dose 12‐hourly from Days 10 to 12 (total dose 5.52 mg/kg dexamethasone over 12 days) (n = 28). Researchers administered all doses intravenously and gave a saline solution to infants in the placebo group (n = 29). Country: USA. Participants were recruited between June and November 1988. Supported in part (grant No. 052) by Washington Square Health Foundation, Inc., Chicago, Illinois. </p> <p><a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a> reported a multi‐centre randomised double‐blind clinical trial of 262 preterm infants (&lt; 2000 grams) who had respiratory distress syndrome and required mechanical ventilation from shortly after birth. The treated group received dexamethasone 0.25 mg/kg/dose 12‐hourly intravenously from Day 1 to Day 7; 0.12 mg/kg/dose 12‐hourly intravenously from Day 8 to Day 14; 0.05 mg/kg/dose 12‐hourly intravenously from Day 15 to Day 21; and 0.02 mg/kg/dose 12‐hourly intravenously from Day 22 to Day 28 (total dose 6.16 mg/kg dexamethasone over 28 days) (n = 132). Control infants received a saline placebo (n = 130). Country: Taiwan. Participants were recruited between October 1992 and April 1995. Supported by grants DOH 82‐HR‐C17, DOH 83‐HR‐217, and DOH 84‐HR‐217 from the National Health Research Institute and Department of Health, Taiwan, Republic of China. </p> </section> <section id="CD001146-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies. See <a href="./references#CD001146-sec-0115" title="">Characteristics of excluded studies</a>. </p> <p>We excluded studies for a variety of reasons. In one study, the primary outcome was the need for an epinephrine infusion 12 hours after treatment (<a href="./references#CD001146-bbs2-0042" title="GaissmaierRE , PohlandtF .Single-dose dexamethasone treatment of hypotension in preterm infants. Journal of Pediatrics1999;134(6):701-5. [DOI: 10.1016/s0022-3476(99)70284-2] [PMID: 10356137]">Gaissmaier 1999</a>). Study authors reported no long‐term outcomes. Two studies were not RCTs; one <a href="./references#CD001146-bbs2-0058" title="TsukaharaH , WatanabeY , YasutomiM , KobataR , TamuraS , KimuraK , et al.Early (4-7 days of age) dexamethasone therapy for prevention of chronic lung disease in preterm infants. Biology of the Neonate1999;76(5):283-90. [DOI: 10.1159/000014170] [PMID: 10516395]">Tsukahara 1999</a> comprised 26 study infants and 12 historical controls; <a href="./references#CD001146-bbs2-0057" title="SmolkinT , UlanovskyI , JubranH , BlazerS , MakhoulIR .Experience with oral betamethasone in extremely low birthweight infants with bronchopulmonary dysplasia. Archives of Disease in Childhood. Fetal and Neonatal Edition2014;99(6):F517-8. [DOI: 10.1136/archdischild-2014-306619] [PMID: 25074982]">Smolkin 2014</a> comprised 35 infants treated with betamethasone with no controls. Two studies were RCTS of hydrocortisone to treat low blood pressure. In one such study (<a href="./references#CD001146-bbs2-0035" title="BourchierD , WestonPJ .Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;76(3):F174-8. [DOI: 10.1136/fn.76.3.f174] [PMID: 9175947]">Bouchier 1997</a>), hydrocortisone (n = 21) was compared with dopamine (n = 19) in very low birth weight infants. Although this was an RCT that did report some in‐hospital outcomes relevant to the current review, there was no comparison of hydrocortisone with either placebo or nothing. In the other such study (<a href="./references#CD001146-bbs2-0055" title="SalasG , TravagliantiM , LeoneA , CouceiroC , RodríguezS , FariñaD .Hydrocortisone for the treatment of refractory hypotension:a randomised controlled trial [Hidrocortisona para el tratamiento de hipotensión refractaria: ensayo clínico controlado y aleatorizado]. Anales de Pediatria2014;80(6):387-93. [DOI: 10.1016/j.anpedi.2013.08.004] [PMID: 24139558]">Salas 2014</a>), hydrocortisone was compared with placebo but no important outcomes relevant to the current review were reported. Investigators in one trial randomised 120 very low birth weight infants to both hydrocortisone and caffeine as active treatments, compared with treatment described in “standard guidelines”, which presumably meant no hydrocortisone or caffeine (<a href="./references#CD001146-bbs2-0039" title="DobryanskyD , BorysiukO , SalabayZ , DubrovnaY .Clinical effectiveness of early administration of caffeine and low-dose hydrocortisone to preterm newborns with a high risk of BPD development. Archives of Disease in Childhood2012;97:A119. [DOI: 10.1136/archdischild-2012-302724.0405]">Dobryansky 2012</a>). Major outcomes reported were BPD and BPD combined with mortality. As caffeine alone reduces BPD (<a href="./references#CD001146-bbs2-0095" title="SchmidtB , RobertsRS , DavisP , DoyleLW , BarringtonKJ , OhlssonA , et al, Caffeine for Apnea of Prematurity Trial Group.Caffeine therapy for apnea of prematurity. New England Journal of Medicine2006;354(20):2112-21. [DOI: 10.1056/NEJMoa054065] [PMID: 16707748]">Schmidt 2006</a>), the independent effect of hydrocortisone cannot be determined. Although researchers in another trial randomly allocated 29 very low birth weight infants to dexamethasone or placebo before six hours of age, they reported none of the outcomes that are applicable to this review (<a href="./references#CD001146-bbs2-0061" title="YaseenH , OkashI , HanifM , al-UmranK , al-FaraidyA .Early dexamethasone treatment in preterm infants treated with surfactant: a double blind controlled trial. Journal of Tropical Pediatrics1999;45(5):304-6. [DOI: 10.1093/tropej/45.5.304] [PMID: 10584476]">Yaseen 1999</a>). Outcomes reported comprised only changes in mean values over the first five days for oxygenation, blood pressure, and serum creatinine, urea, and glucose ‐ not rates of BPD, hypertension, or hypoglycaemia, for example. <a href="./references#CD001146-bbs2-0043" title="GrossSJ , AnbarRD , MettelmanBB .Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics2005;115(3):681-7. [10.1542/peds.2004-0956] [PMID: 15741372]">Gross 2005</a> was reporting outcomes at 15 years of age for survivors from an RCT that is included in the “Late” review under a different name (<a href="./references#CD001146-bbs2-0038" title="CummingsJJ , D'EugenioDB , GrossSJ .A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. New England Journal of Medicine1989;320(23):1505-10. [DOI: 10.1056/NEJM198906083202301] [PMID: 2657423]CummingsJJ .Personal communication. email2002. GrossSJ , AnbarRD , MettelmanBB .Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics2005;115(3):681-7. [DOI: 10.1542/peds.2004-0956] [PMID: 15741372]">Cummings 1989</a>); relevant outcomes at 15 years are included in the “Late” review. </p> <p>We excluded 23 studies in which treatment was started after the first week of life that are included in the review titled “Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants” (<a href="./references#CD001146-bbs2-0033" title="AriagnoRL , SweeneyTE , BaldwinRB , InguilloD , MartinD .Controlled trial of dexamethasone in preterm infants at risk for bronchopulmonary dysplasia: lung function, clinical course and outcome at three years (as supplied 2000). Data on file. AriagnoRL , SweeneyTJ , BaldwinRB , InguilloD , MartinD .Dexamethasone effects on lung function and risks in 3 week old ventilatory dependent preterm infants. American Reviews of Respiratory Disease1987;135:A125. ">Ariagno 1987</a>; <a href="./references#CD001146-bbs2-0034" title="AveryGB , FletcherAB , KaplanM , BrudnoDS .Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics1985;75(1):106-11. [PMID: 3880879]">Avery 1985</a>; <a href="./references#CD001146-bbs2-0036" title="BrozanskiBS , JonesJG , GilmourCH , BalsanMJ , VazquezRL , IsraelBA , et al.Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. Journal of Pediatrics1995;126(5 Pt 1):769-76. [DOI: 10.1016/s0022-3476(95)70410-8] [PMID: 7752005]GilmourCH , Sentipal-WaleriusJM , JonesJG , DoyleJM , BrozanskiBS , BalsanMJ , et al.Pulse dexamethasone does not impair growth and body composition of very low birth weight infants. Journal of the American College of Nutrition1995;14(5):455-62. [DOI: 10.1080/07315724.1995.10718536] [PMID: 8522724]HofkoshD , BrozanskiBS , EdwardsDE , WilliamsLA , JonesJG , ChengKP .One year outcome of infants treated with pulse dexamethasone for prevention of BPD. Pediatric Research1995;37(4):259A. ">Brozanski 1995</a>; <a href="./references#CD001146-bbs2-0037" title="Collaborative Dexamethasone Trial Group.Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics1991;88(3):421-7. [PMID: 1881718]JonesR , WincottE , ElbourneD , GrantA .Controlled trial of dexamethasone in neonatal chronic lung disease: a 3-year follow-up. Pediatrics1995;96(5 Pt 1):897-906. [PMID: 7478833]JonesRA , Collaborative Dexamethasone Trial Follow-up Group.Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: I. Neurologic, psychological, and educational outcomes. Pediatrics1995;116(2):370-8. [DOI: 10.1542/peds.2004-1818] [PMID: 16061591]JonesRA , Collaborative Dexamethasone Trial Follow-up Group.Randomized, controlled trial of dexamethasone in neonatal chronic lung disease: 13- to 17-year follow-up study: II. Respiratory status, growth, and blood pressure. Pediatrics2005;116(2):379-84. [DOI: 10.1542/peds.2004-1819] [PMID: 16061592]">CDTG 1991</a>; <a href="./references#CD001146-bbs2-0038" title="CummingsJJ , D'EugenioDB , GrossSJ .A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. New England Journal of Medicine1989;320(23):1505-10. [DOI: 10.1056/NEJM198906083202301] [PMID: 2657423]CummingsJJ .Personal communication. email2002. GrossSJ , AnbarRD , MettelmanBB .Follow-up at 15 years of preterm infants from a controlled trial of moderately early dexamethasone for the prevention of chronic lung disease. Pediatrics2005;115(3):681-7. [DOI: 10.1542/peds.2004-0956] [PMID: 15741372]">Cummings 1989</a>; <a href="./references#CD001146-bbs2-0040" title="DoyleLW , DavisPG , MorleyCJ , McPheeA , CarlinJB , DART Study Investigators.Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone. Pediatrics2007;119(4):716-21. [DOI: 10.1542/peds.2006-2806] [PMID: 17403842 ]DoyleLW , DavisPG , MorleyCJ , McPheeA , CarlinJB .Low-dose dexamethasone facilitates extubation among chronically ventilator-dependent infants: a multicenter, international, randomized, controlled trial. Pediatrics2006;117(1):75-83. [DOI: 10.1542/peds.2004-2843] [PMID: 16396863]">Doyle 2006</a>; <a href="./references#CD001146-bbs2-0041" title="DurandM , SardesaiS , McEvoyC .Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics1995;95(4):584-90. [PMID: 7700763]">Durand 1995</a>; <a href="./references#CD001146-bbs2-0044" title="HarkavyKL , ScanlonJW , ChowdhryPK , GrylackLJ .Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial. Journal of Pediatrics1989;115(6):979-83. [DOI: 10.1016/s0022-3476(89)80754-1] [PMID: 2685220]">Harkavy 1989</a>; <a href="./references#CD001146-bbs2-0045" title="KariMA , HeinonenK , IkonenRS , KoivistoM , RaivioKO .Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Archives of Disease in Childhood1993;68(5 Spec No):566-9. [DOI: 10.1136/adc.68.5_spec_no.566] [PMID: 8323356]KariMA , RaivioKO , VengeP , HallmanM .Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens. Pediatric Research1994;36(3):387-93. [DOI: 10.1203/00006450-199409000-00020] [PMID: 7808837]MieskonenS , EronenM , MalmbergLP , TurpeinenM , KariMA , HallmanM .Controlled trial of dexamethasone in neonatal chronic lung disease: an 8-year follow-up of cardiopulmonary function and growth. Acta Paediatrica2003;92(8):896-904. [PMID: 12948063]">Kari 1993</a>; <a href="./references#CD001146-bbs2-0046" title="KazziNJ , BransYW , PolandRL .Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics1990;86(5):722-7. [PMID: 2235226]">Kazzi 1990</a>; <a href="./references#CD001146-bbs2-0047" title="BenskyAS , KothadiaJM , CovitzW .Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics1996;97(6 Pt 1):818-21. [PMID: 8657520]GoldsteinDJ , WaldrepEL , VanPeltJC , O'SheaTM .Developmental outcome at 5 years following dexamethasone use for very low birth weight infants. Pediatric Research2000;47(4):310A. KothadiaJM , O'SheaTM , RobertsD , AuringerST , Weaver RG 3rd, DillardRG .Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics1999;104(1 Pt 1):22-7 Erratum in: Pediatrics 2004;114(6):1746. [DOI: 10.1542/peds.104.1.22] [PMID: 10390255]NixonPA , WashburnLK , SchechterMS , O'SheaTM .Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. Journal of Pediatrics2007;150(4):345-50. [DOI: 10.1016/j.jpeds.2006.12.013] [PMID: 17382108]O'SheaTM , GoldsteinDJ , JacksonBG , KothadiaJM , DillardRG .Randomized trial of a 42-day tapering course of dexamethasone in very low birth weight infants: neurological, medical and functional outcome at 5 years of age. Pediatric Research2000;47(4):319A. [DOI: 10.1016/j.jpeds.2019.04.047] [PMID: 31349916]O'SheaTM , KothadiaJM , KlinepeterKL , GoldsteinDJ , JacksonBG , Weaver RG 3rd, et al.Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics1999;104(1 Pt 1):15-21. [DOI: 10.1542/peds.104.1.15] [PMID: 10390254]WashburnLK , NixonPA , O'SheaTM .Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. Pediatrics2006;118(4):1592-9. [DOI: 10.1542/peds.2006-0973] [PMID: 17015551]">Kothadia 1999</a>; <a href="./references#CD001146-bbs2-0048" title="KovacsL , DavisGM , FaucherD , PapageorgiouA .Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatrica1998;87(7):792-8. [DOI: 10.1080/080352598750013905] [PMID: 9722255]">Kovacs 1998</a>; <a href="./references#CD001146-bbs2-0049" title="Noble-JamiesonCM , RegevR , SilvermanM .Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. European Journal of Pediatrics1989;148(4):365-7. [DOI: 10.1007/BF00444135] [PMID: 2651132]">Noble‐Jamieson 1989</a>; <a href="./references#CD001146-bbs2-0050" title="OhlssonA , CalvertSA , HoskingM , ShennanAT .Randomized controlled trial of dexamethasone treatment in very-low-birth-weight infants with ventilator-dependent chronic lung disease. Acta Paediatrica1992;81(10):751-6. [DOI: 10.1111/j.1651-2227.1992.tb12096.x] [PMID: 1421877]">Ohlsson 1992</a>; <a href="./references#CD001146-bbs2-0051" title="OnlandW , CoolsF , KroonA , RademakerK , MerkusMP , DijkPH , et al, Stop-BPD Study Group.Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA2019;321:354-63. [DOI: 10.1001/jama.2018.21443] [PMID: 30694322]">Onland 2019</a>: <a href="./references#CD001146-bbs2-0052" title="PapileLA , TysonJE , StollBJ , WrightLL , DonovanEF , BauerCR , et al.A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. New England Journal of Medicine1998;338(16):1112-8. [DOI: 10.1056/NEJM199804163381604] [PMID: 9545359]StollBJ , TemprosaM , TysonJE , PapileLA , WrightLL , BauerCR , et al.Dexamethasone therapy increases infection in very low birth weight infants. Pediatrics1999;104(5):e63. [DOI: 10.1542/peds.104.5.e63] [PMID: 10545589]">Papile 1998</a>; <a href="./references#CD001146-bbs2-0053" title="ParikhNA , KennedyKA , LaskyRE , McDavidGE , TysonJE .Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes. Journal of Pediatrics2013;162(4):685-90. [DOI: 10.1016/j.jpeds.2012.09.054] [PMID: 23140612]">Parikh 2013</a>; <a href="./references#CD001146-bbs2-0054" title="RomagnoliC , VentoG , ZeccaE , TortoroloG , PapacciP , De CarolisM , et al.Dexamethasone for the prevention of chronic lung disease in preterm neonates: a prospective randomized study [II desametazone nella prevenzione della patologia polmonare cronica del neonato pretermine: studio prospettico randomizzato]. Rivista Italiana di Pediatria [Italian Journal of Pediatrics]1997;24:283-8. RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .A three year follow up of preterm infants after moderately early treatment with dexamethasone. Archives of Disease in Childhood. Fetal and Neonatal Edition2002;87(1):F55-8. [DOI: 10.1136/fn.87.1.f55] [PMID: 12091294]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1997</a>; <a href="./references#CD001146-bbs2-0056" title="ScottSM , BackstromC , BessmanS .Effect of five days of dexamethasone therapy on ventilator dependence and adrenocorticotropic hormone-stimulated cortisol concentrations. Journal of Perinatology1997;17(1):24-8. [PMID: 9069060]">Scott 1997</a>; <a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a>; <a href="./references#CD001146-bbs2-0059" title="VincerMJ , AllenAC .Double blind randomized controlled trial of 6-day pulse of dexamethasone for very low birth weight infants (VLBW &lt;1500 grams) who are ventilator dependent at 4 weeks of age. Pediatric Research1998;43:201A. ">Vincer 1998</a>; <a href="./references#CD001146-bbs2-0060" title="WaltherFJ , FindlayRD , DurandM .Adrenal suppression and extubation rate after moderately early low-dose dexamethasone therapy in very preterm infants. Early Human Development2003;74(1):37-45. [DOI: 10.1016/s0378-3782(03)00082-3] [PMID: 14512180]">Walther 2003</a>; <a href="./references#CD001146-bbs2-0062" title="YatesH , ChiocchiaV , LinsellL , OrsiN , JuszczakE , JohnsonK , et al.Very low-dose dexamethasone to facilitate extubation of preterm babies at risk of bronchopulmonary dysplasia: the MINIDEX feasibility RCT. Efficacy and Mechanism Evaluation2019;6:8. [DOI: 10.3310/eme06080] [PMID: 31479218]">Yates 2019</a>). One of the studies listed as excluded had data for two separate cohorts of infants ‐ the first cohort included those 10 days of age when randomised (it is these data that are excluded from this “Early” review), whereas the second cohort included those four days of age when randomised (hence they are included in this “Early” review) (<a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a>). </p> <p>We found no studies that are currently awaiting further assessment.</p> </section> </section> <section id="CD001146-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>The overall risk of bias was low (<a href="#CD001146-fig-0002">Figure 2</a>; <a href="#CD001146-fig-0003">Figure 3</a>). All studies were RCTs, although the method of random allocation is not always clear. Allocation concealment applied to most studies. Blinding of investigators and others was achieved most often through the use of placebo, usually saline solution. Follow‐up reporting for short‐term outcomes most often was complete but was more variable for long‐term outcomes beyond discharge and later into childhood. Most studies reported primary outcomes as specified in their methods. </p> <div class="figure" id="CD001146-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias table." data-id="CD001146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias table.</p> </div> </div> </div> <div class="figure" id="CD001146-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001146-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p><a href="./references#CD001146-bbs2-0001" title="AnttilaE , PeltonemiO , HaumontD , HertingE , ter HorstH , HeinonenK , et al.Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics2005;164(8):472-81. [DOI: 10.1007/s00431-005-1645-8] [PMID: 15864643]">Anttila 2005</a> carried out randomisation in the pharmacy of the coordinating centre using coded vials, with blinding of study investigators. Open‐label dexamethasone was allowed when deemed necessary by the attending neonatologist, but its use was discouraged. Trialists performed intention‐to‐treat analysis and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0002" title="BadenM , BauerCR , ColeE , KleinG , TaeuschHW , SternL .A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics1972;50(4):526-34. [PMID: 4561296]FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Baden 1972</a> performed randomisation by using vials and a table of random numbers. Clinical personnel were not aware of the content of any vial. Study authors reported outcomes for all enrolled infants. Follow‐up consisted of the following: one paediatrician and one psychologist saw survivors at 12 months of age, corrected for prematurity. A neurologist saw all children with abnormal neurological signs. Observers were blinded to treatment group allocation. The follow‐up rate of survivors was 93% (25/27). Study authors did not specify criteria for the diagnosis of cerebral palsy, nor did they provide specific criteria for blindness or deafness (children were tested by free‐field pure‐tone audiometry). Psychological assessment consisted of the Griffiths Scales. Study authors did not report major neurosensory disability (<a href="./references#CD001146-bbs2-0076" title="FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Fitzhardinge 1974</a>). </p> <p><a href="./references#CD001146-bbs2-0003" title="BattonBJ , LiL , NewmanNS , DasA , WatterbergKL , YoderBA , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics2012;161(1):65-9. [DOI: 10.1016/j.jpeds.2012.01.014] [PMID: 22336574]">Batton 2012</a> did not state the method of randomisation used. Trialists administered an identical placebo and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0004" title="BaudO , BiranV , TroussonC , LeroyE , MohamedD , AlbertiC .Two-year outcomes after prophylactic hydrocortisone in extremely preterm neonates. In: European Journal of Pediatrics. Vol. 175. 2016:1507. BaudO , MauryL , LebailF , RamfulD , El MoussawiF , NicaiseC , et al, PREMILOC Trial Study Group.Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet2016;387(10030):1827-36. [DOI: 10.1016/S0140-6736(16)00202-6] [PMID: 26916176]BaudO , TroussonC , BiranV , LeroyE , MohamedD , AlbertiC , PREMILOC Trial Group.Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA2017;317(13):1329-37. [DOI: 10.1001/jama.2017.2692] [PMID: 28384828]">Baud 2016</a> generated the randomisation sequence electronically using nQuery. After enrolment, researchers assigned treatment through a secure study website after verifying eligibility and consent status. They electronically randomised all infants before they reached 24 completed hours after birth and reported short‐term outcomes for all but two participants who were randomised. They followed up on 93% of survivors at 22 months' corrected age, although only 75% were given the full neurodevelopmental assessment battery. Investigators maintained double‐blinding through all aspects of the study. </p> <p><a href="./references#CD001146-bbs2-0005" title="BiswasS , BufferyJ , EnochH , BlandM , MarkiewiczM , WaltersD .Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial - thyroid hormone replacement in neonates. Pediatric Research2003;53(1):48-56. [DOI: 10.1203/00006450-200301000-00011] [PMID: 12508081]BiswasS .Personal communication. email2002. ">Biswas 2003</a> conducted randomisation as performed by the Perinatal Trials Unit in Oxford, with stratification for centre and gender, and the study pharmacist held the code. Controls received an equal infusion rate of 5% dextrose. One pharmacy made the syringes and transported them to individual study centres. Short‐term outcomes were reported for all enrolled infants. Study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0006" title="BonsanteF , LatorreG , LacobelliS , ForziatiV , LaforgiaN , EspositoL , et al.Early low-dose hydrocortisone in very preterm infants: a randomized placebo-controlled trial. Neonatology2007;91(4):217-21. [DOI: 10.1159/000098168] [PMID: 17568152]">Bonsante 2007</a> conducted centralised randomisation using a computer‐generated random number sequence. Researchers stratified infants into six risk groups to ensure a homogeneous number of infants with regard to birth weight, gestation, and antenatal corticosteroid administration. They prepared drugs each day in the pharmacy, and the care team, parents, and personnel collecting data had no knowledge of the random assignment at any time. Study authors reported results of follow‐up at two years of age (follow‐up component) in conjunction with data from another study but did not describe clinical criteria for various outcomes (<a href="./references#CD001146-bbs2-0090" title="PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]">Peltoniemi 2009</a>). Study authors reported follow‐up data for 92% (33/36) of survivors up to hospital discharge. </p> <p><a href="./references#CD001146-bbs2-0007" title="EfirdMM , HeerensAT , GordonPV , BoseCL , YoungDA .A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology2005;25(2):119-24. [DOI: 10.1038/sj.jp.7211193] [PMID: 15329742]">Efird 2005</a> performed randomisation by opening sequentially numbered, opaque envelopes containing pre‐assigned treatment designations. Investigators randomised infants of multiple gestations as separate participants and blinded clinicians to treatment identity. If hypotension persisted, the randomisation assignment could be unblinded and hydrocortisone administered if the infant had been assigned to the placebo group. Study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0008" title="GarlandJS , AlexCP , PaulyTH , WhiteheadVL , BrandJ , WinstonJF , et al.A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics1999;104(1 Pt 1):91-9. [DOI: 10.1542/peds.104.1.91] [PMID: 10390266]">Garland 1999</a> randomised infants at each centre within each of four strata on the basis of birth weight (≤ 1000 grams, &gt; 1000 grams) and a/A ratio before surfactant (≤ 0.15, &gt; 0.15). Study pharmacists at each centre maintained randomisation codes. Investigators, caregivers, and parents were blinded to treatment allocation. The first interim analysis (n = 75) showed increased risk of gastrointestinal perforation in the dexamethasone group. After adjustment for severity of illness, the difference was not sufficiently statistically significant to stop enrolment. However, to ensure participant safety, the Data Monitoring Committee recommended that the dexamethasone dose should be reduced. Investigators changed the dosing schedule to four doses of 0.25 mg/kg/dose every 12 hours, begun at 24 to 48 hours, followed by doses of 0.125 mg/kg and 0.05 mg/kg at the next two 12‐hour periods, respectively. After the first interim analysis, all enrolled infants received ranitidine therapy during the first three days of the study. It appears that study authors reported outcome measures for all 241 infants enrolled in the study and included no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0009" title="HalacE , HalacJ , BegueEF , CasañasJM , IndiveriDR , PetitJF , et al.Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics1990;117(1 Pt 1):132-8. [DOI: 10.1016/s0022-3476(05)72461-6] [PMID: 2196355]">Halac 1990</a> used a table of random numbers for randomisation, along with placebo blinding. Study authors stated that they had excluded from the study deaths before 10 days of age; they reported a total of five early deaths from sepsis, but it was not clear how often this occurred in each group. Apart from these infants, investigators provided outcome data for all remaining enrolled infants. They reported limited follow‐up to six months of age but provided no follow‐up results (apart from a statement that "growth and development were not hampered in any of these patients"). </p> <p><a href="./references#CD001146-bbs2-0010" title="HochwaldO , PalegraG , OsiovichO .Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian Journal of Pediatrics2014;81(8):808-10. [DOI: 10.1007/s12098-013-1151-3] [PMID: 23904065]">Hochwald 2014</a> did not state methods used for random sequence generation, allocation concealment, blinding of personnel and families, and blinding of outcomes, apart from use of a placebo, and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0011" title="KopelmanAE , MoiseAA , HolbertD , HegemierSE .A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics1999;135(3):345-50. [DOI: 10.1016/s0022-3476(99)70132-0] [PMID: 10484801]">Kopelman 1999</a> performed randomisation in the pharmacy after stratifying infants for treatment with antenatal corticosteroids. The blinded clinical team provided care. Study authors provided outcome data for all enrolled infants and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0012" title="LauterbachR , Szymura-OleksiakJ , PawlikD , WarcholJ , Lisowska-MiszczykI , RytlewskiK .Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. Journal of Maternal-Fetal &amp; Neonatal Medicine2006;19(7):433-8. [DOI: 10.1080/14767050600736754] [PMID: 16923699]">Lauterbach 2006</a> used a computer‐generated random number table for randomisation. Investigators allocated infants to groups by opening numbered containers on the fourth day of life. They provided no placebo for the dexamethasone arm and hence reported no blinding of dexamethasone treatment. Study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0013" title="LinYJ , YehTF , HsiehWS , ChiYC , LinHC , LinCH .Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology1999;27(1):21-6. [DOI: 10.1002/(sici)1099-0496(199901)27:1&lt;21::aid-ppul5&gt;3.0.co;2-y] [PMID: 10023787]">Lin 1999</a> performed randomisation by opening sealed envelopes in the pharmacy. This study used a sequential analysis design and paired 12 infants successfully. Study authors reported outcome measures for all 40 enrolled infants, including those who remained unpaired. They described no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0014" title="MukhopadhyayK , KumarP , NarangA .Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics1998;35(2):117-22. [PMID: 9707853]">Mukhopadhyay 1998</a> did not state the method of randomisation used. Investigators were able to provide ventilation for only 28 of 43 eligible infants and subsequently excluded eight infants owing to non‐availability of blood gases due to a technical fault, and excluded one baby because of congenital heart block. This left 19 infants included in the study: 10 received intravenous dexamethasone, and nine received no drug treatment. Study authors did not mention placebo. They reported outcome measures for these 19 infants and described no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0015" title="NgPC , LeeCH , BnurFL , ChanIH , LeeAW , WongE , et al.A double-blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics2006;117(2):367-75. [DOI: 10.1542/peds.2005-0869] [PMID: 16452355]">Ng 2006</a> performed randomisation by using computer‐generated random numbers and by opening sequentially numbered, sealed, opaque envelopes in the pharmacy. They assigned infants in blocks of six, and once an envelope was opened, an infant would be irrevocably entered into the trial. To ensure effective blinding of medications, both types of trial drug were colourless and odourless and were filled to the same volume before they were sent to the ward. Study authors reported no follow‐up component. </p> <p>In the <a href="./references#CD001146-bbs2-0016" title="PeltoniemiO , KariA , HeinonenK , SaarelaT , NikolajevK , AnderssonS , et al.Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics2005;146(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040] [PMID: 15870666]PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2005</a> study, non‐clinical staff achieved randomisation centrally, independent of the chief investigators, using random variation in block sizes of two to eight, separately for each centre. Study authors did not specify the method used for randomisation. Researchers had syringes prepared and labelled identically in the pharmacy department of the centre, thereby concealing allocation from study site investigators and caregivers of the infant. Open‐label corticosteroids were discouraged after randomisation but were not prohibited; some infants may have received both a second course of their initially allocated study drug and open‐label corticosteroids. No one apart from the pharmacist at study sites had access to the treatment codes. Study authors reported short‐term outcomes for all enrolled infants. Follow‐up consisted of the following: investigators assessed surviving children at 24 months of age, corrected for prematurity, and at five to seven years of age, when it was not stated that age was corrected for prematurity. Paediatricians, paediatric neurologists, speech therapists, and psychologists at individual study sites were blinded to treatment group allocation. At two years, children were considered to have a major neurosensory impairment if they had cerebral palsy, blindness (inability to see any objects, with the exception of light), deafness (failure to pass an evoked otoacoustic emission test during the neonatal period and no response in brainstem auditory evoked potentials), or developmental delay (defined as a Mental Developmental Index (MDI) on the Bayley Scales of Infant Development &lt; 70 (&lt; ‐2 standard deviations (SDs)) or a developmental quotient &lt; 70 on the Griffiths Cognitive Scales). Researchers assessed cognitive development of children at five to seven years of age by using the Wechsler Presechool and Primary Scale of Intelligence ‐ Revised (WPPSI‐R). They diagnosed minor neurological dysfunction on the basis of the number of dysfunctional domains. Speech assessment included the Reynell Developmental Language Scale III (RDLS III). Study authors did not provide the criteria for blindness or deafness and reported the follow‐up rate of survivors at two years (98%; 45/46) and at five to seven years of age (80%; 37/46) (<a href="./references#CD001146-bbs2-0090" title="PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]">Peltoniemi 2009</a>; <a href="./references#CD001146-bbs2-0091" title="PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2016</a>). </p> <p><a href="./references#CD001146-bbs2-0017" title="MoralesP , RastogiA , BezML , AkintorinSM , PyatiS , AndesSM , et al.Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology1998;19(3):225-9. [DOI: 10.1007/s002469900290] [PMID: 9568218]RastogiA , AkintorinSM , BezML , MoralesP , PildesPS .A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics1996;98(2 Pt 1):204-10. [PMID: 8692619]">Rastogi 1996</a> performed randomisation in the pharmacy, using a random number list after stratifying infants for birth weight into three groups: 700 grams to 999 grams, 1000 grams to 1249 grams, and 1250 grams to 1500 grams. The clinical team and other study personnel were blinded to assignments until the study was completed, and they recorded all outcome variables for all infants. Study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0018" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [PMID: 12042579]RomagnoliC , ZeccaE , VentoG , De CarolisMP , PapacciP , TortoroloG .Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine1999;25(7):717-21. [DOI: 10.1007/s001340050935] [PMID: 10470576]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1999</a> achieved randomisation through random number allocation by opening numbered, sealed envelopes. Trialists excluded infants with prenatal infections, congenital malformations, and evidence of sepsis at randomisation. They did not mention placebo and reported outcome measures for all 50 enrolled infants. Follow‐up consisted of the following: one paediatrician and one neurologist saw survivors at 34 to 42 months of age, corrected for prematurity, and observers were blinded to treatment group allocation. The follow‐up rate of survivors was 100% (45/45). The neurologist diagnosed cerebral palsy, but study authors did not specify the criteria used for this, nor for the diagnosis of blindness or deafness. Psychological assessment included the Stanford‐Binet 3rd Revision, and intellectual impairment comprised an intelligence quotient (IQ) &lt; 70. Major neurosensory impairment consisted of either blindness or deafness (<a href="./references#CD001146-bbs2-0093" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [DOI: 10.1542/peds.109.6.e85] [PMID: 12042579]">Romagnoli 2002</a>). </p> <p><a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a> randomised participants in the pharmacy after opening sealed envelopes. Dexamethasone or placebo was dispensed via labelled syringes. Clinical personnel were not aware of assignment of the intervention. Study authors reported outcomes for all 40 enrolled infants. Follow‐up consisted of the following: a paediatrician, a neurologist, and a psychologist saw survivors at mean ages of 64 (SD 8) months (dexamethasone) and 61 (SD 4) months (controls), not corrected for prematurity, with observers blinded to treatment group allocation. Researchers sought additional data from parents and teachers. The follow‐up rate of survivors was 100% (31/31). The criterion for the diagnosis of cerebral palsy was a fixed motor deficit diagnosed by the neurologist. Blindness comprised visual acuity &lt; 6/60 in the better eye, and study authors defined deafness as the need for a hearing aid. Psychological assessment was based on the Wechsler Scales (Wechsler Intelligence Scale for Children (WISC) and WPPSI‐R) ‐ intellectual impairment comprised a full‐scale IQ &lt; 70. Study authors did not specify major neurosensory disability and planned further follow‐up at 15 years of age (Sinkin 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a>)). </p> <p><a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a> supplied each participating unit with numbered sets of syringes containing dexamethasone or physiological saline. Syringes containing dexamethasone were not distinguishable from those containing saline. Syringe sets were numbered according to a random number list and stratified randomisation by centre and by two birth weight groups: 500 grams to 1000 grams, and 1001 grams to 2000 grams. No investigators knew the drug assignment until after the three‐month observation period of the last enrolled infant. Study authors reported outcomes for 248 of 255 enrolled infants. The seven infants subsequently excluded from analysis included three with major congenital abnormalities (two with myotonic dystrophy and one with cyanotic congenital heart disease), three with errors in drug administration, and one randomised after the age of 12 hours. Follow‐up consisted of the following: survivors were seen at a mean age of 53 (SD 18; range 24 to 71) months, presumably not corrected for prematurity. Multiple paediatricians saw these children at multiple follow‐up clinics, with observers blinded to treatment group allocation. The follow‐up rate of survivors was 83% (159/190). Trialists did not specify criteria for the diagnosis of cerebral palsy, but neurologists made the diagnosis in all cases. Study authors did not specify criteria for blindness but defined deafness as the need for hearing aids. Study personnel performed no formal psychological assessments, and multiple assessors assigned the judgement of developmental delay. Major neurosensory disability comprised any of non‐ambulant cerebral palsy, global retardation (not specified), blindness, or deafness. Researchers planned further follow‐up at school age (<a href="./references#CD001146-bbs2-0102" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]">Shinwell 2002</a>). </p> <p><a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a> performed randomisation with stratification by centre, using a set of sealed envelopes in the pharmacy. It appears that study authors provided outcome data for all enrolled infants. Follow‐up consisted of the following (Sinkin 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a>)): researchers obtained data from one of the four original centres in the study, from follow‐up clinic appointments, and from questionnaires completed by parents and paediatricians. A paediatrician, a neurologist, and a psychologist saw survivors at approximately 12 months of age, corrected for prematurity, with observers blinded to treatment group allocation. The follow‐up rate of survivors was 13% (41/311) at 36 weeks' postmenstrual age overall but was confined to one of four individual study centres, within which the follow‐up rate was 100% (41/41). The criterion for the diagnosis of cerebral palsy was a fixed motor deficit diagnosed by the neurologist. Blindness comprised visual acuity &lt; 6/60 in the better eye, and study authors defined deafness as the need for a hearing aid. Psychological assessment included the Bayley Scales of Infant Development. Investigators did not specify major neurosensory disability. </p> <p><a href="./references#CD001146-bbs2-0022" title="SollRF , Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research1999;45:226A. Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics2001;108(3):741-8. [DOI: 10.1542/peds.108.3.741] [PMID: 11533345]">Soll 1999</a> performed randomisation in hospital pharmacies after opening opaque, sealed envelopes supplied by the Vermont Oxford Neonatal Network. The study was stopped before sample size goals were met owing to concern regarding adverse effects in the early corticosteroid therapy group. It appears that outcome measures were reported for most of the 542 enrolled infants. Study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0023" title="StarkAR , CarloWA , TysonJE , PapileLA , WrightLL , ShankaranS , et al, National Institute of Child Health and Human Development Neonatal Research Network.Adverse effects of early dexamethasone in extremely-low-birth-weight infants. New England Journal of Medicine2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203] [PMID: 11150359]StarkAR , CarloWA , VohrBR , PapileL , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2001</a> performed random allocation in hospital pharmacies using a random number scheme. This study used a factorial design, so that infants were also randomised to routine ventilator management or to a strategy of minimal ventilator support aimed at reducing mechanical lung injury. After 220 infants were enrolled from a sample estimated to include 1200, the trial was halted. It appears that study authors have reported outcome measures for all 220 participants enrolled in the trial. Follow‐up consisted of the following: trained developmental observers blinded to treatment group allocation saw survivors at 18 to 22 months of age, corrected for prematurity. The follow‐up rate of survivors was 88% (144/164). Criteria for the diagnosis of cerebral palsy included non‐progressive abnormalities of tone in at least one limb and abnormal control of movement and posture. Study authors defined blindness as no useful vision in either eye, and deafness as disability with bilateral hearing amplification. Psychological assessment included the MDI and the Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development‐II (<a href="./references#CD001146-bbs2-0066" title="Bayley, N.Bayley Scales of Infant Development. 2nd edition. San Antonio: The Psychological Corporation, 1993.">Bayley 1993</a>). Major neurosensory disability comprised any of moderate or severe cerebral palsy (sitting independently with support or worse), blindness, deafness, or an MDI or PDI &lt; ‐2 SD (<a href="./references#CD001146-bbs2-0104" title="StarkAR , CarloWA , VohrBR , PapileLA , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2014</a>). </p> <p><a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a> performed block randomisation by using computer‐generated random numbers and sealed envelopes. Researchers used no placebo and provided no evidence of blinding of clinicians. Study authors reported outcome measures for all enrolled infants. Follow‐up consisted of the following (Subhedar 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a>)): one developmental paediatrician who was blinded to treatment group allocation saw survivors at 30 months of age, corrected for prematurity. The follow‐up rate of survivors was 95% (21/22). Study authors specified criteria for the diagnosis of cerebral palsy but not for deafness; an ophthalmologist diagnosed blindness. Psychological assessment included the MDI and the PDI of the Bayley Scales of Infant Development. Major neurosensory disability comprised any of cerebral palsy, MDI or PDI &lt; 71, blindness, or deafness. </p> <p><a href="./references#CD001146-bbs2-0025" title="SuskeG , OestreichK , VarnholtV , LaschP , KachelW .Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica1996;85(6):713-8. [DOI: 10.1111/j.1651-2227.1996.tb14132.x] [PMID: 8816210]">Suske 1996</a> performed randomisation by drawing lots; lot numbers corresponded to numbers on non‐transparent envelopes. A neutral, uninvolved person drew random lots and envelopes. This was considered a pilot trial conducted before a multi‐centre study was begun, and researchers planned that the trial would be stopped if they found a statistically significant difference between groups. A total of 41 infants met the inclusion criteria. Owing to lack of co‐operation and co‐ordination at the beginning of the study, investigators did not randomise nine infants. They excluded four infants after randomisation because they showed definitive signs of septicaemia. Study authors reported results for 26 of the 28 remaining infants and described no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0026" title="TapiaJL , RamirezR , CifuentesJ , FabresJ , HubnerME , BancalariA , et al.The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics1998;132(1):48-52. [DOI: 10.1016/s0022-3476(98)70483-4] [PMID: 9469999]">Tapia 1998</a> achieved random assignment at each centre using ampoules of dexamethasone and saline prepared in the hospital pharmacy at one of the centres. Researchers reported outcomes for 109 of 113 enrolled infants. They excluded two infants from the dexamethasone group ‐ one because of congenital cystic adenomatoid malformation, and the other because of early sepsis. Investigators also excluded two patients from the placebo group ‐ one because of early sepsis, and the other because of transfer to another hospital at two weeks of age. Study authors did not provide further data on outcomes and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a> did not state the method of randomisation used. Whether clinicians caring for infants were blinded to treatment allocation remains unclear. Control infants did not receive a placebo, and study authors reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0028" title="WangJY , YehTF , LinYC , MiyamuraK , HolmskovU , ReidKB .Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax1996;51(9):907-13. [DOI: 10.1136/thx.51.9.907] [PMID: 8984701]WangJY , YehTF , LinYJ , ChenWY , LinCH .Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatric Pulmonology1997;23(3):193-7. [DOI: 10.1002/(sici)1099-0496(199703)23:3&lt;193::aid-ppul4&gt;3.0.co;2-p] [PMID: 9094727]">Wang 1996</a> reported that random allocation was double‐blind but did not describe the exact method used. Study authors reported outcome measures for all 63 infants enrolled in the study and reported no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a> randomised Infants at each centre by using a constant block design with four participants per block to minimise imbalance over time. Investigators used separate randomisation tables for infants exposed to antenatal corticosteroids. Hospital pharmacies prepared hydrocortisone doses and the placebo of normal saline. Study authors reported outcome measures for all of the 40 infants enrolled in the trial. Follow‐up consisted of the following (Watterberg 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>)): a neonatologist and a physiotherapist saw survivors at a regular follow‐up clinic for one of the two study sites at a mean age of 11 (SD 2) months, corrected for prematurity, with observers blinded to treatment group allocation. The follow‐up rate of survivors was 53% (18/34) for the study overall, but 86% (18/21) for the study centre with follow‐up data. Researchers specified criteria for the diagnosis of cerebral palsy, which comprised abnormal tone and movement. An ophthalmologist diagnosed blindness, and investigators screened participants for deafness in early infancy and at follow‐up. They performed no formal psychological testing and did not define major neurosensory disability. </p> <p><a href="./references#CD001146-bbs2-0030" title="WatterbergKL , GerdesJS , ColeCH , AucottSW , ThiloEH , MammelMC , et al.Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics2004;114(6):1649-57. [DOI: 10.1542/peds.2004-1159] [PMID: 15574629]WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2004</a> performed randomisation centrally, stratifying infants for birth weight (500 grams to 749 grams, and 750 grams to 999 grams) and by centre, using permuted block sizes of six within each stratum. Only pharmacists at individual sites who prepared the drug were aware of group assignment. All other personnel were masked. Twins were randomised together to the same study arm. Researchers reported mortality for all enrolled infants but described other short‐term outcomes for all but three infants who were withdrawn from the study. Follow‐up consisted of the following: assessors at individual study sites who were blinded to treatment group allocation assessed surviving children at 18 to 22 months of age, corrected for prematurity. They considered children to have a neurodevelopmental (neurosensory) impairment if they had cerebral palsy (criteria included abnormalities of tone, movement, and posture), functional blindness (inability to complete the Bayley Scales of Infant Development ‐ Second Edition (BSID‐II) because of visual impairment), functional deafness (inability to complete BSID‐II because of hearing impairment), developmental delay (defined as MDI on the BSID‐II &lt; 70 (&lt; ‐2 SD)), or motor delay (defined as a PDI on the BSID‐II &lt; 70 (&lt; ‐2 SD)) (<a href="./references#CD001146-bbs2-0066" title="Bayley, N.Bayley Scales of Infant Development. 2nd edition. San Antonio: The Psychological Corporation, 1993.">Bayley 1993</a>). The follow‐up rate of survivors at 18 to 22 months was 86% (252/294), or 87% (252/291) when three children whose families had withdrawn consent were excluded (<a href="./references#CD001146-bbs2-0108" title="WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and developmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2007</a>). </p> <p><a href="./references#CD001146-bbs2-0031" title="YehTF , TorreJA , RastogiA , AnyebunoMA , PildesRS .Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. Journal of Pediatrics1990;117(2 Pt 1):273-82. [DOI: 10.1016/s0022-3476(05)80547-5] [PMID: 2199642]">Yeh 1990</a> performed randomisation in the pharmacy using balanced blocks of 10. Personnel working in the pharmacy labelled vials, and clinical staff were unaware of assignment. Trialists included 60 infants in the study and subsequently withdrew three: one because of death from <i>Haemophilus influenzae</i> septicaemia six hours after enrolment, and two because of an error in measurement of birth weight (581 grams and 2200 grams). Study authors did not report outcomes for these three infants and described no follow‐up component. </p> <p><a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a> completed randomisation in the central pharmacy using an assignment list. Investigators calculated sample size on the basis of an expected 50% reduction in the incidence of BPD with early dexamethasone, allowing a 5% chance of a type I error, and a 10% chance of a type II error. Study authors reported short‐term outcome data for all 262 enrolled infants and described the study as double‐blind. Follow‐up consisted of the following: in 1998, researchers reported that one neurologist and one psychologist saw survivors at a mean age of 25 months, corrected for prematurity, with observers blinded to treatment group allocation (<a href="./references#CD001146-bbs2-0111" title="YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]">Yeh 1998</a>). The follow‐up rate of survivors was 81% (133/164). Study authors did not specify criteria for the diagnosis of cerebral palsy, blindness, or deafness. Psychological assessment included the MDI and the PDI of the Bayley Scales of Infant Development. Major neurosensory disability comprised severe motor dysfunction (child non‐ambulant) or MDI or PDI &lt; ‐2 SD. In 2004, investigators in the Yeh trial reported that trial personnel re‐assessed survivors at seven to nine years of age (<a href="./references#CD001146-bbs2-0112" title="YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 2004</a>). The follow‐up rate of survivors was 92% (146/159). Assessors were blind to treatment allocation. A paediatric neurologist evaluated children for cerebral palsy, assessing motor skills using the Movement ABC, and IQ using the WISC‐III. Trial personnel formally evaluated vision and hearing. Major neurological disability comprised any of cerebral palsy, vision worse than 20/60, deafness requiring hearing aids, or an IQ &lt; 5th centile. Whether age was corrected for prematurity remained unclear. We used data for cerebral palsy at eight years in the meta‐analysis, as the diagnosis of cerebral palsy is more certain at eight years than at two years of age, and because the follow‐up rate was higher when participants were eight years of age. Trialists measured blood pressure, height, weight, and head circumference at eight years of age but did not report these as standardised scores (SD or Z‐scores), to enable pooling of data for meta‐analysis. </p> <section id="CD001146-sec-0045"> <h4 class="title">Allocation</h4> <p>We found little evidence of allocation bias overall; most studies had no evidence of allocation bias, and in a small minority the risk was unclear. </p> </section> <section id="CD001146-sec-0046"> <h4 class="title">Blinding</h4> <p>We found little evidence of blinding bias overall; most studies had no evidence of blinding bias, but small minorities had unclear or high risk of blinding bias. </p> </section> <section id="CD001146-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>We found little evidence of attrition bias overall; most studies had no evidence of attrition bias, and a small minority had unclear risk. </p> </section> <section id="CD001146-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Just over one‐half of studies had no evidence of selective reporting bias; the remainder had unclear risk of selective reporting bias. </p> </section> <section id="CD001146-sec-0049"> <h4 class="title">Other potential sources of bias</h4> <p>A majority of studies used a valid method of random sequence generation, but in approximately 40% of studies, the methods used for randomisation were unclear. </p> </section> </section> <section id="CD001146-sec-0050"> <h3 class="title" id="CD001146-sec-0050">Effects of interventions</h3> <p>See: <a href="./full#CD001146-tbl-0001"><b>Summary of findings 1</b> Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</a> </p> <section id="CD001146-sec-0051"> <h4 class="title">Results of meta‐analysis</h4> <p>Meta‐analysis of these 32 studies of early postnatal corticosteroid treatment yielded the following results. </p> <section id="CD001146-sec-0052"> <h5 class="title">Mortality</h5> <p>No evidence suggests that early postnatal corticosteroid treatment reduced mortality at 28 days of life (typical risk ratio (RR) 1.01, 95% confidence interval (CI) 0.87 to 1.18; typical risk difference (RD) 0.00, 95% CI ‐0.03 to 0.03; 20 studies, 2933 infants; <a href="./references#CD001146-fig-0010" title="">Analysis 1.1</a>), at 36 weeks' postmenstrual age (typical RR 1.01, 95% CI 0.90 to 1.13; typical RD 0.00, 95% CI ‐0.02 to 0.03; 27 studies, 4176 infants; <a href="./references#CD001146-fig-0011" title="">Analysis 1.2</a>), before discharge (typical RR 0.96, 95% CI 0.85 to 1.07; typical RD ‐0.01, 95% CI ‐0.03, 0.01; 29 studies, 4164 infants; <a href="./references#CD001146-fig-0012" title="">Analysis 1.3</a>), or at the latest age possible to determine the outcome (typical RR 0.95, 95% CI 0.85 to 1.06; typical RD ‐0.01, 95% CI ‐0.04 to 0.01; 31 studies, 4373 infants; <a href="./references#CD001146-fig-0013" title="">Analysis 1.4</a>). We found little evidence of publication bias for mortality at the latest age overall (Egger test, P = 0.20), or for studies examining treatment with dexamethasone (Egger test, P = 0.37) or hydrocortisone (Egger test, P = 0.40) separately (<a href="#CD001146-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001146-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Mortality, outcome: 1.4 Mortality at latest reported age." data-id="CD001146-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mortality, outcome: 1.4 Mortality at latest reported age. </p> </div> </div> </div> </section> <section id="CD001146-sec-0053"> <h5 class="title">Bronchopulmonary dysplasia</h5> <p>Early systemic corticosteroids reduced the incidence of BPD, defined as needing oxygen supplementation at 28 days of life (typical RR 0.86, 95% CI 0.80 to 0.93; typical RD ‐0.07, 95% CI ‐0.11 to ‐0.04; 15 studies, 2580 infants; <a href="./references#CD001146-fig-0014" title="">Analysis 2.1</a>), and at 36 weeks' postmenstrual age (typical RR 0.80, 95% CI 0.73 to 0.88; typical RD ‐0.06, 95% CI ‐0.09 to ‐0.03; 26 studies, 4167 infants; <a href="./references#CD001146-fig-0015" title="">Analysis 2.2</a>). We found some evidence of publication bias for BPD at 36 weeks' postmenstrual age overall (Egger test, P = 0.046) but little evidence of publication bias in either subgroup (Egger test: dexamethasone, P = 0.10; hydrocortisone, P = 0.47; <a href="#CD001146-fig-0005">Figure 5</a>). There was a reduction in BPD at 36 weeks' postmenstrual age among survivors (typical RR 0.79, 95% CI 0.72 to 0.87; typical RD ‐0.08, 95% CI ‐0.11 to ‐0.05; 24 studies, 3093 infants; <a href="./references#CD001146-fig-0016" title="">Analysis 2.3</a>). Early systemic corticosteroids reduced the need for later corticosteroid treatment overall (typical RR 0.79, 95% CI 0.73 to 0.86; typical RD ‐0.10, 95% CI ‐0.13 to ‐0.07; 15 studies, 3004 infants; <a href="./references#CD001146-fig-0017" title="">Analysis 2.4</a>), and among survivors (typical RR 0.77, 95% CI 0.67 to 0.89; typical RD ‐0.11, 95% CI ‐0.17 to ‐0.05; 7 studies, 895 infants; <a href="./references#CD001146-fig-0018" title="">Analysis 2.5</a>). Results of analysis show no significant reduction in the proportion of survivors discharged home on oxygen, although fewer studies were able to determine this outcome (typical RR 0.86, 95% CI 0.70 to 1.07; 9 studies, 1442 infants; <a href="./references#CD001146-fig-0019" title="">Analysis 2.6</a>). </p> <div class="figure" id="CD001146-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 Bronchopulmonary dysplasia (BPD), outcome: 2.2 BPD (36 weeks' postmenstrual age)." data-id="CD001146-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Bronchopulmonary dysplasia (BPD), outcome: 2.2 BPD (36 weeks' postmenstrual age). </p> </div> </div> </div> </section> <section id="CD001146-sec-0054"> <h5 class="title">Mortality or bronchopulmonary dysplasia</h5> <p>Early systemic corticosteroids reduced the incidence of mortality or BPD, defined as needing oxygen supplementation at 28 days of life (typical RR 0.92, 95% CI 0.87 to 0.96; typical RD ‐0.06, 95% CI ‐0.09 to ‐0.03; 14 studies, 2471 infants; <a href="./references#CD001146-fig-0020" title="">Analysis 3.1</a>), or at 36 weeks' postmenstrual age (typical RR 0.89, 95% CI 0.83 to 0.94; typical RD ‐0.06, 95% CI ‐0.09 to ‐0.03; 26 studies, 4167 infants; <a href="./references#CD001146-fig-0021" title="">Analysis 3.2</a>). We found little evidence of publication bias for mortality or BPD at 36 weeks overall (Egger test, P = 0.11), or for studies involving either dexamethasone (Egger test, P = 0.15) or hydrocortisone (Egger test, P = 0.41; <a href="#CD001146-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD001146-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 3 Death or bronchopulmonary dysplasia (BPD), outcome: 3.2 Death or BPD at 36 weeks' postmenstrual age." data-id="CD001146-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Death or bronchopulmonary dysplasia (BPD), outcome: 3.2 Death or BPD at 36 weeks' postmenstrual age. </p> </div> </div> </div> </section> <section id="CD001146-sec-0055"> <h5 class="title">Failure to extubate</h5> <p>Early systemic corticosteroids reduced rates of failure to extubate at three days (typical RR 0.85, 95% CI 0.75 to 0.95; typical RD ‐0.09, 95% CI ‐0.16 to ‐0.03; 4 studies, 887 infants; <a href="./references#CD001146-fig-0022" title="">Analysis 4.1</a>), seven days (typical RR 0.76, 95% CI 0.68 to 0.85; typical RD ‐0.12, 95% CI ‐ 0.17 to ‐0.07; 8 studies, 1448 infants; <a href="./references#CD001146-fig-0023" title="">Analysis 4.2</a>), 14 days (typical RR 0.77, 95% CI 0.62 to 0.97; typical RD ‐0.10, 95% CI ‐0.19 to ‐0.02; 4 studies, 443 infants; <a href="./references#CD001146-fig-0024" title="">Analysis 4.3</a>), and 28 days of life (typical RR 0.84, 95% CI 0.72 to 0.98; typical RD ‐0.07, 95% CI ‐0.13 to ‐0.01; 7 studies, 902 infants; <a href="./references#CD001146-fig-0025" title="">Analysis 4.4</a>). </p> </section> <section id="CD001146-sec-0056"> <h5 class="title">Complications during primary hospitalisation</h5> <section id="CD001146-sec-0057"> <h6 class="title">Metabolic complications</h6> <p>Early systemic corticosteroids increased risks of hyperglycaemia (typical RR 1.26, 95% CI 1.15 to 1.37; typical RD 0.09, 95% CI 0.05 to 0.12; 14 studies, 2688 infants; <a href="./references#CD001146-fig-0027" title="">Analysis 5.2</a>) and hypertension (typical RR 1.85, 95% CI 1.54 to 2.22; typical RD 0.10, 95% CI 0.07 to 0.13; 11 studies, 1993 infants; <a href="./references#CD001146-fig-0028" title="">Analysis 5.3</a>). </p> </section> <section id="CD001146-sec-0058"> <h6 class="title">Gastrointestinal complications</h6> <p>Early systemic corticosteroids increased risks of gastrointestinal bleeding (typical RR 1.86, 95% CI 1.35 to 2.55; typical RD 0.05, 95% CI 0.03 to 0.08; 12 studies, 1816 infants; <a href="./references#CD001146-fig-0039" title="">Analysis 5.14</a>) and gastrointestinal perforation (typical RR 1.84, 95% CI 1.36 to 2.49; typical RD 0.03, 95% CI 0.02 to 0.05; 16 studies, 3040 infants; <a href="./references#CD001146-fig-0040" title="">Analysis 5.15</a>), but we found no evidence of an effect on the incidence of necrotising enterocolitis (typical RR 0.90, 95% CI 0.74 to 1.11; 25 studies, 4050 infants; <a href="./references#CD001146-fig-0038" title="">Analysis 5.13</a>). We found little evidence of publication bias on a funnel plot for the outcome of gastrointestinal perforation (<a href="#CD001146-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD001146-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 Complications during primary hospitalisation, outcome: 5.15 Gastrointestinal perforation." data-id="CD001146-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Complications during primary hospitalisation, outcome: 5.15 Gastrointestinal perforation. </p> </div> </div> </div> </section> <section id="CD001146-sec-0059"> <h6 class="title">Other effects</h6> <p>Early systemic corticosteroids increased risks of hypertrophic cardiomyopathy (RR 4.33, 95% CI 1.40 to 13.4; RD 0.40, 95% CI 0.17 to 0.63; 1 study, 50 infants; <a href="./references#CD001146-fig-0029" title="">Analysis 5.4</a>) and growth failure (RR 6.67, 95% CI 2.27 to 19.6; RD 0.68, 95% CI 0.48 to 0.88; 1 study, 50 infants; <a href="./references#CD001146-fig-0030" title="">Analysis 5.5</a>) in the only study in which these were reported. Early systemic corticosteroids reduced the risk of patent ductus arteriosus (typical RR 0.78, 95% CI 0.72 to 0.85; typical RD ‐0.09, 95% CI ‐0.12 to ‐0.06; 24 studies, 4013 infants; <a href="./references#CD001146-fig-0032" title="">Analysis 5.7</a>). Results show no significant effects on infection (typical RR 1.05, 95% CI 0.96 to 1.15; 25 studies, 4101 infants; <a href="./references#CD001146-fig-0026" title="">Analysis 5.1</a>), pulmonary air leaks (typical RR 0.90, 95% CI 0.73 to 1.11; 17 studies, 3276 infants; <a href="./references#CD001146-fig-0031" title="">Analysis 5.6</a>), severe intraventricular haemorrhage (typical RR 0.97, 95% CI 0.84 to 1.12; 26 studies, 4103 infants; <a href="./references#CD001146-fig-0033" title="">Analysis 5.8</a>), periventricular leukomalacia (typical RR 1.12, 95% CI 0.83 to 1.53; 15 studies, 2807 infants; <a href="./references#CD001146-fig-0035" title="">Analysis 5.10</a>), or pulmonary haemorrhage (typical RR 1.16, 95% CI 0.87 to 1.54; 10 studies, 1820 infants; <a href="./references#CD001146-fig-0041" title="">Analysis 5.16</a>). Early systemic corticosteroids reduced any retinopathy of prematurity (typical RR 0.88, 95% CI 0.80 to 0.97; 9 studies, 1345 infants; <a href="./references#CD001146-fig-0042" title="">Analysis 5.17</a>) and both severe retinopathy of prematurity (typical RR 0.81, 95% CI 0.67 to 0.99; RD ‐0.03, 95% CI ‐0.05 to ‐0.00; 14 studies, 2577 infants; <a href="./references#CD001146-fig-0043" title="">Analysis 5.18</a>) and severe retinopathy of prematurity among survivors (typical RR 0.77, 95% CI 0.64 to 0.94; RD ‐0.05, 95% CI ‐0.09 to ‐0.01; 12 studies, 1575 infants; <a href="./references#CD001146-fig-0044" title="">Analysis 5.19</a>). </p> </section> </section> </section> <section id="CD001146-sec-0060"> <h4 class="title">Follow‐up data</h4> <p>Follow‐up studies are few compared with the total number of studies: of 32 studies, 13 provided some follow‐up data. </p> <section id="CD001146-sec-0061"> <h5 class="title">Developmental delay</h5> <p>No evidence suggests that corticosteroids increased developmental delay in three studies that assessed development on the Bayley Scales of Infant Development and defined developmental delay as either MDI or PDI more than two SD below the mean (<a href="./references#CD001146-fig-0045" title="">Analysis 6.1</a>; <a href="./references#CD001146-fig-0046" title="">Analysis 6.2</a>; <a href="./references#CD001146-fig-0047" title="">Analysis 6.3</a>; <a href="./references#CD001146-fig-0048" title="">Analysis 6.4</a>), nor in two studies that defined developmental delay by other criteria (<a href="./references#CD001146-fig-0049" title="">Analysis 6.5</a>). </p> </section> <section id="CD001146-sec-0062"> <h5 class="title">Cerebral palsy</h5> <p>Evidence indicates that early systemic corticosteroids increased cerebral palsy (typical RR 1.43, 95% CI 1.07 to 1.92; typical RD 0.02, 95% CI 0.00 to 0.05; 13 studies, 1973 infants; <a href="./references#CD001146-fig-0055" title="">Analysis 6.11</a>), but results show little difference in the combined outcome, mortality or cerebral palsy (typical RR 1.03, 95% CI 0.91 to 1.16; 13 studies, 1973 infants; <a href="./references#CD001146-fig-0057" title="">Analysis 6.13</a>). We noted little evidence of publication bias for the outcome of cerebral palsy (Egger test, P = 0.82; <a href="#CD001146-fig-0008">Figure 8</a>) or for the combined outcome, mortality or cerebral palsy (Egger test, P = 0.67; <a href="#CD001146-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD001146-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.11 Cerebral palsy." data-id="CD001146-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.11 Cerebral palsy.</p> </div> </div> </div> <div class="figure" id="CD001146-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.13 Death or cerebral palsy." data-id="CD001146-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-09.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.13 Death or cerebral palsy. </p> </div> </div> </div> </section> <section id="CD001146-sec-0063"> <h5 class="title">Major neurosensory disability</h5> <p>No evidence suggests effects of early systemic corticosteroids on major neurosensory disability (typical RR 1.08, 95% CI 0.89 to 1.33; 7 studies, 1703 infants; <a href="./references#CD001146-fig-0059" title="">Analysis 6.15</a>) nor on the combined outcome, mortality or major neurosensory disability (typical RR 0.97, 95% CI 0.87 to 1.08; 7 studies, 1703 infants; <a href="./references#CD001146-fig-0061" title="">Analysis 6.17</a>). </p> </section> <section id="CD001146-sec-0064"> <h5 class="title">Abnormal neurological examination</h5> <p>Evidence indicates that early systemic corticosteroids increased the rate of abnormal neurological examination findings (typical RR 1.81, 95% CI 1.33 to 2.47; typical RD 0.10, 95% CI 0.05 to 0.15; 5 studies, 829 infants; <a href="./references#CD001146-fig-0063" title="">Analysis 6.19</a>) and the combined outcome, mortality or abnormal neurological examination (typical RR 1.23, 95% CI 1.06 to 1.42; typical RD 0.10, 95% CI 0.03 to 0.16; 5 studies, 829 infants; <a href="./references#CD001146-fig-0065" title="">Analysis 6.21</a>). Although criteria for this diagnosis were vague and varied between studies, the size of the difference in this outcome in trials for which data were available was similar to the size of the difference in cerebral palsy in the corresponding study. <a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a> provided data for cerebral palsy obtained at age eight to nine years, whereas other investigators reported date for abnormal examination from earlier in childhood ‐ typically around two years of age. </p> </section> <section id="CD001146-sec-0065"> <h5 class="title">Other long‐term outcomes</h5> <p>Results show no significant effects on other long‐term outcomes of blindness, deafness, formal psychometric testing, abnormal electroencephalogram (EEG), behaviour problems, or re‐hospitalisation in infancy. </p> </section> </section> <section id="CD001146-sec-0066"> <h4 class="title">Subgroup analysis by type of corticosteroid used</h4> <section id="CD001146-sec-0067"> <h5 class="title">Mortality</h5> <p>Data show little difference in the effects of early dexamethasone or hydrocortisone on mortality at 28 days of life (typical RR dexamethasone 1.05, 95% CI 0.90 to 1.23; 16 studies, 2576 infants; typical RR hydrocortisone 0.77, 95% CI 0.49 to 1.21; 4 studies, 357 infants; P value for interaction = 0.20; <a href="./references#CD001146-fig-0010" title="">Analysis 1.1</a>) or of early dexamethasone on mortality at 36 weeks' postmenstrual age (typical RR dexamethasone 1.08, 95% CI 0.94 to 1.23; 17 studies, 2791 infants; <a href="./references#CD001146-fig-0011" title="">Analysis 1.2</a>) before discharge (typical RR dexamethasone 1.03, 95% CI 0.90 to 1.19; 18 studies, 2731 infants; <a href="./references#CD001146-fig-0012" title="">Analysis 1.3</a>), or at the latest age possible to determine the outcome (typical RR dexamethasone 1.02, 95% CI 0.90 to 1.16; 20 studies, 2940 infants; <a href="./references#CD001146-fig-0013" title="">Analysis 1.4</a>). However, some evidence shows that early hydrocortisone reduced mortality to discharge (typical RR hydrocortisone 0.80, 95% CI 0.65 to 0.99; 11 studies, 1433 infants; P value for interaction = 0.05; <a href="./references#CD001146-fig-0012" title="">Analysis 1.3</a>) and at the latest age possible to determine the outcome (typical RR hydrocortisone 0.80, 95% CI 0.65 to 0.99; 11 studies, 1433 infants; P value for interaction = 0.05; <a href="./references#CD001146-fig-0013" title="">Analysis 1.4</a>), but less evidence for an effect of early hydrocortisone on mortality at 36 weeks (typical RR hydrocortisone 0.85, 95% CI 0.67 to 1.06; 10 studies, 1385 infants; P value for interaction = 0.07; <a href="./references#CD001146-fig-0011" title="">Analysis 1.2</a>). </p> </section> <section id="CD001146-sec-0068"> <h5 class="title">Bronchopulmonary dysplasia</h5> <p>Most of the benefit of early systemic corticosteroids in reducing the incidence of BPD was provided by dexamethasone, with little effect of hydrocortisone, regardless of the definition of BPD: needing oxygen supplementation at 28 days of life (typical RR dexamethasone 0.84, 95% CI 0.78 to 0.91; typical RD ‐0.08, 95% CI ‐0.12 to ‐0.05; 14 studies, 2327 infants; typical RR hydrocortisone 1.00, 95% CI 0.85 to 1.18; 1 study, 253 infants; P value for interaction = 0.07; <a href="./references#CD001146-fig-0014" title="">Analysis 2.1</a>), or needing oxygen at 36 weeks' postmenstrual age (typical RR dexamethasone 0.72, 95% CI 0.63 to 0.82; typical RD ‐0.08, 95% CI ‐0.12 to ‐0.05; 17 studies, 2791 infants; typical RR hydrocortisone 0.92, 95% CI 0.81 to 1.06; 9 studies, 1376 infants; P value for interaction = 0.01; <a href="./references#CD001146-fig-0015" title="">Analysis 2.2</a>). Benefits of reducing the need for oxygen at 36 weeks in survivors or of providing late rescue with postnatal corticosteroids were also largely confined to the dexamethasone group (oxygen at 36 weeks in survivors; typical RR dexamethasone 0.72, 95% CI 0.63 to 0.82; typical RD ‐0.10, 95% CI ‐0.14 to ‐0.06; 15 studies, 1948 infants; typical RR hydrocortisone 0.89, 95% CI 0.78 to 1.02; 9 studies, 1145 infants; P value for interaction = 0.02; <a href="./references#CD001146-fig-0016" title="">Analysis 2.3</a>) (late rescue with postnatal corticosteroids; typical RR dexamethasone 0.72, 95% CI 0.65 to 0.80; typical RD ‐0.14, 95% CI ‐0.18 to ‐0.10; 10 studies, 1974 infants; typical RR hydrocortisone 0.94, 95% CI 0.81 to 1.09; 5 studies, 1030 infants; P value for interaction = 0.003; <a href="./references#CD001146-fig-0017" title="">Analysis 2.4</a>). Strong evidence shows subgroup differences with low P values for interactions in <a href="./references#CD001146-fig-0015" title="">Analysis 2.2</a>, <a href="./references#CD001146-fig-0016" title="">Analysis 2.3</a>, and <a href="./references#CD001146-fig-0017" title="">Analysis 2.4</a>, but with lower power to detect subgroup differences for the first comparison (BPD at 28 days) because only one study provided data for hydrocortisone. </p> </section> <section id="CD001146-sec-0069"> <h5 class="title">Mortality or bronchopulmonary dysplasia</h5> <p>Most of the benefit of early systemic corticosteroids in reducing the incidence of the combined outcome, mortality or bronchopulmonary dysplasia at 28 days of life, was provided by dexamethasone, with little effect of hydrocortisone (typical RR dexamethasone 0.88, 95% CI 0.85 to 0.95; typical RD ‐0.07, 95% CI ‐0.10 to ‐0.03; 13 studies, 2218 infants; typical RR hydrocortisone 1.00, 95% CI 0.90 to 1.12; 1 study, 253 infants; <a href="./references#CD001146-fig-0020" title="">Analysis 3.1</a>), but both drugs reduced the combined outcome of mortality or bronchopulmonary dysplasia at 36 weeks' postmenstrual age (typical RR dexamethasone 0.88, 95% CI 0.81 to 0.95; typical RD ‐0.06, 95% CI ‐0.09 to ‐0.02; 17 studies, 2791 infants; typical RR hydrocortisone 0.90, 95% CI 0.82 to 0.99; typical RD ‐0.06, 95% CI ‐0.11 to ‐0.00; 9 studies, 1376 infants; <a href="./references#CD001146-fig-0021" title="">Analysis 3.2</a>). Heterogeneity was substantial for the first comparison (<a href="./references#CD001146-fig-0020" title="">Analysis 3.1</a>), and there was low power to detect subgroup differences because only one study provided data for hydrocortisone. </p> </section> <section id="CD001146-sec-0070"> <h5 class="title">Complications during primary hospitalisation</h5> <p>Of the short‐term complications observed with early systemic corticosteroids, only hyperglycaemia was related more to dexamethasone than to hydrocortisone (typical RR dexamethasone 1.35, 95% CI 1.21 to 1.49; typical RD 0.11, 95% CI 0.08 to 0.15; 12 studies, 2117 infants; typical RR hydrocortisone 1.01, 95% CI 0.84 to 1.22; 2 studies, 571 infants; P = 0.009 for subgroup interaction; <a href="./references#CD001146-fig-0027" title="">Analysis 5.2</a>), Both hypertension and gastrointestinal haemorrhage were more common with dexamethasone compared with control, but there were too few studies of hydrocortisone to ensure any effects of that drug on hypertension (typical RR dexamethasone 1.84, 95% CI 1.53 to 2.21; typical RD 0.10, 95% CI 0.07 to 0.13; 10 studies, 1943 infants; typical RR hydrocortisone 3.00, 95% CI 0.33 to 26.92; 1 study, 50 infants) or gastrointestinal haemorrhage (typical RR dexamethasone 1.87, 95% CI 1.35 to 2.58; typical RD 0.05, 95% CI 0.03 to 0.08; 10 studies, 1725 infants; typical RR hydrocortisone 1.53, 95% CI 0.27 to 8.74; 2 studies, 91 infants; <a href="./references#CD001146-fig-0039" title="">Analysis 5.14</a>). However, both types of corticosteroid were associated with greater gastrointestinal perforation (typical RR dexamethasone 1.73, 95% CI 1.20 to 2.51; typical RD 0.03, 95% CI 0.01 to 0.05; 9 studies, 1936 infants; typical RR hydrocortisone 2.05, 95% CI 1.21 to 3.47; typical RD 0.04, 95% CI 0.01 to 0.06; 7 studies, 1104 infants; <a href="./references#CD001146-fig-0040" title="">Analysis 5.15</a>) and lower rates of patent ductus arteriosus (typical RR dexamethasone 0.76, 95% CI 0.69 to 0.84; typical RD ‐0.10, 95% CI ‐0.13 to ‐0.06; 17 studies, 2706 infants; typical RR hydrocortisone 0.82, 95% CI 0.71 to 0,95; typical RD ‐0.07, 95% CI ‐0.12 to ‐0.02; 7 studies, 1307 infants; <a href="./references#CD001146-fig-0032" title="">Analysis 5.7</a>). Only dexamethasone was associated with reductions in rates of any retinopathy of prematurity (typical RR dexamethasone 0.84, 95% CI 0.72 to 0.99; 8 studies, 1042 infants; typical RR hydrocortisone 0.93, 95% CI 0.84 to 1.04; 1 study, 303 infants; <a href="./references#CD001146-fig-0042" title="">Analysis 5.17</a>), severe retinopathy of prematurity (typical RR dexamethasone 0.77, 95% CI 0.60 to 0.99; 8 studies, 1507 infants; typical RR hydrocortisone 0.89, 95% CI 0.65 to 1.23; 6 studies, 1070 infants; <a href="./references#CD001146-fig-0043" title="">Analysis 5.18</a>), and severe retinopathy of prematurity among survivors (typical RR dexamethasone 0.75, 95% CI 0.59 to 0.95; 10 studies, 1238 infants; typical RR hydrocortisone 0.83, 95% CI 0.60 to 1.17; 2 studies, 337 infants; <a href="./references#CD001146-fig-0044" title="">Analysis 5.19</a>), but power to detect subgroup differences was low. </p> </section> <section id="CD001146-sec-0071"> <h5 class="title">Follow‐up data</h5> <p>Cerebral palsy and the combined outcome, mortality or cerebral palsy, were more common with dexamethasone than with hydrocortisone (cerebral palsy: typical RR dexamethasone 1.77, 95% CI 1.21 to 2.58; typical RD 0.05, 95% CI 0.01 to 0.09; 7 studies, 921 infants; typical RR hydrocortisone 1.05, 95% CI 0.66 to 1.66; 6 studies, 1052 infants; P = 0.09 for subgroup interaction; <a href="./references#CD001146-fig-0055" title="">Analysis 6.11</a>; mortality or cerebral palsy: typical RR dexamethasone 1.18, 95% CI 1.01 to 1.37; typical RD 0.07, 95% CI 0.01 to 0.13; 7 studies, 921 infants; typical RR hydrocortisone 0.86, 95% CI 0.71 to 1.05; typical RD ‐0.04, 95% CI ‐0.09 to 0.01; 6 studies, 1052 infants; P = 0.02 for subgroup interaction; <a href="./references#CD001146-fig-0057" title="">Analysis 6.13</a>). </p> </section> </section> <section id="CD001146-sec-0072"> <h4 class="title">Sensitivity analyses</h4> <section id="CD001146-sec-0073"> <h5 class="title">Excluding studies with higher risk of bias</h5> <p>Five studies had higher risk of bias, largely because they included no control groups and hence blinding to knowledge of treatment allocation was not possible. All five studies involved dexamethasone, and none involved hydrocortisone (<a href="./references#CD001146-bbs2-0012" title="LauterbachR , Szymura-OleksiakJ , PawlikD , WarcholJ , Lisowska-MiszczykI , RytlewskiK .Nebulized pentoxifylline for prevention of bronchopulmonary dysplasia in very low birth weight infants: a pilot clinical study. Journal of Maternal-Fetal &amp; Neonatal Medicine2006;19(7):433-8. [DOI: 10.1080/14767050600736754] [PMID: 16923699]">Lauterbach 2006</a>; <a href="./references#CD001146-bbs2-0014" title="MukhopadhyayK , KumarP , NarangA .Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics1998;35(2):117-22. [PMID: 9707853]">Mukhopadhyay 1998</a>; <a href="./references#CD001146-bbs2-0018" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [PMID: 12042579]RomagnoliC , ZeccaE , VentoG , De CarolisMP , PapacciP , TortoroloG .Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine1999;25(7):717-21. [DOI: 10.1007/s001340050935] [PMID: 10470576]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1999</a>; <a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a>; <a href="./references#CD001146-bbs2-0025" title="SuskeG , OestreichK , VarnholtV , LaschP , KachelW .Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica1996;85(6):713-8. [DOI: 10.1111/j.1651-2227.1996.tb14132.x] [PMID: 8816210]">Suske 1996</a>; <a href="#CD001146-fig-0003">Figure 3</a>). Excluding these five studies from major outcomes of mortality at latest age, BPD at 36 weeks, combined mortality or BPD at 36 weeks, gastrointestinal perforation, cerebral palsy, or mortality or cerebral palsy had little effect on any RR nor on any CI, and no conclusions were altered (data not shown). </p> </section> <section id="CD001146-sec-0074"> <h5 class="title">By indication for hydrocortisone</h5> <section id="CD001146-sec-0075"> <h6 class="title">Mortality to latest age</h6> <p>No evidence suggests a differential effect of hydrocortisone on mortality to latest age by the main indication for the drug, whether given to treat lung problems or to treat low blood pressure (<a href="./references#CD001146-fig-0077" title="">Analysis 7.1</a>). </p> </section> <section id="CD001146-sec-0076"> <h6 class="title">Bronchopulmonary dysplasia at 36 weeks</h6> <p>No evidence suggests a differential effect of hydrocortisone on BPD at 36 weeks by the main indication for the drug, whether given to treat lung problems or to treat low blood pressure (<a href="./references#CD001146-fig-0078" title="">Analysis 7.2</a>). </p> </section> <section id="CD001146-sec-0077"> <h6 class="title">Mortality or bronchopulmonary dysplasia at 36 weeks</h6> <p>No evidence suggests a differential effect of hydrocortisone on the combined outcome, mortality or BPD at 36 weeks, by the main indication for the drug, whether given to treat lung problems or to treat low blood pressure (<a href="./references#CD001146-fig-0079" title="">Analysis 7.3</a>). </p> </section> </section> </section> <section id="CD001146-sec-0078"> <h4 class="title">Results of individual trials</h4> <p><a href="./references#CD001146-bbs2-0001" title="AnttilaE , PeltonemiO , HaumontD , HertingE , ter HorstH , HeinonenK , et al.Early neonatal dexamethasone treatment for prevention of bronchopulmonary dysplasia. Randomised trial and meta-analysis evaluating the duration of dexamethasone therapy. European Journal of Pediatrics2005;164(8):472-81. [DOI: 10.1007/s00431-005-1645-8] [PMID: 15864643]">Anttila 2005</a>: primary outcome was survival without BPD, intraventricular haemorrhage (grade 3 or 4), or periventricular leukomalacia, and although this tended to be greater in the dexamethasone group, differences compared with controls were not statistically significant. The RR for mortality or BPD at 36 weeks' postmenstrual age was 0.78 (95% CI 0.54 to 1.13) overall, and 0.61 (95% CI 0.33 to 1.11) in the subgroup with birth weight 750 grams to 999 grams. We noted no detectable trends in mortality, severe intraventricular haemorrhage, or periventricular leukomalacia. Rates of patent ductus arteriosus, retinopathy of prematurity, or sepsis did not differ between groups. Mean arterial blood pressures were increased in the dexamethasone group during the first week (P = 0.015), and the dexamethasone group tended to need more insulin therapy (49% versus 39%; P = 0.25). </p> <p><a href="./references#CD001146-bbs2-0002" title="BadenM , BauerCR , ColeE , KleinG , TaeuschHW , SternL .A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics1972;50(4):526-34. [PMID: 4561296]FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Baden 1972</a>: results of this study show no significant effects on blood gases, pH, oxygen requirement, need for assisted ventilation, or survival. Data indicate no significant differences in rates of cerebral palsy or deafness among survivors, in mean scores on Griffiths Scales, or in the combined rate of mortality or cerebral palsy (<a href="./references#CD001146-bbs2-0076" title="FitzhardingePM , EisenA , LejtenyiC , MetrakosK , RamsayM .Sequelae of early steroid administration to the newborn infant. Pediatrics1974;53(6):877-83. [PMID: 4598934]">Fitzhardinge 1974</a>). </p> <p><a href="./references#CD001146-bbs2-0003" title="BattonBJ , LiL , NewmanNS , DasA , WatterbergKL , YoderBA , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Feasibility study of early blood pressure management in extremely preterm infants. Journal of Pediatrics2012;161(1):65-9. [DOI: 10.1016/j.jpeds.2012.01.014] [PMID: 22336574]">Batton 2012</a>: data show minimal effects on rates of mortality during primary hospitalisation, intraventricular haemorrhage, periventricular leukomalacia, or necrotising enterocolitis. BPD, which was undefined by both criteria and timing, occurred in two of four infants in the hydrocortisone group and in three of six in the control group; these data could not be added to 28‐day or 36‐week data for BPD because of lack of information about timing. </p> <p><a href="./references#CD001146-bbs2-0004" title="BaudO , BiranV , TroussonC , LeroyE , MohamedD , AlbertiC .Two-year outcomes after prophylactic hydrocortisone in extremely preterm neonates. In: European Journal of Pediatrics. Vol. 175. 2016:1507. BaudO , MauryL , LebailF , RamfulD , El MoussawiF , NicaiseC , et al, PREMILOC Trial Study Group.Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet2016;387(10030):1827-36. [DOI: 10.1016/S0140-6736(16)00202-6] [PMID: 26916176]BaudO , TroussonC , BiranV , LeroyE , MohamedD , AlbertiC , PREMILOC Trial Group.Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA2017;317(13):1329-37. [DOI: 10.1001/jama.2017.2692] [PMID: 28384828]">Baud 2016</a>: mortality or BPD at 36 weeks' gestational age occurred in 40% (102/255) of the hydrocortisone group compared with 49% (130/266) of the placebo group (odds ratio (OR) 0.82, 95% CI 0.67 to 0.99). Rates of any neurodevelopmental impairment (NDI) among assessed survivors were similar in the two groups (hydrocortisone 27% (53/194); placebo 30% (55/185)), as were rates of moderate to severe impairment (hydrocortisone 7% (14/194); placebo 11% (21/185)). The combined outcome, mortality or moderate severe impairment in all randomised infants, was lower in the hydrocortisone group than in the control group (hydrocortisone 24% (62/255); placebo 33% (88/266); OR 0.73, 95% CI 0.56 to 0.97). Data were also reported by Shaffer and colleagues (<a href="./references#CD001146-bbs2-0097" title="ShafferMI , BaudO , Lacaze-MasmonteilT , PeltoniemiOM , BonsanteF , WatterbergKL .Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. Journal of Pediatrics2019;207:136-42. [DOI: 10.1016/j.jpeds.2018.10.004] [PMID: 30416014]">Shaffer 2019</a>). </p> <p><a href="./references#CD001146-bbs2-0005" title="BiswasS , BufferyJ , EnochH , BlandM , MarkiewiczM , WaltersD .Pulmonary effects of triiodothyronine (T3) and hydrocortisone (HC) supplementation in preterm infants less than 30 weeks gestation: results of the THORN trial - thyroid hormone replacement in neonates. Pediatric Research2003;53(1):48-56. [DOI: 10.1203/00006450-200301000-00011] [PMID: 12508081]BiswasS .Personal communication. email2002. ">Biswas 2003</a>: results show no significant effects of infusion of hydrocortisone and T3 on the primary endpoint of mortality or failure to extubate by seven days, nor mortality or oxygen dependency at 14 days. Patent ductus arteriosus was significantly reduced in the treatment group (41/125 versus 60/128; RR 0.70, 95% CI 0.51 to 0.96), but data show no other significant differences in secondary outcomes. </p> <p><a href="./references#CD001146-bbs2-0006" title="BonsanteF , LatorreG , LacobelliS , ForziatiV , LaforgiaN , EspositoL , et al.Early low-dose hydrocortisone in very preterm infants: a randomized placebo-controlled trial. Neonatology2007;91(4):217-21. [DOI: 10.1159/000098168] [PMID: 17568152]">Bonsante 2007</a>: oxygen‐free survival was significantly greater in the hydrocortisone group than in the control group (64% versus 32%; P = 0.023). The effect of hydrocortisone was particularly evident in the subgroup not exposed to prenatal corticosteroids. Four infants in the hydrocortisone group died compared with 10 in the control group (16% versus 40%; P = 0.05). Duration of ventilation, patent ductus arteriosus, severe retinopathy of prematurity, severe intraventricular haemorrhage, and periventricular leukomalacia were not different between groups. Data were also reported by Shaffer and colleagues (<a href="./references#CD001146-bbs2-0097" title="ShafferMI , BaudO , Lacaze-MasmonteilT , PeltoniemiOM , BonsanteF , WatterbergKL .Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. Journal of Pediatrics2019;207:136-42. [DOI: 10.1016/j.jpeds.2018.10.004] [PMID: 30416014]">Shaffer 2019</a>). </p> <p><a href="./references#CD001146-bbs2-0007" title="EfirdMM , HeerensAT , GordonPV , BoseCL , YoungDA .A randomized-controlled trial of prophylactic hydrocortisone supplementation for the prevention of hypotension in extremely low birth weight infants. Journal of Perinatology2005;25(2):119-24. [DOI: 10.1038/sj.jp.7211193] [PMID: 15329742]">Efird 2005</a>: vasopressor was used less in the hydrocortisone‐treated group, significantly so on the second day of life. Results show no significant differences in cortisol levels between groups at any time point, and no significant differences in mortality, duration of ventilation, BPD (oxygen at 36 weeks' postmenstrual age), nosocomial infections, necrotising enterocolitis, spontaneous intestinal perforations, or intraventricular haemorrhage. No infants were treated or removed from the study as a result of hypertension. Data show no differences in the rate of glucose intolerance between groups, but two infants in the hydrocortisone group received insulin for five days. </p> <p><a href="./references#CD001146-bbs2-0008" title="GarlandJS , AlexCP , PaulyTH , WhiteheadVL , BrandJ , WinstonJF , et al.A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics1999;104(1 Pt 1):91-9. [DOI: 10.1542/peds.104.1.91] [PMID: 10390266]">Garland 1999</a>: early dexamethasone‐treated infants were more likely than placebo‐treated controls to survive without BPD (83/118 versus 71/123; P = 0.03). They also were less likely to develop BPD if they survived to 28 days of life (16/99 versus 27/98; P = 0.042). Mortality rates were not significantly different. Subsequent dexamethasone therapy was used less often among early dexamethasone‐treated infants who survived (68/99 versus 81/98; P = 0.01). Intestinal perforation was more common, but not significantly so, among dexamethasone‐treated infants (12/118 versus 7/122; P = 0.20); during the first week of life, the difference was significant (9/118 versus 1/122; P = 0.009). Infants in the dexamethasone group also spent less time receiving oxygen (median days 43 versus 50; P = 0.04). Any grade of intraventricular haemorrhage (36% versus 52%; P = 0.02) and of patent ductus arteriosus ligation (14% versus 28%; P = 0.01) was also less common in the dexamethasone group. Hypertension (P &lt; 0.001) and treatment with insulin (P = 0.007) occurred more often among dexamethasone‐treated infants than controls. </p> <p><a href="./references#CD001146-bbs2-0009" title="HalacE , HalacJ , BegueEF , CasañasJM , IndiveriDR , PetitJF , et al.Prenatal and postnatal corticosteroid therapy to prevent neonatal necrotizing enterocolitis: a controlled trial. Journal of Pediatrics1990;117(1 Pt 1):132-8. [DOI: 10.1016/s0022-3476(05)72461-6] [PMID: 2196355]">Halac 1990</a>: investigators reported no substantial or statistically significant effects of dexamethasone on neonatal mortality, mortality to hospital discharge, necrotising enterocolitis, sepsis, patent ductus arteriosus, or severe intraventricular haemorrhage. </p> <p><a href="./references#CD001146-bbs2-0010" title="HochwaldO , PalegraG , OsiovichO .Adding hydrocortisone as 1st line of inotropic treatment for hypotension in very low birth weight infants. Indian Journal of Pediatrics2014;81(8):808-10. [DOI: 10.1007/s12098-013-1151-3] [PMID: 23904065]">Hochwald 2014</a>: data show no statistically significant effects of hydrocortisone on mortality to hospital discharge, BPD, mortality or BPD, necrotising enterocolitis, or sepsis. </p> <p><a href="./references#CD001146-bbs2-0011" title="KopelmanAE , MoiseAA , HolbertD , HegemierSE .A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. Journal of Pediatrics1999;135(3):345-50. [DOI: 10.1016/s0022-3476(99)70132-0] [PMID: 10484801]">Kopelman 1999</a>: intermittent mandatory ventilation (IMV) rate and ventilation index improved more rapidly in the dexamethasone‐treated group. Mean blood pressure was higher in the dexamethasone group after the first day. Patent ductus arteriosus was less common in dexamethasone‐treated infants (13/37 versus 19/33; P = 0.08), and fewer received indomethacin (8/37 versus 15/33; P = 0.03). At the study hospital, where early extubation was practised, more dexamethasone‐treated infants were extubated during the first week (10/22 versus 2/16, P &lt; 0.03). Results show no difference in intraventricular haemorrhage and no occurrence of adverse effects. </p> <p><a href="./references#CD001146-bbs2-0013" title="LinYJ , YehTF , HsiehWS , ChiYC , LinHC , LinCH .Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatric Pulmonology1999;27(1):21-6. [DOI: 10.1002/(sici)1099-0496(199901)27:1&lt;21::aid-ppul5&gt;3.0.co;2-y] [PMID: 10023787]">Lin 1999</a>: for the endpoint of BPD at 28 days of life, statistical significance favouring dexamethasone was reached when analysis of 12 consecutive pairs in which one infant had BPD and the other did not showed that 10 pairs favoured dexamethasone and two pairs favoured control. Data presented for 40 infants (20 in each group) show a lower incidence of BPD at 28 days of life in the dexamethasone group (n = 4) than in the control group (n = 11; P &lt; 0.05). Duration of oxygen therapy was also shorter in the dexamethasone group, at 7 ± 6 days versus 13 ± 12 days (P &lt; 0.05). Among survivors, 12 of 15 in the dexamethasone group were extubated at the end of the study compared with 9 of 16 in the control group. Infants in the treated group had transient hyperglycaemia and hypertension, but data show no differences between groups for mortality, incidence of sepsis, or intraventricular haemorrhage. </p> <p><a href="./references#CD001146-bbs2-0014" title="MukhopadhyayK , KumarP , NarangA .Role of early postnatal dexamethasone in respiratory distress syndrome. Indian Pediatrics1998;35(2):117-22. [PMID: 9707853]">Mukhopadhyay 1998</a>: oxygen requirement was lower in the treated group than in the control group on Days 3, 4, and 5, although differences were not statistically significant. Mean duration of ventilation was shorter in the dexamethasone group (87 ± 42 hours) than in the control group (120 ± 46 hours; P value not given). Study authors reported one case of culture‐positive sepsis in the dexamethasone group, and two in the control group. None of the infants developed BPD (definition not given). Four infants in the dexamethasone group developed a pneumothorax versus three in the control group. Survival was 60% in the treated group and 55% in the control group. </p> <p><a href="./references#CD001146-bbs2-0015" title="NgPC , LeeCH , BnurFL , ChanIH , LeeAW , WongE , et al.A double-blind randomized controlled study of a stress dose of hydrocortisone for rescue treatment of refractory hypotension in preterm infants. Pediatrics2006;117(2):367-75. [DOI: 10.1542/peds.2005-0869] [PMID: 16452355]">Ng 2006</a>: 19 infants (79%) in the hydrocortisone group were weaned from vasopressor support within 72 hours compared with eight controls (33%) (P &lt; 0.001). Cumulative doses of dopamine and dobutamine after randomisation were significantly lower in the hydrocortisone group. Duration of ventilation, duration of oxygen, and incidence of BPD (oxygen at 36 weeks' postmenstrual age) were not significantly different between groups. Results show no differences between groups for highest serum glucose, culture‐proven sepsis, necrotising enterocolitis, intestinal perforation, duration of hospitalisation, and mortality. However, significantly more hydrocortisone‐treated infants had glycosuria (P = 0.029). </p> <p><a href="./references#CD001146-bbs2-0016" title="PeltoniemiO , KariA , HeinonenK , SaarelaT , NikolajevK , AnderssonS , et al.Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics2005;146(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040] [PMID: 15870666]PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2005</a>: hydrocortisone‐treated infants did not show a significant increase in survival without BPD (64% versus 54% placebo) nor a significant decrease in BPD among survivors (OR 0.53, 95% CI 0.17 to 1.71). However, the study enrolled only 16% of its intended sample size. Two infants in the hydrocortisone group and three in the placebo group died. During the first week of life, infants in the hydrocortisone group needed lower mean airway pressures than infants in the placebo group (P = 0.03). Patent ductus arteriosus (36% versus 73%; P = 0.01) and duration of oxygen therapy (34 versus 62 days; P = 0.02) occurred less often in the hydrocortisone group, but intraventricular haemorrhage, cystic periventricular leukomalacia, retinopathy of prematurity, sepsis, necrotising enterocolitis, gastrointestinal haemorrhage, open corticosteroid treatment, and duration of intubation and of hospitalisation were not different between groups. Risk of gastrointestinal perforation was increased in the hydrocortisone group (16% versus 0%; P = 0.05). Data show no differences in the rate of hyperglycaemia requiring insulin nor in blood pressures (diastolic and systolic). At six‐year follow‐up, data show no substantial differences between groups in rates of cerebral palsy, blindness, deafness, and intellectual impairment (IQ &lt; 69; steroid group 8% (2/25) versus placebo group 4% (1/26)). However, scores for performance IQ on the WPPSI‐R were lower among those treated with hydrocortisone (mean difference ‐10.8, 95% CI ‐20.8 to ‐0.8). Data were also reported by Shaffer and colleagues (<a href="./references#CD001146-bbs2-0097" title="ShafferMI , BaudO , Lacaze-MasmonteilT , PeltoniemiOM , BonsanteF , WatterbergKL .Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. Journal of Pediatrics2019;207:136-42. [DOI: 10.1016/j.jpeds.2018.10.004] [PMID: 30416014]">Shaffer 2019</a>). </p> <p><a href="./references#CD001146-bbs2-0017" title="MoralesP , RastogiA , BezML , AkintorinSM , PyatiS , AndesSM , et al.Effect of dexamethasone therapy on the neonatal ductus arteriosus. Pediatric Cardiology1998;19(3):225-9. [DOI: 10.1007/s002469900290] [PMID: 9568218]RastogiA , AkintorinSM , BezML , MoralesP , PildesPS .A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics1996;98(2 Pt 1):204-10. [PMID: 8692619]">Rastogi 1996</a>: ventilator variables at 5 to 14 days were significantly improved among infants who received dexamethasone compared with infants who received placebo. The effect seemed to be more marked among infants weighing less than 1250 grams at birth. Significantly more infants could be extubated by 14 days in the dexamethasone group (26/32 versus 14/32; P = 0.004). Dexamethasone therapy reduced the incidence of BPD at 28 days of life (OR 0.10, 95% CI 0.03 to 0.30) and eliminated BPD at 36 weeks' postmenstrual age. Dexamethasone‐treated infants were more likely to show weight loss at 14 days (12.9% versus 3.7%; P = 0.01) and higher blood pressure from Days 3 to 10. However, data show no differences in time to regain birth weight, hypertension (one infant in each group), nor incidence of intraventricular haemorrhage. </p> <p><a href="./references#CD001146-bbs2-0018" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [PMID: 12042579]RomagnoliC , ZeccaE , VentoG , De CarolisMP , PapacciP , TortoroloG .Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants. Intensive Care Medicine1999;25(7):717-21. [DOI: 10.1007/s001340050935] [PMID: 10470576]RomagnoliC , ZeccaE , VentoG , MaggioL , PapacciP , TortoroloG .Effect on growth of two different dexamethasone courses for preterm infants at risk of chronic lung disease. A randomized controlled trial. Pharmacology1999;59(5):266-74. [DOI: 10.1159/000028329] [PMID: 10529659]">Romagnoli 1999</a>: the incidence of BPD at 28 days of life and at 36 weeks' postmenstrual age was significantly lower in the dexamethasone group than in the control group (P &lt; 0.001). Infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (P &lt; 0.001). Hyperglycaemia, hypertension, growth failure, and hypertrophy of the left ventricle were transient side effects of early corticosteroid administration. Data show no significant differences in rates of cerebral palsy, blindness, deafness, or intellectual impairment, nor in mean IQ, or in the combined rate of mortality or cerebral palsy (<a href="./references#CD001146-bbs2-0093" title="RomagnoliC , ZeccaE , LucianoR , TorrioliG , TortoroloG .Controlled trial of early dexamethasone treatment for the prevention of chronic lung disease in preterm infants: a 3-year follow-up. Pediatrics2002;109(6):e85. [DOI: 10.1542/peds.109.6.e85] [PMID: 12042579]">Romagnoli 2002</a>). </p> <p><a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a>: the dexamethasone group required less ventilatory support (mean airway, peak inspiratory and end‐expiratory pressures, and IMV) and supplemental oxygen after study Day 4 (all P &lt; 0.05). Improved tidal volume in the dexamethasone group, as assessed by pulmonary function testing of infants who remained intubated, was seen on study Day 7 (P = 0.02). The dexamethasone group required a shorter time in hospital (median 95 days versus 106 days; P = 0.01). Survival in the dexamethasone group was 89% versus 67% in the placebo group (P = 0.08). Survival without BPD was 68% in the dexamethasone group versus 43% in the placebo group (P = 0.14). Mean blood pressure was elevated on study Days 4 to 7. Data show no differences in rates of hyperglycaemia, incidence or severity of intraventricular haemorrhage, or days to regain birth weight, and no significant differences in rates of cerebral palsy, blindness, deafness, or intellectual impairment, nor in the combined rate of mortality or cerebral palsy (Sinkin 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0019" title="SandersRJ , CoxC , PhelpsDL , SinkinRA .Two doses of early intravenous dexamethasone for the prevention of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Research1994;36(1 Pt 1):122-8. [DOI: 10.1203/00006450-199407001-00022] [PMID: 7936832]SinkinRA .Personal communication. email2002. ">Sanders 1994</a>)). </p> <p><a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a>: results show no differences in any outcome variable, except a reduction in the need for mechanical ventilation at three days in dexamethasone‐treated infants (54/122, 44% versus 71/106, 67%; P = 0.001). Gastrointestinal haemorrhage, hypertension, and hyperglycaemia were more common among treated infants, but no life‐threatening complications, such as gastrointestinal perforation, were encountered. Follow‐up of survivors at two to six years shows no significant differences in rates of blindness, deafness, or major neurosensory disability, nor in the combined rate of mortality or major neurosensory disability. However, data show significant increases in rates of abnormal neurological examination findings, developmental delay, and cerebral palsy, and a significant increase in the combined rate of mortality or cerebral palsy (<a href="./references#CD001146-bbs2-0102" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]">Shinwell 2002</a>). </p> <p><a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a>: results show no differences between dexamethasone and placebo groups, respectively, for the primary outcomes of survival (79% versus 83%), survival without oxygen at 36 weeks' postmenstrual age (both 59%), and survival without oxygen at 36 weeks' postmenstrual age without late corticosteroids (46% versus 44%). We noted no significant differences between groups for median time in oxygen (50 versus 56 days), ventilation (20 versus 27 days), time to regain birth weight (15.5 versus 15.0 days), nor length of stay (88 versus 89 days). Infants given early dexamethasone were less likely to receive late corticosteroids for BPD during their hospital stay (25% versus 35%; P = 0.042). We noted no clinically significant side effects in the dexamethasone group, although transient elevations in blood glucose and blood pressure with return to baseline were evident by study Day 10. Among infants who died (40 versus 33), data show no differences in median days on oxygen, ventilation, or length of hospital stay. However, among survivors (149 versus 162), we observed the following: median days on oxygen 37 versus 45, ventilation 14 versus 19 days, and length of stay 79 versus 81 days, for dexamethasone versus placebo groups, respectively. Data show no significant differences in rates of cerebral palsy, in the combined rate of mortality or cerebral palsy, nor in mean Bayley scores (Sinkin 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0021" title="D'AngioCT , ManiscalcoWM , RyanRM , AvissarNE , BasavegowdaK , SinkinRA .Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biology of the Neonate1999;76(5):266-73. [DOI: 10.1159/000014168] [PMID: 10516393]SinkinRA , DweckHS , HorganMJ , GallaherKJ , CoxC , ManiscalcoWM , et al.Early dexamethasone - attempting to prevent chronic lung disease. Pediatrics2000;105(3 Pt 1):542-8. [DOI: 10.1542/peds.105.3.542] [PMID: 10699107]SinkinRA .Personal communication. email2002. ">Sinkin 2000</a>)). </p> <p><a href="./references#CD001146-bbs2-0022" title="SollRF , Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research1999;45:226A. Vermont Oxford Network Steroid Study Group.Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatrics2001;108(3):741-8. [DOI: 10.1542/peds.108.3.741] [PMID: 11533345]">Soll 1999</a>: results show no differences in the primary outcome of BPD or mortality at 36 weeks' postmenstrual age (early therapy 135/272 versus 143/267; RR 0.93, 95% CI 0.79 to 1.09). Infants who received early corticosteroid therapy were less likely to need late treatment (114/270 versus 164/267; RR 0.69, 95% CI 0.58 to 0.81). They also had lower risk of patent ductus arteriosus (92/272 versus 117/269; RR 0.78, 95% 0.63 to 0.96) and were less likely to receive indomethacin therapy (132/273 versus 176/269; RR 0.74, 95% CI 0.64 to 0.86). However, infants who received early corticosteroid therapy were more likely to have complications such as hyperglycaemia (200/271 versus 151/263; RR 1.29, 95% CI 1.13 to 1.46) and to require insulin therapy (168/271 versus 102/267; RR 1.62, 95% CI 1.36 to 1.94). Data show trends towards increased gastrointestinal haemorrhage (33/271 versus 21/267; RR 2.55, 95% CI 0.92 to 2.61) and gastrointestinal perforation (31/271 versus 20/267; RR 1.53, 95% CI 0.89 to 2.61). Infants who had cranial ultrasound scans showed a trend towards an increase in periventricular leukomalacia in the early corticosteroid group (18/252 versus 8/250; RR 2.23, 95% CI 0.99 to 5.04). Infants who received early corticosteroid therapy received fewer days of supplemental oxygen but experienced poorer weight gain. </p> <p><a href="./references#CD001146-bbs2-0023" title="StarkAR , CarloWA , TysonJE , PapileLA , WrightLL , ShankaranS , et al, National Institute of Child Health and Human Development Neonatal Research Network.Adverse effects of early dexamethasone in extremely-low-birth-weight infants. New England Journal of Medicine2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203] [PMID: 11150359]StarkAR , CarloWA , VohrBR , PapileL , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2001</a>: corticosteroid‐treated infants had a lower incidence of the primary outcome, mortality or BPD at 36 weeks' postmenstrual age (63% versus 69%; P &lt; 0.05). Fewer infants in the corticosteroid group had pulmonary interstitial emphysema (9% versus 23%; P &lt; 0.05), required oxygen at 28 days of life (78% versus 94%; P &lt; 0.05), or received subsequent corticosteroid treatment (34% versus 51%; P &lt; 0.05). Rates of severe intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, and nosocomial infection were similar. Hypertension and hyperglycaemia were more frequent in the corticosteroid group (27% versus 4% and 23% versus 12%, respectively; both with P &lt; 0.05). During the first 14 days, 14/111 (13%) infants in the corticosteroid group and 3/109 (3%) in the placebo group had spontaneous gastrointestinal perforation without necrotising enterocolitis (P &lt; 0.05). Spontaneous perforation was also associated with indomethacin treatment (P = 0.005), as was an interaction between indomethacin and corticosteroid therapy (P = 0.04). Data show no significant differences in rates of cerebral palsy, developmental delay, or major neurosensory disability, in the combined rate of mortality or cerebral palsy, nor in the combined rate of mortality or major neurosensory disability (<a href="./references#CD001146-bbs2-0023" title="StarkAR , CarloWA , TysonJE , PapileLA , WrightLL , ShankaranS , et al, National Institute of Child Health and Human Development Neonatal Research Network.Adverse effects of early dexamethasone in extremely-low-birth-weight infants. New England Journal of Medicine2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203] [PMID: 11150359]StarkAR , CarloWA , VohrBR , PapileL , SahaS , BauerCR , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. Journal of Pediatrics2014;164(1):34-9 e2. [DOI: 10.1016/j.jpeds.2013.07.027] [PMID: 23992673]">Stark 2001</a>). </p> <p><a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a>: results show no differences in the combined incidence of BPD and/or mortality before discharge from hospital between infants treated with dexamethasone and control infants (RR 0.95, 95% CI 0.79 to ‐1.18) or between those treated with inhaled nitric oxide and controls (RR 1.05, 95% CI 0.84 to 1.25). Data show no significant differences in rates of cerebral palsy, blindness, deafness, developmental delay, the combined rate of mortality or cerebral palsy, nor the combined rate of mortality or major neurosensory disability (Subhedar 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0024" title="SubhedarNV , BennettAJ , WardleSP , ShawNJ .More trials on early treatment with corticosteroids are needed. BMJ2000;320(7239):941. [PMID: 10742018 ]SubhedarNV , RyanSW , ShawNJ .Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition1997;77(3):F185-90. [DOI: 10.1136/fn.77.3.f185] [PMID: 9462187]SubhedarNV .Personal communication. email2002. ">Subhedar 1997</a>)). </p> <p><a href="./references#CD001146-bbs2-0025" title="SuskeG , OestreichK , VarnholtV , LaschP , KachelW .Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatrica1996;85(6):713-8. [DOI: 10.1111/j.1651-2227.1996.tb14132.x] [PMID: 8816210]">Suske 1996</a>: infants in the dexamethasone group were extubated earlier (6.6 days versus 14.2 days; P &lt; 0.02) and required less time on supplemental oxygen (4.2 days versus 12.5 days; P &lt; 0.02). Pulmonary complications tended to be fewer in the dexamethasone group (1/14 versus 4/12), and retinopathy of prematurity tended to occur less frequently (2/14 versus 6/12; P &lt; 0.05). </p> <p><a href="./references#CD001146-bbs2-0026" title="TapiaJL , RamirezR , CifuentesJ , FabresJ , HubnerME , BancalariA , et al.The effect of early dexamethasone administration on bronchopulmonary dysplasia in preterm infants with respiratory distress syndrome. Journal of Pediatrics1998;132(1):48-52. [DOI: 10.1016/s0022-3476(98)70483-4] [PMID: 9469999]">Tapia 1998</a>: results show no significant differences in mortality and/or BPD between groups. The number of infants requiring oxygen at 36 weeks' postmenstrual age was significantly reduced in the dexamethasone group (8% versus 33%; P &lt; 0.05). Stepwise logistic regression analysis with oxygen dependency at 36 weeks as the dependent variable, and birth weight, gestational age, gender, prenatal corticosteroids, and study treatment as the independent variables, shows that study treatment was the only variable significantly associated with oxygen dependency at 36 weeks. Data show no differences between groups in the number of days of mechanical ventilation and oxygen treatment, and no differences in the incidence of major morbidity and possible complications related to corticosteroid administration, except a lower incidence of necrotising enterocolitis in the dexamethasone group. </p> <p><a href="./references#CD001146-bbs2-0027" title="VentoG , MatassaPG , ZeccaE , TortoroloL , MartelliM , De CarolisMP , et al.Effect of dexamethasone on tracheobronchial aspirate fluid cytology and pulmonary mechanics in preterm infants. Pharmacology2004;71(3):113-9. [DOI: 10.1159/000077444] [PMID: 15161992]">Vento 2004</a>: seven dexamethasone‐treated infants and two control infants were extubated during the study period of seven days. Data show no differences between groups for respiratory distress syndrome, patent ductus arteriosus, nor severe intraventricular haemorrhage (grade 3 or 4). Dexamethasone‐treated infants had lower absolute cell count and proportion of polymorphs in tracheal aspirate fluid compared with control infants as early as Day 1 of treatment. They also had significantly higher dynamic compliance values compared with control infants (P &lt; 0.01) as early as Day 2 of treatment. Inspired oxygen concentrations were significantly lower on Day 2 (0.24 versus 0.31; P &lt; 0.05), and mean airway pressure on Day 5 (4.8 versus 7.2 cmH₂O; P &lt; 0.05). </p> <p><a href="./references#CD001146-bbs2-0028" title="WangJY , YehTF , LinYC , MiyamuraK , HolmskovU , ReidKB .Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax1996;51(9):907-13. [DOI: 10.1136/thx.51.9.907] [PMID: 8984701]WangJY , YehTF , LinYJ , ChenWY , LinCH .Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatric Pulmonology1997;23(3):193-7. [DOI: 10.1002/(sici)1099-0496(199703)23:3&lt;193::aid-ppul4&gt;3.0.co;2-p] [PMID: 9094727]">Wang 1996</a>: dexamethasone treatment decreased fractional inspired oxygen concentration, arterial carbon dioxide tension, and mean airway pressure, and facilitated successful weaning from mechanical ventilation. Surfactant protein (SP)‐A concentrations in tracheal aspirates were increased at Days 7 and 14, and SP‐D concentrations were increased from Days 3 to 14 in the dexamethasone‐treated group, compared with the control group. </p> <p><a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>: in this study, more infants treated with hydrocortisone survived without supplemental oxygen at 36 weeks' postmenstrual age (12/20 versus 7/20; P = 0.023). Hydrocortisone treatment was also associated with a reduction in duration of oxygen &gt; 40% (7 versus 28 days; P = 0.06), duration of oxygen &gt; 25% (48 versus 69 days; P = 0.02), and duration of mechanical ventilation (25 versus 32 days; P = 0.03). Data show no differences in rates of mortality, sepsis, patent ductus arteriosus, necrotising enterocolitis, gastrointestinal perforation, intraventricular haemorrhage, nor retinopathy of prematurity, and no significant differences in rates of cerebral palsy, blindness, or deafness, nor in the combined rate of mortality or cerebral palsy (Watterberg 2002 (personal communication follow‐up to <a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>)). </p> <p><a href="./references#CD001146-bbs2-0030" title="WatterbergKL , GerdesJS , ColeCH , AucottSW , ThiloEH , MammelMC , et al.Prophylaxis of early adrenal insufficiency to prevent bronchopulmonary dysplasia: a multicenter trial. Pediatrics2004;114(6):1649-57. [DOI: 10.1542/peds.2004-1159] [PMID: 15574629]WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and neurodevelopmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2004</a>: results show no differences in primary outcomes between groups (hydrocortisone versus placebo): survival without BPD (35% versus 34%), mortality before 36 weeks' postmenstrual age (15% versus 16%), and mortality before discharge (16% versus 17%). In a subgroup of infants exposed to chorioamnionitis, the hydrocortisone‐treated group had significantly improved survival without BPD (38% versus 24%; P = 0.005) and lower mortality at 36 weeks' postmenstrual age (10% versus 18%; P = 0.02) and before discharge (12% versus 21%; P = 0.02). During treatment, rates of hyponatraemia, hypernatraemia, hyperkalaemia, hyperglycaemia, hypertension, and gastrointestinal bleeding were similar between groups. Seventy‐four infants (41%) in the hydrocortisone group and 62 (34%) in the placebo group were treated with insulin (P = 0.19). Serum sodium and mean arterial blood pressure were significantly higher in hydrocortisone‐treated infants (P &lt; 0.001 and P = 0.022, respectively). Other outcomes included no differences in weight gain or head circumference, nor in duration of oxygen and ventilation, pulmonary air leaks, pulmonary haemorrhage, patent ductus arteriosus, sepsis, intraventricular haemorrhage, periventricular leukomalacia, retinopathy of prematurity, and necrotising enterocolitis. However, hydrocortisone‐treated infants were less likely to receive open‐label corticosteroids during the treatment period (18% versus 28%; P = 0.02) and were more likely to have a spontaneous gastrointestinal perforation (9% versus 2%; P = 0.01). Follow‐up data reveal no significant differences in rates of cerebral palsy, major neurological disability, developmental delay, or re‐hospitalisation, nor in combined rates of mortality or cerebral palsy, or mortality or major neurological disability (<a href="./references#CD001146-bbs2-0108" title="WatterbergKL , ShafferML , MishefskeMJ , LeachCL , MammelMC , CouserRJ , et al.Growth and developmental outcomes after early low-dose hydrocortisone treatment in extremely low birth weight infants. Pediatrics2007;120(1):40-8. [DOI: 10.1542/peds.2006-3158] [PMID: 17606560]">Watterberg 2007</a>). Data were also reported by Shaffer and colleagues (<a href="./references#CD001146-bbs2-0097" title="ShafferMI , BaudO , Lacaze-MasmonteilT , PeltoniemiOM , BonsanteF , WatterbergKL .Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. Journal of Pediatrics2019;207:136-42. [DOI: 10.1016/j.jpeds.2018.10.004] [PMID: 30416014]">Shaffer 2019</a>). </p> <p><a href="./references#CD001146-bbs2-0031" title="YehTF , TorreJA , RastogiA , AnyebunoMA , PildesRS .Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. Journal of Pediatrics1990;117(2 Pt 1):273-82. [DOI: 10.1016/s0022-3476(05)80547-5] [PMID: 2199642]">Yeh 1990</a>: infants in the dexamethasone group had significantly higher pulmonary compliance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 versus 8/29; P &lt; 0.025) at two weeks of age. Nineteen infants (65%) in the placebo group and 11 (39%) in the dexamethasone group (P &lt; 0.05) had lung injury characterised by the following: surviving infants with BPD; infants who died of intractable respiratory failure and had evidence of BPD at autopsy; and infants who died of intractable respiratory failure with clinical evidence of BPD. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and delayed somatic growth. </p> <p><a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a>: infants in the dexamethasone group had a significantly lower incidence of BPD than those in the placebo group, judged at 28 postnatal days (21/132 versus 40/130; P &lt; 0.05) or at 36 weeks' postmenstrual age (20/132 versus 37/130; P &lt; 0.05). More infants in the dexamethasone group were extubated during the study. Data show no difference in mortality between groups (39/130 versus 44/132); however, a higher proportion of infants in the dexamethasone group died during the late study period, probably as the result of infection. Results show no differences between groups in duration of oxygen therapy and hospitalisation. Significantly more infants in the dexamethasone group had bacteraemia or clinical sepsis (44/132 versus 27/130; P &lt; 0.05). Other immediate but transient side effects observed in the dexamethasone group were hyperglycaemia, hypertension, cardiac hypertrophy, hyperparathyroidism, and delay in growth rate. At 25 months of age, data reveal no significant differences in rates of blindness, developmental delay, or major neurosensory disability, nor in the combined rate of mortality or cerebral palsy, or the combined rate of mortality or major neurosensory disability. However, we noted significant increases in rates of abnormal neurological examination and cerebral palsy among survivors (<a href="./references#CD001146-bbs2-0111" title="YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]">Yeh 1998</a>). The follow‐up rate of survivors at eight years was 92% (146/159). Although rates of cerebral palsy were not significantly higher in the dexamethasone group, overall motor performance on the Movement ABC was worse than among controls. IQ and other cognitive performance were significantly worse in the dexamethasone group. Overall, survivors in the dexamethasone group had greater major neurological disability. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001146-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001146-sec-0079"></div> <p>Corticosteroids are potent drugs that may improve lung function in infants with bronchopulmonary dysplasia (BPD) through several different mechanisms. It has been suggested that corticosteroids might play a role in prevention of BPD by suppressing the inflammatory response in the lungs of infants at risk (<a href="./references#CD001146-bbs2-0080" title="GroneckP , SpeerCP .Inflammatory mediators and bronchopulmonary dysplasia. Archives of Disease in Childhood. Fetal and Neonatal Edition1995;73(1):F1-3. [DOI: 10.1136/fn.73.1.f1] [PMID: 7552588]">Groneck 1995</a>). It has been shown that infants who develop BPD have low cortisol levels following adrenocorticotrophic hormone (ACTH) stimulation during the first week of life (<a href="./references#CD001146-bbs2-0029" title="WatterbergKL , GerdesJS , GiffordKL , LinHM .Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics1999;104(6):1258-63. [DOI: 10.1542/peds.104.6.1258] [PMID: 10585975]WatterbergKL .Personal communication. email2002. ">Watterberg 1999</a>). To be effective in preventing BPD, corticosteroids may have to be given within the first few days of life. </p> <p>This review has demonstrated that early corticosteroid treatment facilitates weaning from the ventilator. Additional advantages include increased survival without BPD at 28 days of life and at 36 weeks' postmenstrual age, reduced risks of BPD at 28 days of life and at 36 weeks' postmenstrual age, and reduced risks of late treatment with corticosteroids, patent ductus arteriosus, and retinopathy of prematurity. On the other hand, risks of gastrointestinal bleeding, intestinal perforation, hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure may be increased. </p> <p>Potential hazards of corticosteroid treatment for the neonate include growth restriction, protein breakdown, cardiac hypertrophy, and possible adverse effects on development of the central nervous system and lungs (<a href="./references#CD001146-bbs2-0077" title="GibsonAT , PearseRG , WalesJKH .Growth retardation after dexamethasone administration: assessment by knemometry. Archives of Disease in Childhood1993;69(5 Spec No):505-9. [DOI: 10.1136/adc.69.5_spec_no.505] [PMID: 8285754]">Gibson 1993</a>; <a href="./references#CD001146-bbs2-0079" title="GramsbergenA , MulderEJ .The influence of betamethasone and dexamethasone on motor development in young rats. Pediatric Research1998;44(1):105-10. [DOI: 10.1203/00006450-199807000-00017] [PMID: 9667379]">Gramsbergen 1998</a>; <a href="./references#CD001146-bbs2-0106" title="TschanzSA , DamkeBM , BurriPH .Influence of postnatally administered glucocorticoids on rat lung growth. Biology of the Neonate1995;68(4):229-45. [DOI: 10.1159/000244241] [PMID: 8580214]">Tschanz 1995</a>; <a href="./references#CD001146-bbs2-0107" title="Van GoudoeverJB , WattimenaJD , CarnielliVP , SulkersEJ , DegenhartHJ , SauerPJ .Effect of dexamethasone on protein metabolism in infants with bronchopulmonary dysplasia. Journal of Pediatrics1994;124(1):112-8. [DOI: 10.1016/s0022-3476(94)70265-9] [PMID: 8283359]">van Goudoever 1994</a>; <a href="./references#CD001146-bbs2-0109" title="WeichselME .The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurologic hazards. Annals of Neurology1977;2(5):364-6. [DOI: 10.1002/ana.410020503] [PMID: 617574]">Weichsel 1977</a>; <a href="./references#CD001146-bbs2-0110" title="WernerJC , SicardRE , HansenTWR , SolomonE , CowettRM , OhW .Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. Journal of Pediatrics1992;120(2 Pt 1):286-91. [DOI: 10.1016/s0022-3476(05)80446-9] [PMID: 1735831]">Werner 1992</a>). One study showed a significant decline in the growth of head circumference with early corticosteroid treatment (<a href="./references#CD001146-bbs2-0089" title="PapileLA , StollB , DonovanE , TysonI , BauerC , WrightL , et al.Dexamethasone therapy in infants at risk for chronic lung disease (CLD): a multicenter, randomized, double-masked trial. Pediatric Research1996;39:236A. [DOI: 10.1203/00006450-199604001-01422]">Papile 1996</a>). Long‐term follow‐up results show that early corticosteroid treatment is associated with a significant increase in risks of developmental delay and cerebral palsy, and has significant effects on the combined outcome of mortality or cerebral palsy in the subgroup of infants treated with dexamethasone. One study in which the rate of cerebral palsy was significantly higher at two years of age used a four‐week tapering course of dexamethasone, so is similar in duration to the six‐week tapering course of late systemic corticosteroids reported by Kothadia and colleagues, and is included in the systematic review of late systemic corticosteroids (<a href="./references#CD001146-bbs2-0113" title="DoyleLW , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews2014, Issue 5. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub4]">Doyle 2014a</a>; <a href="./references#CD001146-bbs2-0047" title="BenskyAS , KothadiaJM , CovitzW .Cardiac effects of dexamethasone in very low birth weight infants. Pediatrics1996;97(6 Pt 1):818-21. [PMID: 8657520]GoldsteinDJ , WaldrepEL , VanPeltJC , O'SheaTM .Developmental outcome at 5 years following dexamethasone use for very low birth weight infants. Pediatric Research2000;47(4):310A. KothadiaJM , O'SheaTM , RobertsD , AuringerST , Weaver RG 3rd, DillardRG .Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics1999;104(1 Pt 1):22-7 Erratum in: Pediatrics 2004;114(6):1746. [DOI: 10.1542/peds.104.1.22] [PMID: 10390255]NixonPA , WashburnLK , SchechterMS , O'SheaTM .Follow-up study of a randomized controlled trial of postnatal dexamethasone therapy in very low birth weight infants: effects on pulmonary outcomes at age 8 to 11 years. Journal of Pediatrics2007;150(4):345-50. [DOI: 10.1016/j.jpeds.2006.12.013] [PMID: 17382108]O'SheaTM , GoldsteinDJ , JacksonBG , KothadiaJM , DillardRG .Randomized trial of a 42-day tapering course of dexamethasone in very low birth weight infants: neurological, medical and functional outcome at 5 years of age. Pediatric Research2000;47(4):319A. [DOI: 10.1016/j.jpeds.2019.04.047] [PMID: 31349916]O'SheaTM , KothadiaJM , KlinepeterKL , GoldsteinDJ , JacksonBG , Weaver RG 3rd, et al.Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics1999;104(1 Pt 1):15-21. [DOI: 10.1542/peds.104.1.15] [PMID: 10390254]WashburnLK , NixonPA , O'SheaTM .Follow-up of a randomized, placebo-controlled trial of postnatal dexamethasone: blood pressure and anthropometric measurements at school age. Pediatrics2006;118(4):1592-9. [DOI: 10.1542/peds.2006-0973] [PMID: 17015551]">Kothadia 1999</a>; <a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a>). However, in <a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a>, the numbers of surviving children with cerebral palsy declined between two and eight to nine years of age, and the difference became statistically non‐significant. In the 2002 follow‐up study to the 1996 Shinwell study, adverse long‐term neurological outcomes were reported in children treated with only a three‐day course of early dexamethasone starting within 12 hours of birth (<a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a>; <a href="./references#CD001146-bbs2-0102" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]">Shinwell 2002</a>). This finding is of extreme importance and concern, as data show about a three‐fold increased risk of cerebral palsy among survivors, including children with spastic diplegia, spastic quadriplegia, and hemiplegia. Why dexamethasone given early for a short course should have such devastating effects remains unknown. Certainly some infants would have been treated with repeat courses of dexamethasone, but this would have been more likely among control infants. Periventricular leukomalacia is an obvious cause of cerebral palsy, but studies have shown no excess of this disorder in corticosteroid‐treated infants compared with controls. Despite an increase in the diagnosis of cerebral palsy, it is important to note that this does not necessarily translate into major functional disability for the children concerned. </p> <section id="CD001146-sec-0080"> <h3 class="title" id="CD001146-sec-0080">Summary of main results</h3> <p>This systematic review found that early (≤ 7 days) systemic postnatal corticosteroids for prevention of BPD in preterm infants, in the regimens used, have had significant short‐term and long‐term effects ‐ both beneficial and harmful. A significant problem in interpreting late follow‐up data is that only 13 of 32 trials of early systemic postnatal corticosteroids have reported follow‐up results; therefore, the possibility of follow‐up bias and publication bias must be considered. Potential limitations of the study with a significant increase in the rate of cerebral palsy are that only 84% of surviving infants were examined, and children were assessed during early childhood (<a href="./references#CD001146-bbs2-0020" title="ShinwellES , KarplusM , ReichD , WeintraubZ , BlazerS , BaderD , et al.Early postnatal dexamethasone treatment and incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition2000;83(3):F177-81. [DOI: 10.1136/fn.83.3.f177] [PMID: 11040164]ShinwellES , KarplusM , ZmoraE , ReichD , RothschildA , BlazerS , et al.Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition1996;74(1):F33-7. [DOI: 10.1136/fn.74.1.f33] [PMID: 8653433]ShinwellES .Early dexamethasone therapy is associated with increased incidence of cerebral palsy. Hot Topics' 99 in Neonatology1999:240-54. ShinwellES .Personal communication. email2002. ">Shinwell 1996</a>). It is important to remember that cerebral palsy had been diagnosed before children were five years of age in most studies; diagnosing cerebral palsy with certainty before five years of age is problematic (<a href="./references#CD001146-bbs2-0103" title="StanleyFJ .Using cerebral palsy data in the evaluation of neonatal intensive care: a warning. Developmental Medicine and Child Neurology1982;24(1):93-4. [DOI: 10.1111/j.1469-8749.1982.tb13594.x] [PMID: 7106413]">Stanley 1982</a>). In another study, in which the rate of cerebral palsy was significantly worse at two years of age, with 81% follow‐up, the difference became non‐significant at eight to nine years ‐ an age when the diagnosis of cerebral palsy is more certain, and when the follow‐up rate was much better (92%), illustrating the importance of age of assessment and high follow‐up rates (<a href="./references#CD001146-bbs2-0032" title="LinYJ , LinCH , WuJM , TsaiWH , YehTF .The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatrica2005;94(3):310-6. [DOI: 10.1111/j.1651-2227.2005.tb03073.x] [PMID: 16028649]LinYJ , YehTF , LinHC , WuJM , LinCH , YuCY .Effects of early postnatal dexamethasone therapy on calcium homeostasis and bone growth in preterm infants with respiratory distress syndrome. Acta Paediatrica1998;87(10):1061-5. [DOI: 10.1080/080352598750031383] [PMID: 9825973]PengCT , LinHC , LinYJ , TsaiCH , YehTF .Early dexamethasone therapy and blood cell count in preterm infants. Pediatrics1999;104(3 Pt 1):476-81. [DOI: 10.1542/peds.104.3.476] [PMID: 10469772]YehTF , LinI , ShiehW , LinH , ChenJ , KaoS .Prevention of chronic lung disease (CLD) in premature RDS infants with early and prolonged dexamethasone (D) therapy - a multicenter double-blind controlled study. Pediatric Research1994;35(4):262A. YehTF , LinYJ , HsiehWS , LinHC , LinCH , ChenJY , et al.Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediatrics1997;100(4):E3. [DOI: 10.1542/peds.100.4.e3] [PMID: 9310536]YehTF , LinYJ , HuangCC , ChenYJ , LinCH , LinHC , et al.Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics1998;101(5):E7. [DOI: 10.1542/peds.101.5.e7] [PMID: 9565440]YehTF , LinYJ , LinHC , HuangCC , HsiehWS , LinCH , et al.Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. New England Journal of Medicine2004;350(13):1304-13. [DOI: 10.1056/NEJMoa032089] [PMID: 15044641]">Yeh 1997</a>). No study was designed primarily to test effects of postnatal systemic corticosteroids on adverse long‐term neurosensory outcomes, and all studies were underpowered to detect clinically important differences in long‐term neurosensory outcomes. </p> <p>Subgroup analyses by type of corticosteroid reveal that most beneficial and harmful effects were attributable to dexamethasone, and that hydrocortisone had little effect in most analyses, but the power to detect beneficial or harmful effects of hydrocortisone was low for most comparisons. However, the addition of data from the largest randomised controlled trial of early hydrocortisone reported by Baud and colleagues has revealed some advantages for early hydrocortisone in improving rates of mortality, extubation failure, and patent ductus arteriosus (<a href="./references#CD001146-bbs2-0004" title="BaudO , BiranV , TroussonC , LeroyE , MohamedD , AlbertiC .Two-year outcomes after prophylactic hydrocortisone in extremely preterm neonates. In: European Journal of Pediatrics. Vol. 175. 2016:1507. BaudO , MauryL , LebailF , RamfulD , El MoussawiF , NicaiseC , et al, PREMILOC Trial Study Group.Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet2016;387(10030):1827-36. [DOI: 10.1016/S0140-6736(16)00202-6] [PMID: 26916176]BaudO , TroussonC , BiranV , LeroyE , MohamedD , AlbertiC , PREMILOC Trial Group.Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA2017;317(13):1329-37. [DOI: 10.1001/jama.2017.2692] [PMID: 28384828]">Baud 2016</a>). </p> <p>Sensitivity analysis by indication for treatment with hydrocortisone (lung problems versus low blood pressure) revealed little difference in major outcomes of mortality, BPD or combined mortality, or BPD.  </p> </section> <section id="CD001146-sec-0081"> <h3 class="title" id="CD001146-sec-0081">Overall completeness and applicability of evidence</h3> <p>Data on in‐hospital outcomes were relatively complete, but data on longer‐term outcomes were incomplete. Results are applicable largely to ventilator‐dependent preterm infants in the first week after birth. </p> </section> <section id="CD001146-sec-0082"> <h3 class="title" id="CD001146-sec-0082">Quality of the evidence</h3> <p>Review authors assessed the certainty of evidence for six major outcomes, not only overall but also in subgroups by type of corticosteroid investigated (dexamethasone or hydrocortisone) (<a href="./full#CD001146-tbl-0001">summary of findings Table 1</a>). We assessed the evidence as high certainty for mortality at latest age, mortality or BPD, gastrointestinal perforation, cerebral palsy, and mortality or cerebral palsy. We downgraded the outcome of BPD at 36 weeks by one level to moderate certainty because of evidence of publication bias in studies overall, but not within subgroups. </p> <p>Although methods of random allocation were not fully described for all studies, we considered that the effect of this on overall results was not likely to be major, and hence we did not downgrade the level of evidence for any outcomes for this reason alone. </p> <p>Excluding five studies at higher risk of bias from a sensitivity analysis altered no conclusions. </p> </section> <section id="CD001146-sec-0083"> <h3 class="title" id="CD001146-sec-0083">Potential biases in the review process</h3> <p>Although Embase was searched in 2017, it was not searched for this update. Although Embase records are included in CENTRAL, we acknowledge that its omission in this update may have reduced the sensitivity of our search. </p> </section> <section id="CD001146-sec-0084"> <h3 class="title" id="CD001146-sec-0084">Agreements and disagreements with other studies or reviews</h3> <p>The overall evidence on benefits and risks from systemic corticosteroids started before seven days of age for major outcomes is consistent with the previous published version of this review (<a href="./references#CD001146-bbs2-0114" title="DoyleLW , CheongJLY , EhrenkranzRA , HallidayHL .Early (&lt; 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 10. Art. No: CD001146. [DOI: 10.1002/14651858.CD001146.pub5]">Doyle 2017a</a>). </p> <p>In an observational study of infants born after antenatal corticosteroid therapy, an excess of periventricular leukomalacia was evident among those whose mothers had received dexamethasone rather than betamethasone (<a href="./references#CD001146-bbs2-0065" title="BaudO , Foix-L'HeliasL , KaminskiM , AudibertF , JarreauPH , PapiernikE , et al.Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very preterm infants. New England Journal of Medicine1999;341(16):1190-6. [DOI: 10.1056/NEJM199910143411604] [PMID: 10519896]">Baud 1999</a>). Most studies of postnatal systemic corticosteroids used dexamethasone in high doses, at 0.5 to 1.0 mg/kg/d. Other systemic corticosteroids or lower doses of dexamethasone may prove to be safer, and emerging evidence supports the use of hydrocortisone as prophylaxis for BPD. However, the only study of hydrocortisone with school‐age outcomes reported lower scores on the performance scale of the Wechsler Presechool and Primary Scale of Intelligence ‐ Revised (WPPSI‐R) for children treated with hydrocortisone compared with placebo (<a href="./references#CD001146-bbs2-0016" title="PeltoniemiO , KariA , HeinonenK , SaarelaT , NikolajevK , AnderssonS , et al.Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infants. Journal of Pediatrics2005;146(5):632-7. [DOI: 10.1016/j.jpeds.2004.12.040] [PMID: 15870666]PeltoniemiOM , LanoA , PuosiR , YlihervaA , BonsanteF , KariMA , et al, Neonatal Hydrocortisone Working Group.Trial of early neonatal hydrocortisone: two-year follow-up. Neonatology2009;95(3):240-7. [DOI: 10.1159/000164150] [PMID: 18931525]PeltoniemiOM , LanoA , YlihervaA , KariMA , HallmanM , Neonatal Hydrocortisone Working Group.Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta Paediatrica2016;105(2):159-64. [DOI: 10.1111/apa.13074] [PMID: 26058477]">Peltoniemi 2005</a>). Further studies are needed to compare lower doses of corticosteroids, other corticosteroids, and alternative routes of administration (e.g. inhalation) (see Cochrane Review ‐ <a href="./references#CD001146-bbs2-0101" title="ShahhVS , OhlssonA , HallidayHL , DunnM .Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD001969. [DOI: 10.1002/14651858.CD001969.pub4]">Shah 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001146-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update." data-id="CD001146-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias table." data-id="CD001146-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias table.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001146-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Mortality, outcome: 1.4 Mortality at latest reported age." data-id="CD001146-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Mortality, outcome: 1.4 Mortality at latest reported age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 Bronchopulmonary dysplasia (BPD), outcome: 2.2 BPD (36 weeks' postmenstrual age)." data-id="CD001146-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 Bronchopulmonary dysplasia (BPD), outcome: 2.2 BPD (36 weeks' postmenstrual age). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 3 Death or bronchopulmonary dysplasia (BPD), outcome: 3.2 Death or BPD at 36 weeks' postmenstrual age." data-id="CD001146-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 3 Death or bronchopulmonary dysplasia (BPD), outcome: 3.2 Death or BPD at 36 weeks' postmenstrual age. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 Complications during primary hospitalisation, outcome: 5.15 Gastrointestinal perforation." data-id="CD001146-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 Complications during primary hospitalisation, outcome: 5.15 Gastrointestinal perforation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.11 Cerebral palsy." data-id="CD001146-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.11 Cerebral palsy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.13 Death or cerebral palsy." data-id="CD001146-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Funnel plot of comparison: 6 Long‐term follow‐up, outcome: 6.13 Death or cerebral palsy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-FIG-09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at different ages, Outcome 1: Neonatal mortality (up to 28 days)" data-id="CD001146-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Mortality at different ages, Outcome 1: Neonatal mortality (up to 28 days) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at different ages, Outcome 2: Mortality at 36 weeks" data-id="CD001146-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Mortality at different ages, Outcome 2: Mortality at 36 weeks</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at different ages, Outcome 3: Mortality to hospital discharge" data-id="CD001146-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Mortality at different ages, Outcome 3: Mortality to hospital discharge</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Mortality at different ages, Outcome 4: Mortality at latest reported age" data-id="CD001146-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Mortality at different ages, Outcome 4: Mortality at latest reported age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 1: BPD (28 days of life)" data-id="CD001146-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 1: BPD (28 days of life) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 2: BPD (36 weeks' postmenstrual age)" data-id="CD001146-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 2: BPD (36 weeks' postmenstrual age) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 3: BPD at 36 weeks' postmenstrual age in survivors to 36 weeks" data-id="CD001146-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 3: BPD at 36 weeks' postmenstrual age in survivors to 36 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 4: Late rescue with corticosteroids" data-id="CD001146-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 4: Late rescue with corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 5: Survivors who had late rescue with corticosteroids" data-id="CD001146-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 5: Survivors who had late rescue with corticosteroids </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 6: Survivors discharged home on oxygen" data-id="CD001146-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Bronchopulmonary dysplasia (BPD) at different ages, Outcome 6: Survivors discharged home on oxygen </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mortality or bronchopulmonary dysplasia (BPD) at different ages, Outcome 1: Death or BPD at 28 days of life" data-id="CD001146-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Mortality or bronchopulmonary dysplasia (BPD) at different ages, Outcome 1: Death or BPD at 28 days of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Mortality or bronchopulmonary dysplasia (BPD) at different ages, Outcome 2: Death or BPD at 36 weeks' postmenstrual age" data-id="CD001146-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Mortality or bronchopulmonary dysplasia (BPD) at different ages, Outcome 2: Death or BPD at 36 weeks' postmenstrual age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Failure to extubate at different ages, Outcome 1: Failure to extubate by third day" data-id="CD001146-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Failure to extubate at different ages, Outcome 1: Failure to extubate by third day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Failure to extubate at different ages, Outcome 2: Failure to extubate by seventh day" data-id="CD001146-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Failure to extubate at different ages, Outcome 2: Failure to extubate by seventh day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Failure to extubate at different ages, Outcome 3: Failure to extubate by 14th day" data-id="CD001146-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Failure to extubate at different ages, Outcome 3: Failure to extubate by 14th day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Failure to extubate at different ages, Outcome 4: Failure to extubate by 28th day" data-id="CD001146-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Failure to extubate at different ages, Outcome 4: Failure to extubate by 28th day </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 1: Infection" data-id="CD001146-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 1: Infection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 2: Hyperglycaemia" data-id="CD001146-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 2: Hyperglycaemia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 3: Hypertension" data-id="CD001146-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 3: Hypertension</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 4: Hypertrophic cardiomyopathy" data-id="CD001146-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 4: Hypertrophic cardiomyopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 5: Growth failure" data-id="CD001146-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 5: Growth failure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 6: Pulmonary air leak" data-id="CD001146-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 6: Pulmonary air leak </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 7: Patent ductus arteriosus (PDA)" data-id="CD001146-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 7: Patent ductus arteriosus (PDA) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 8: Severe IVH" data-id="CD001146-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 8: Severe IVH</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 9: Severe intraventricular haemorrhage (IVH) in infants examined" data-id="CD001146-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 9: Severe intraventricular haemorrhage (IVH) in infants examined </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 10: Periventricular leukomalacia (PVL)" data-id="CD001146-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 10: Periventricular leukomalacia (PVL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 11: PVL in infants with cranial ultrasound scans" data-id="CD001146-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 11: PVL in infants with cranial ultrasound scans </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 12: PVL in survivors seen at follow‐up" data-id="CD001146-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 12: PVL in survivors seen at follow‐up </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 13: Necrotising enterocolitis (NEC)" data-id="CD001146-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 13: Necrotising enterocolitis (NEC) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 14: Gastrointestinal bleeding" data-id="CD001146-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 14: Gastrointestinal bleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 15: Gastrointestinal perforation" data-id="CD001146-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 15: Gastrointestinal perforation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 16: Pulmonary haemorrhage" data-id="CD001146-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.16</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 16: Pulmonary haemorrhage </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 17: Any retinopathy of prematurity (ROP)" data-id="CD001146-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.17</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 17: Any retinopathy of prematurity (ROP) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 18: Severe ROP" data-id="CD001146-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.18</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 18: Severe ROP</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-005.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Complications during primary hospitalisation, Outcome 19: Severe ROP in survivors" data-id="CD001146-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-005.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.19</div> <div class="figure-caption"> <p>Comparison 5: Complications during primary hospitalisation, Outcome 19: Severe ROP in survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-005.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 1: Bayley Mental Developmental Index (MDI) &lt; ‐2 SD" data-id="CD001146-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 1: Bayley Mental Developmental Index (MDI) &lt; ‐2 SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 2: Bayley MDI &lt; ‐2 SD in tested survivors" data-id="CD001146-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 2: Bayley MDI &lt; ‐2 SD in tested survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 3: Bayley Psychomotor Developmental Index (PDI) &lt; ‐2 SD" data-id="CD001146-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 3: Bayley Psychomotor Developmental Index (PDI) &lt; ‐2 SD </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 4: Bayley PDI &lt; ‐2 SD in tested survivors" data-id="CD001146-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 4: Bayley PDI &lt; ‐2 SD in tested survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 5: Developmental delay (other criteria)" data-id="CD001146-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 5: Developmental delay (other criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 6: Developmental delay (other criteria) in tested survivors" data-id="CD001146-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 6: Developmental delay (other criteria) in tested survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 7: Blindness" data-id="CD001146-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 7: Blindness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 8: Blindness in survivors assessed" data-id="CD001146-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 8: Blindness in survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 9: Deafness" data-id="CD001146-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 9: Deafness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 10: Deafness in survivors assessed" data-id="CD001146-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 10: Deafness in survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 11: Cerebral palsy" data-id="CD001146-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 11: Cerebral palsy</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 12: Death before follow‐up in trials assessing cerebral palsy" data-id="CD001146-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 12: Death before follow‐up in trials assessing cerebral palsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 13: Death or cerebral palsy" data-id="CD001146-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 13: Death or cerebral palsy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 14: Cerebral palsy in survivors assessed" data-id="CD001146-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 14: Cerebral palsy in survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.14.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.15" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 15: Major neurosensory disability (variable criteria ‐ see individual studies)" data-id="CD001146-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.15.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.15.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 15: Major neurosensory disability (variable criteria ‐ see individual studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.15.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.16" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 16: Death before follow‐up in trials assessing major neurosensory disability (variable criteria)" data-id="CD001146-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.16.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.16.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 16: Death before follow‐up in trials assessing major neurosensory disability (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.16.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.17" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 17: Death or major neurosensory disability (variable criteria)" data-id="CD001146-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.17.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.17.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 17: Death or major neurosensory disability (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.17.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.18" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 18: Major neurosensory disability in survivors examined (variable criteria)" data-id="CD001146-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.18.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.18.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.18</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 18: Major neurosensory disability in survivors examined (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.18.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.19" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 19: Abnormal neurological exam (variable criteria ‐ see individual studies)" data-id="CD001146-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.19.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.19.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.19</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 19: Abnormal neurological exam (variable criteria ‐ see individual studies) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.19.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.20" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 20: Death before follow‐up in trials assessing abnormal neurological exam (variable criteria)" data-id="CD001146-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.20.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.20.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.20</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 20: Death before follow‐up in trials assessing abnormal neurological exam (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.20.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.21" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 21: Death or abnormal neurological exam (variable criteria)" data-id="CD001146-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.21.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.21.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.21</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 21: Death or abnormal neurological exam (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.21.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.22" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 22: Abnormal neurological exam in tested survivors (variable criteria)" data-id="CD001146-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.22.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.22.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.22</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 22: Abnormal neurological exam in tested survivors (variable criteria) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.22.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.23" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 23: Intellectual impairment (IQ &lt; 70)" data-id="CD001146-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.23.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.23.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.23</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 23: Intellectual impairment (IQ &lt; 70) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.23.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.24" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 24: Intellectual impairment (IQ &lt; 70) in survivors assessed" data-id="CD001146-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.24.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.24.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.24</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 24: Intellectual impairment (IQ &lt; 70) in survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.24.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.25" target="_blank"><b></b></a></p> </div><img alt='Comparison 6: Long‐term follow‐up into later childhood, Outcome 25: "Major neurosensory impairment" ‐ blindness or deafness' data-id="CD001146-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.25.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.25.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.25</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 25: "Major neurosensory impairment" ‐ blindness or deafness </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.25.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.26" target="_blank"><b></b></a></p> </div><img alt='Comparison 6: Long‐term follow‐up into later childhood, Outcome 26: "Major neurosensory impairment" ‐ blindness or deafness ‐ in survivors assessed' data-id="CD001146-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.26.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.26.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.26</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 26: "Major neurosensory impairment" ‐ blindness or deafness ‐ in survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.26.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.27" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 27: Behaviour abnormalities" data-id="CD001146-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.27.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.27.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.27</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 27: Behaviour abnormalities</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.27.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.28" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 28: Behaviour abnormalities in 3‐year‐old survivors assessed" data-id="CD001146-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.28.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.28.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.28</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 28: Behaviour abnormalities in 3‐year‐old survivors assessed </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.28.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.29" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 29: Abnormal EEG" data-id="CD001146-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.29.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.29.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.29</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 29: Abnormal EEG</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.29.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.30" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 30: Abnormal EEG in tested survivors" data-id="CD001146-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.30.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.30.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.30</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 30: Abnormal EEG in tested survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.30.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.31" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 31: Re‐hospitalisation in infancy" data-id="CD001146-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.31.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.31.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.31</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 31: Re‐hospitalisation in infancy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.31.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-006.32" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Long‐term follow‐up into later childhood, Outcome 32: Re‐hospitalisation in infancy in survivors" data-id="CD001146-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.32.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-006.32.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.32</div> <div class="figure-caption"> <p>Comparison 6: Long‐term follow‐up into later childhood, Outcome 32: Re‐hospitalisation in infancy in survivors </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-006.32.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 1: Mortality to latest age" data-id="CD001146-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 1: Mortality to latest age </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 2: Bronchopulmonary dysplasia at 36 weeks" data-id="CD001146-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 2: Bronchopulmonary dysplasia at 36 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001146-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/urn:x-wiley:14651858:media:CD001146:CD001146-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 3: Mortality or bronchopulmonary dysplasia at 36 weeks" data-id="CD001146-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_t/tCD001146-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Sensitivity analyses by indication for hydrocortisone, Outcome 3: Mortality or bronchopulmonary dysplasia at 36 weeks </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/media/CDSR/CD001146/image_n/nCD001146-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001146-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Early systemic postnatal corticosteroids (dexamethasone and hydrocortisone) compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> preventing bronchopulmonary dysplasia in preterm infants<br/><b>Setting:</b> multiple neonatal intensive care units, most from high‐income countries<br/><b>Intervention:</b> early systemic postnatal corticosteroids<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>No. of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="table-header separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with early systemic postnatal corticosteroids</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.95<br/>(0.85 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4373<br/>(31 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> <p>P = 0.05 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>232 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>221 per 1000<br/>(197 to 246) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.02<br/>(0.90 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2940<br/>(20 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>236 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>241 per 1000</p> <p>(212 to 274)</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.65 to 0.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1433<br/>(11 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000<br/>(146 to 222) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>BPD (36 weeks' PMA)</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.80<br/>(0.73 to 0.88) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4167<br/>(26 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>important</p> <p>P = 0.01 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>247 per 1000<br/>(225 to 271) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.72<br/>(0.63 to 0.82) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2791<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>269 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>194 per 1000<br/>(170 to 221) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.92<br/>(0.81 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1376<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>385 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>354 per 1000<br/>(312 to 408) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality or BPD at 36 weeks' PMA</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.84 to 0.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>4167<br/>(26 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>515 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000<br/>(432 to 484) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.88<br/>(0.81 to 0.95 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>2791<br/>(17 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>487 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>429 per 1000<br/>(395 to 463) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.90<br/>(0.82 to 0.99 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1376<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>569 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>512 per 1000<br/>(467 to 563) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Gastrointestinal perforation during primary hospitalisation</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.84<br/>(1.36 to 2.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3040<br/>(16 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>71 per 1000<br/>(53 to 96) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.73<br/>(1.20 to 2.51 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1936<br/>(9 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>41 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>71 per 1000<br/>(50 to 104) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of infants treated with hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 2.05<br/>(1.21 to 3.47 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1104<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>important</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>70 per 1000<br/>(41 to 118) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Cerebral palsy at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.42<br/>(1.06 to 1.91) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1973<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> <p>P = 0.09 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>106 per 1000<br/>(79 to 142) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.77<br/>(1.21 to 2.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>921<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>89 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>158 per 1000<br/>(108 to 230) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.05<br/>(0.66 to 1.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1052<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>65 per 1000<br/>(41 to 103) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Mortality or cerebral palsy at latest reported age</p> <p> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (studies treating with dexamethasone or hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.03<br/>(0.91 to 1.16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1973<br/>(13 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> <p>P = 0.02 for subgroup differences</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>335 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>345 per 1000<br/>(305 to 389) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Study population (subgroup of studies treating with dexamethasone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.18<br/>(1.01 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>921<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>critical</p> <p> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>383 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>452 per 1000<br/>(387 to 525) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population (subgroup of studies treating with hydrocortisone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.86<br/>(0.71 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1052<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>critical</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>295 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>254 per 1000<br/>(210 to 310) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>BPD:</b> bronchopulmonary dysplasia; <b>CI:</b> confidence interval; <b>PMA:</b> postmenstrual age; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> </p> <p><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect. </p> <p><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> <p><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations owing to evidence of publication bias for studies overall, but not within subgroups. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Early systemic postnatal corticosteroids compared with placebo or no treatment for preventing bronchopulmonary dysplasia in preterm infants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/full#CD001146-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mortality at different ages</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Neonatal mortality (up to 28 days) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2933</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.87, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.90, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.49, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Mortality at 36 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.67, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mortality to hospital discharge <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.85, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2731</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.90, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Mortality at latest reported age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.85, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2940</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Mortality at different ages</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bronchopulmonary dysplasia (BPD) at different ages</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 BPD (28 days of life) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.80, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.78, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.85, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 BPD (36 weeks' postmenstrual age) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.73, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.81, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 BPD at 36 weeks' postmenstrual age in survivors to 36 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.72, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.63, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.78, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Late rescue with corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.73, 0.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.65, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1030</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Survivors who had late rescue with corticosteroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>895</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.67, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>853</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.68, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.24, 0.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Survivors discharged home on oxygen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.70, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.48, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1036</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.70, 1.13]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Bronchopulmonary dysplasia (BPD) at different ages</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality or bronchopulmonary dysplasia (BPD) at different ages</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Death or BPD at 28 days of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.87, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.86, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.90, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Death or BPD at 36 weeks' postmenstrual age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4167</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.83, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.81, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.82, 0.99]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Mortality or bronchopulmonary dysplasia (BPD) at different ages</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Failure to extubate at different ages</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Failure to extubate by third day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>887</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.75, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>381</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.62, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>506</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.82, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Failure to extubate by seventh day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1448</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.68, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.61, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>745</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.69, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Failure to extubate by 14th day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.62, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Failure to extubate by 28th day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Failure to extubate at different ages</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Complications during primary hospitalisation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Infection <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.96, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2821</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.91, 1.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1280</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.94, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Hyperglycaemia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2688</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.15, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.21, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>571</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.84, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Hypertension <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.54, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1943</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.53, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [0.33, 26.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Hypertrophic cardiomyopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.33 [1.40, 13.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Growth failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.67 [2.27, 19.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.6 Pulmonary air leak <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3276</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.73, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2041</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.66, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.72, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.7 Patent ductus arteriosus (PDA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.72, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2706</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.69, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.71, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.8 Severe IVH <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.84, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2736</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.81, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1367</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.76, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.9 Severe intraventricular haemorrhage (IVH) in infants examined <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.59, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>970</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.82, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.10 Periventricular leukomalacia (PVL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.83, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.84, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.10.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1293</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.58, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.11 PVL in infants with cranial ultrasound scans <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1841</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.79, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.12 PVL in survivors seen at follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.60, 2.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.13 Necrotising enterocolitis (NEC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4050</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.69, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.13.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.66, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.14 Gastrointestinal bleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1816</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.35, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1725</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [1.35, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.14.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.27, 8.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.15 Gastrointestinal perforation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3040</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.36, 2.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1936</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.73 [1.20, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.15.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [1.21, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.16 Pulmonary haemorrhage <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.87, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.65, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.16.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.92, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.17 Any retinopathy of prematurity (ROP) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.80, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.72, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.17.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.84, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.18 Severe ROP <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.67, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1507</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.18.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.65, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.19 Severe ROP in survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.64, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.59, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.19.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.60, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Complications during primary hospitalisation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Long‐term follow‐up into later childhood</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Bayley Mental Developmental Index (MDI) &lt; ‐2 SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Bayley MDI &lt; ‐2 SD in tested survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.79, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Bayley Psychomotor Developmental Index (PDI) &lt; ‐2 SD <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.85, 1.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.4 Bayley PDI &lt; ‐2 SD in tested survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.87, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.5 Developmental delay (other criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.93, 2.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>248</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [1.08, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.26, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.6 Developmental delay (other criteria) in tested survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>538</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.05, 2.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [1.30, 2.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.24, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.7 Blindness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.74, 5.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>862</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.01 [0.74, 5.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>456</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.8 Blindness in survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.80, 5.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.80, 5.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>432</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.9 Deafness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.39, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.30, 3.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [0.13, 73.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.10 Deafness in survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.40, 3.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.11 Cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [1.07, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.21, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.66, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.12 Death before follow‐up in trials assessing cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.81, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.12.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.64, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.13 Death or cerebral palsy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1973</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.91, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [1.01, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.13.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1052</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.71, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.14 Cerebral palsy in survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.12, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>587</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [1.31, 2.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.14.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.65, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.15 Major neurosensory disability (variable criteria ‐ see individual studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.89, 1.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.03, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.15.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.64, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.16 Death before follow‐up in trials assessing major neurosensory disability (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.16.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.82, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.16.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.17 Death or major neurosensory disability (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1703</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.87, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.17.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.99, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.17.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.69, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.18 Major neurosensory disability in survivors examined (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.89, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.18.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.05, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.18.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>709</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.65, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.19 Abnormal neurological exam (variable criteria ‐ see individual studies) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.81 [1.33, 2.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.20 Death before follow‐up in trials assessing abnormal neurological exam (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.20.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.79, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.20.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>521</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.54, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.21 Death or abnormal neurological exam (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>829</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [1.06, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.22 Abnormal neurological exam in tested survivors (variable criteria) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>508</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [1.41, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.23 Intellectual impairment (IQ &lt; 70) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.64, 3.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.23.1 Dexamethasone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [0.57, 3.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.23.2 Hydrocortisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.21, 21.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.24 Intellectual impairment (IQ &lt; 70) in survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.47, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.25 "Major neurosensory impairment" ‐ blindness or deafness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.16, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.26 "Major neurosensory impairment" ‐ blindness or deafness ‐ in survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.16, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.27 Behaviour abnormalities <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.16, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.28 Behaviour abnormalities in 3‐year‐old survivors assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.16, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.29 Abnormal EEG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>306</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.66, 2.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.30 Abnormal EEG in tested survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.61, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.31 Re‐hospitalisation in infancy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>672</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.68, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.32 Re‐hospitalisation in infancy in survivors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>430</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.71, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Long‐term follow‐up into later childhood</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001146-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analyses by indication for hydrocortisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Mortality to latest age <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.65, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.1 Lung</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1319</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.66, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1.2 Blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.24, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Bronchopulmonary dysplasia at 36 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.80, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Lung</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1058</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.79, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.66, 1.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Mortality or bronchopulmonary dysplasia at 36 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.80, 0.98]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.1 Lung</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.81, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3.2 Blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.19, 1.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analyses by indication for hydrocortisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001146.pub6/references#CD001146-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001146.pub6&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001146-note-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001146-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001146-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="ko#CD001146-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD001146-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001146-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001146-note-0005">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001146-note-0006">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001146\x2epub6"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001146\x2epub6"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001146\x2epub6"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001146\x2epub6\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001146\x2epub6"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=tIsQXAzh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001146.pub6&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001146.pub6';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001146.pub6/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001146.pub6/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001146.pub6%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724601936"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001146.pub6/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724601940"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001146.pub6/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e66d09eb4f44a',t:'MTc0MDcyNDYwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 